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The integrity of brain white matter is vital for the interneuronal signalling 
between distinct brain regions required for normal cognitive function.   White matter 
integrity is compromised with ageing and could contribute to age-related cognitive 
decline.   Chronic cerebral hypoperfusion is thought to underlie the development of 
white matter pathology and cognitive changes, often seen in the elderly.   
Additionally, the development of regional hypoperfusion and white matter damage 
are thought to be early events in Alzheimer’s disease (AD) pathogenesis.   This thesis 
set out to test the hypothesis that chronic cerebral hypoperfusion underlies the 
development of white matter pathology and cognitive decline and also that chronic 
cerebral hypoperfusion causes the development of Aβ pathology in AD. 
The first aim was to investigate the impact of hypoperfusion on the 
development of white matter damage and different aspect  of cognition in a mouse 
model of chronic cerebral hypoperfusion.   Two studies were undertaken to address 
this.   The first study examined the temporal development of pathology following 
hypoperfusion induced by bilateral carotid artery stenosis (BCAS) using microcoils   
Hypoperfusion was induced in wild type (WT) mice and the pathological changes 
examined at one week, two weeks, one month and two months.   Hypoperfused 
animals developed a diffuse and widespread white matter pathology, present from 
one week, which occurred predominantly in the myelin component of white matter; 
this was accompanied by minimal axonal damage.   A second study examined the 
impact of hypoperfusion on different aspects of spatial memory and further 
investigated pathological changes in the model at one and two months.   Behavioural 
testing revealed a significant impairment in spatial working memory but not episodic 
xvi 
memory or spatial reference memory in hypoperfused animals.   In the same mice, 
pathological assessment indicated that there was a significant increase in levels of 
myelin damage and elevated levels of microglial activ tion as compared to shams.   
These results demonstrate that modest reductions in cerebral blood flow are 
sufficient to cause the development of white matter damage and the development of 
cognitive deficits. 
The second aim was to investigate the impact of hypoperfusion on the 
development of white matter and amyloid pathology in a mouse model (3xTg-AD) of 
AD.   To address this, using 2 different sizes of microcoils (0.18mm and 0.16mm 
internal diameter) BCAS of varying severities was induced in 3xTg-AD mice and 
white matter and Aβ pathology were assessed at one month.   Circle of Willis (CoW) 
architecture was also compared between WT and 3xTg-AD mice.   Overall white 
matter pathology was not exacerbated in experimental 3xTg-AD mice with BCAS 
induced by 0.18mm coils.   However with a greater leve  of stenosis (0.16mm coil) 
ischaemic damage to neuronal perikarya was present in most experimental animals.   
In addition to ischaemic damage, localised areas of evere white matter pathology 
were also observed in conjunction with subtle changes to white matter Aβ levels.   
Hypoperfusion did not impact on the development of intraneuronal Aβ pathology, 
other than in the presence of ischaemic damage when levels were reduced.   
Comparison of CoW architecture between WT and 3xTg-AD mice revealed strain 
specific differences in the presence and morphology of the posterior communicating 
artery which may explain the lack of pathology in 3xTg-AD mice as compared to 
WT following BCAS induced using 0.18mm dia. microcoils. 
xvii 
The third aim was to investigate whether white matter protein composition 
changed with age and also whether ageing conferred increased vulnerability to 
hypoperfusion.   To address this, white matter protein levels were compared between 
young (3-4 months) and old (12-13 months) 3xTg-AD mice.   White matter 
pathology was compared between sham and hypoperfused animals in the aged 
cohort.   Levels of myelin basic protein and 2', 3'-cyclic nucleotide 3'-
phosphodiesterase were found to be significantly increased whilst levels of myelin 
associated glycoprotein were significantly reduced with ageing.   These results 
suggest that changes in myelin protein composition may contribute to the 
development of age related white matter pathology.   White matter pathology was not 
exacerbated in aged hypoperfused animals following one month of hypoperfusion as 
compared to shams. 
The results presented within the thesis demonstrate hat chronic cerebral 
hypoperfusion precipitates the development of selectiv  white matter damage and 
impacts on cognition.   Also it has been shown thatwhere hypoperfusion is severe 
enough to cause ischaemic damage to neuronal perikarya and localised areas of 
severe white matter pathology, alterations in white matter Aβ levels can occur.   
Hypoperfusion does not impact on APP processing or on intraneuronal levels of APP 
or Aβ, other than in the presence of ischaemic damage to n uronal perikarya, when 
levels are reduced.   These findings highlight the importance of early intervention 
strategies in the treatment of vascular risk factors which can lead to hypoperfusion 
and the development of white matter damage and a decline in cognitive function in 
later life.   These findings also suggest that repai  or prevention of white matter 
damage may be an appropriate strategy for the attenua io  of cognitive decline 
xviii 
following onset of hypoperfusion.   This thesis also highlights some of the limitations 
of animal models of human disease. 
xix 
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PLP    proteolipid protein 
PS1    presenilin 1 
PS2    presenilin 2 
xxi 
PVDF     polyvinylidene fluoride 
ROD    relative optical density 
sAPPα    soluble extracellular APP domain 
SDS-PAGE   sodium decyl polyacrylamide gel electrophoresis 
S-MAG   small myelin associated glycoprotein 
SOD    super oxide dismutase 
SPECT   single photon emission computed tomography 
SHRSP   stroke prone spontaneously hypertensive rat 
SRM    spatial reference memory 
St    striatum 
SWM    spatial working memory 
TTC    trials to criterion
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Chapter 1:  Introduction 
The term chronic cerebral hypoperfusion, is used to escribe a subtle, chronic 
reduction in cerebral blood flow (CBF), which in humans, is thought to occur due to 
a loss of vascular integrity (Iadecola, 2010; Gorelick et al., 2011). Unlike in stroke, 
where CBF reduction is acute and often fatal,  these r ductions have been shown to 
develop over prolonged periods in line with normal ageing (Leenders et al., 1990). 
The findings of several studies e.g. (Breteler et al., 1994; Wakita et al., 1994; Shibata 
et al., 2004; Fernando et al., 2006; Farkas et al., 2007) conducted in both human and 
animal cohorts suggest that chronic cerebral hypoperfusion impacts detrimentally on 
the integrity of brain white matter, which is critical for normal cognitive function.   
The presence of white matter damage is a common feature in the brains of elderly 
individuals and is thought to be linked to the development of age related cognitive 
decline.   
Hypoperfusion has also been shown to be one of the earliest features of 
Alzheimer’s disease (AD), occurring in temporo parietal regions, in some cases, up 
to decades prior to onset of clinical AD symptoms.   Whilst a considerable body of 
evidence exists which demonstrates links between hypoperfusion, white matter 
damage and cognitive decline, it is impossible to define in the human brain the 
underlying mechanisms involved due to the presence of multiple confounding factors 
e.g. hypertension, diabetes, and arteriosclerosis. 
The overarching aim of this thesis is to investigate the links between chronic 
cerebral hypoperfusion, the development of white matter pathology and how this 
may impact on cognition.   The impact of hypoperfusion on amyloid and the 
influence of ageing will also be investigated.   Central to the aims of the thesis is the 
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development and characterisation of a mouse model of chronic cerebral 
hypoperfusion. 
 
1.1  White matter 
 
White matter is found ubiquitously throughout the central nervous system 
(CNS) of all vertebrates.   In humans (Fig 1.1a), brain white matter volume accounts 
for over half of total brain volume, this is a far greater fraction than is seen in other 
animals (Fields, 2008) e.g. the mouse, where brain white matter volume accounts for 
approximately only 25% of total brain volume.   Despite this, the functional role of 
white matter has been over looked by researchers until only relatively recently.  
When white matter was first described by Virchow in 1846 it was assumed to 
be some form of connective tissue, a belief which endured for almost a century until 
the pathologists Ramon y Cajal and Rio Hortega characte ised the three major cell 
types of which white matter is comprised.   Namely oligodendrocytes, astrocytes and 
microglia.   As well as these cellular components, white matter is also comprised of 
blood vessels and axons which are the physical connection between nerve cells.   
Axons extend from neuronal cell bodies situated within grey matter regions and 
facilitate the flow of electrical information over long distances as cells communicate 
with one another.   
 
1.1.1  Components of white matter 
In order to understand the functional role of white matter it is necessary to 
describe its vascular network and cellular components; oligodendrocytes, astrocytes 
and microglia (Fig. 1.1b). 
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Figure 1.1a  Location of white and grey matter in the brain 
Schematic of a horizontal section of a human brain showing location of grey and white matter.  









Node of Ranvier  
 
Figure 1.1b  Components of white and grey matter  
Components of grey matter (cell bodies) and white matter (oligodendrocytes, astroglia, microglia and 
axons).  Capillaries comprise the cerebrovascular network which delivers essential nutrients to the 
brain. (Image adapted from The McGraw-Hill Company i c. (www.mcgraw-hill.co.uk)) 
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1.1.1.1  Oligodendrocytes 
The most abundant cell type found in white matter, and arguably the most 
functionally significant is the oligodendrocyte.   Oligodendrocytes are the cells 
which produce myelin, a fatty, whitish substance comprised of lipids and proteins 
(70% lipid/ 30% protein (Quarles, 2006) which gives the white matter its colour.   In 
the CNS oligodendrocytes extend processes composed of myelin which make contact 
with and ensheath neighbouring axons, wrapping around them, forming an insulating 
coating which increases the conduction velocity of nerve impulses, or axon 
potentials, by up to 100 times as compared to unmyelinat d axons (Fields, 2008).   
An appropriate analogy is to imagine the axons as the copper wire in a household 
electrical cable whilst the myelin is the insulating plastic coating.   The three main 
advantages conferred by myelin to the CNS, are highspeed conduction of nerve 
impulses, fidelity of transfer signalling between distinct brain regions (often over 
long distances) and space economy (Baumann and Pham-Dinh, 2001).   
During the process of myelination, each oligodendrocyte may extend 
processes to as many as 40 different axons, such that on the same axon adjacent 
myelin segments originate from different oligodendrocytes (Peters, 1991).   These 
segments of myelin are referred to as internodes and re separated by short 
unmyelinated regions called ‘The Nodes of Ranvier’.   Internodes are between 100-
1700µm in length (depending upon species/ location) whilst the length of Nodes of 
Ranvier is approximately 1µm (Edgar and Nave, 2009).   Voltage gated sodium 
channels are concentrated in the axonal membrane at th  Nodes of Ranvier, thus the 
insulating effect of myelin facilitates saltatory conduction of action potentials along 
the axon as the current ‘leaps’ from one node to the next (Fig 1.1b). 
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Oligodendrocytes may be morphologically divided into four different 
subtypes based upon the thickness of their myelin sheath.   This is related to the 
calibre of the axon they ensheath.   Type I cells typically myelinate between 15-30 
small diameter axons, type II and III cells myelinate larger intermediate diameter 
axons whilst type IV cells form long, thick myelin sheaths around only 1-3 large 
diameter axons (Butt et al., 1995).   This heterogeneity is important as, in order to 
achieve maximum conduction velocity the thickness of the myelin sheath must be 
proportional to the diameter of the axon around which it is wrapped.   This optimal 
ratio, termed the g ratio (axon diameter/ total fibre diameter) has been calculated as 
0.65 (Fields, 2008; Franklin and ffrench-Constant, 2008). 
 
1.1.1.2  Astrocytes 
Astrocytes are the second most abundant cell type found in white matter.   
There are three distinct types of astrocytes; fibrous, protoplasmic and radial.   
Astrocytes in white matter are mainly the fibrous sbtype (Miller and Raff, 1984).   
They are a functionally diverse cell type with contributing roles in white matter 
structure, synapse maintenance, blood brain barrier function, extracellular ion 
concentration homeostasis, intercellular signalling a d injury repair.   Astrocytes also 
provide trophic support to the myelin sheath and play a role in initiating myelination 
(Franklin and ffrench-Constant, 2008). 
 
1.1.1.3  Microglia 
Microglia are the main form of immune defence in the CNS.   In the normal 
healthy brain they are present in what is described as their ‘resting’ state which is 
characterised by a small cell body in conjunction with short outwards extending 
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processes.   However, in response to CNS injury, onset of ischaemia or the presence 
of inflammatory stimuli, they quickly adopt their activated phenotype which is 
associated with cell proliferation and migration to the site of injury, as well as 
phagocytosis of dead and dying cells.   Activation also results in the release of 
inflammatory mediators which recruit more microglia to the site of injury and also 
immuno modulatory cells from the blood stream (Garden and Möller, 2006).   Once 
the activating stimulus begins to diminish, microglia also play a role in the down 
regulation of the inflammatory response.   An increased level of microglial activation 
is a common feature of normal ageing (Von Bernhardi et al., 2010) and also many 
neurodegenerative diseases, where they act to phagocytose abnormal accumulations 
of pathological proteins.   The best documented case of this is in Alzheimer’s disease 
(Rogers et al., 2002; Perry et al., 2010).   In addition to neurodegenerative disease, 
upregulated microglial activation is also commonly observed in the brains of 
individuals at risk of developing vascular disorders (Von Bernhardi et al., 2010) and 
also following vascular insults, such as stroke (Danton and Dietrich, 2003).   
 
1.1.1.4  Blood vessels 
In addition to the cellular components outlined above, white matter also 
contains blood vessels which comprise the vascular network delivering oxygen and 
glucose required for normal cellular function.   Blood supply to the deep sub cortical 
white matter is facilitated through penetrating arterioles which stem from the pial 
network on the surface of the brain.   Penetrating arteries branch off at right angles 
from the subarachnoid vessels and run down through the cortex into the white matter 
(Van Den Bergh et al., 1968).   These arteries do not furcate but instead, give off 
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short branches (distributing vessels) which supply discrete areas of the white matter 
(metabolic units) (Rowbotham and Little, 1965). 
 
1.1.2  The protein architecture of myelin 
The insulating properties of the myelin sheath are l gely due to its unique 
lipid: protein ratio.   Myelin is exceptionally lipid rich and for this reason has very 
low water content (~40% as compared to ~70% in grey matter).   The specific 
glycolipid and protein constituents of myelin are formed by the oligodendrocyte. 
The majority of the proteins which comprise the myelin sheath are specific to 
oligodendrocytes (Campagnoni and Macklin, 1988).   In the CNS the major myelin 
proteins which constitute ~80% of its protein content are myelin basic protein (MBP) 
and proteolipid protein (PLP).   Other protein constituents include the Wolfgram 
family of proteins of which 2’,3’- Cyclic Nucleotide 3’- Phosphodiesterase (CNPase) 
is a member and also the glycoproteins which include the myelin associated 
glycoprotein (MAG). 
 
1.1.2.1  Myelin Basic Protein (MBP) 
MBP is not one, but a family of proteins.   There aseveral isoforms which 
are differentially expressed in both the immature and mature oligodendrocyte.   In 
the adult human the four major isoforms are 21.5, 20.2, 18.5 and 17.2kDa and in the 
mouse they are 21.5, 18.5, 17 and 14kDa (Campagnoni and Macklin, 1988).   These 
isoforms are readily separated using SDS-PAGE gel electrophoresis (see chapter 2).   
The most abundant isoforms in humans are the 18.5 and 17.2kDa isoforms whilst in 
the mouse the most abundant isoforms are the 18.5 and 14kDa isoforms (Staugaitis et 
al., 1990).   The MBP gene is comprised of 7 exons.   I oforms containing exon 2 
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(20.2 and 21.5kDa in the human and 17 and 21.5kDa in the mouse) have been 
identified as being expressed earlier during development and also in chronic lesions 
in MS where their expression correlates with the onset of remyelination (Capello et 
al., 1997).  Exon 2 containing isoforms are distributed diffusely throughout the 
cytoplasm and have been shown to be translocated to cell nuclei via active transport.   
Their distribution, taken together with their expression profile has led to the 
conclusion that these isoforms play a regulatory role in the myelination process 
(Pedraza et al., 1997).   Expression of the more abundant non-exon 2 containing 
isoforms occurs later in development and their cellular location is confined to the 
plasma membrane where they play a role in myelin compaction (Roach et al., 1985).   
Deficiency in MBP has been shown to cause myelin disruption (Privat et al., 1979). 
 
1.1.2.2  2’,3’- Cyclic Nucleotide 3’- Phosphodiesterase (CNPase) 
CNPase is the third most abundant protein in CNS myelin constituting ~4% 
of total myelin protein composition (Kurihara and Tsukada, 1967).   CNPase consists 
of 2 different isoforms which may be visualised using SDS-PAGE gel 
electrophoresis.   They are named CNP1 and CNP2 and are 48-55kDa (species 
dependent).   In the mouse they are 46kDa and 48kDa respectively.   The role of 
CNPase lies in the hydrolysation of 2’3’-cyclic nucleotides into their 2’ derivative 
however the relevance of CNPase to myelin is unclear as the presence of 2’3’-cyclic 
nucleotides has never been demonstrated in oligodendrocytes (Vogel and Thompson, 
1988; Hinman et al., 2008). 
The cellular location of CNPase has been shown to be within the cytoplasm 
of non compacted myelin and also the paranodal loops which are located at the edge 
of the myelin internode at the nodes of Ranvier (Trapp et al., 1988).   In light of the 
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lack of CNPase substrates present in myelin a role for CNPase has been proposed in 
a lipid raft –mediated signalling cascade which regulates interactions between myelin 
and axonal cytoskeletal components (Hinman et al., 2008).   This is based on 
evidence from studies which have shown that a large proportion of CNPase is 
associated with lipid rafts in the plasma membrane (Kim and Pfeiffer, 1999).   
CNPase also meets the criteria for classification as a microtubule associated protein 
(MAP) (Bifulco et al., 1993).   Deficiency, and also CNPase over expression, has 
been shown to cause abnormalities in the myelin sheath which are detectable at the 
ultrastructural level (Gravel et al., 1996; Rasband et al., 2005).  
 
1.1.2.3  Myelin associated glycoprotein (MAG) 
MAG is a 100kDa transmembrane glycoprotein which is found localised 
periaxonally.   As a protein constituent of myelin, it is relatively minor, comprising 
only 1% of total myelin in the CNS (Quarles et al.,1973).   There are two distinct 
MAG isoforms both of which have similar homology to members of the neural cell 
adhesion molecule (NCAM) family.   The isoforms areid ntical to one another, other 
than differences within their cytoplasmic domains (Salzer et al., 1987).   Prior to post 
translational modification, the isoforms are 72kDa and 67kDa large MAG (L-MAG) 
and small MAG (S-MAG) respectively.   These isoforms have a distinct 
chronological pattern of expression during development, however, exist in 
approximately equimolar concentrations in the adult CNS.   Each isoform is thought 
to have a functionally discrete role in the development and maintenance of the 
myelin sheath.   L-MAG is thought to play a role in axon/ glia or glia/ glia signal 
transduction and adhesion whilst S-MAG is involved in myelin maintenance and 
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stabilisation of paranodal loops (Erb et al., 2006).   MAG is also known to play a role 
in inhibition of neurite outgrowth during myelination (McKerracher et al., 1994).   
Studies investigating the impact of ischaemia on white matter have identified 
MAG as one of the most vulnerable proteins (Aboul-Enein et al., 2003).   Studies 
utilising MAG null mice have demonstrated that MAG deficiency leads to the 
development of myelin sheath abnormalities in later lif  and also a ‘dying back 
oligodendrogliopathy’ of the myelin sheath (Lassmann et al., 1997). 
 
1.1.3  White matter and cognition 
The person credited with first describing white matter changes associated 
with cognitive decline is Swiss psychiatrist and neurologist Otto Binswanger.   At 
autopsy, Binswanger described a marked atrophy of the cerebral white matter 
(amongst other pathological changes) in a syphilitic patient who had displayed a 
marked deterioration in cognitive ability and motor function prior to his death (Blass 
et al., 1991).   The advent of sophisticated neuroimaging techniques such as 
computed tomography (CT) and various magnetic resonance imaging (MRI) 
scanning techniques has provided further evidence which shows a clear correlation 
between loss of white matter integrity and the development of detrimental changes in 
cognition (Rosenberg et al., 1979; Breteler et al., 1994; Deary, 2003; Bucur et al., 
2008). 
White matter integrity is critical for normal brain function.   The insulating 
properties of myelin result in saltatory conduction which greatly increases the speed 
of nerve impulses along the axon.   This ability to increase the speed of information 
and also the ability to integrate this information as it flows between distinct brain 
regions is the underlying feature of higher cognitive function (Bartzokis, 2004).   
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Furthermore, increased conduction velocity also allows the temporal coding of 
information in the form of high frequency bursts of signalling between cells.   This 
means that even modest damage to the myelin sheath can lead to slower conduction 
speed and a disruption in inter-cellular signalling, essentially leading to a 
disconnection of brain regions (Peters and Sethares, 2002). 
As well as a decline in normal cognitive function a decline in white matter 
integrity has been recognised as a key feature in ma y neurological and psychiatric 
disorders e.g. dyslexia, post-traumatic stress disor er, multiple sclerosis and 
Alzheimer’s disease to name a few (Fields, 2008).   Furthermore, polymorphisms in 
several of the genes encoding myelin proteins have been linked to the development 
of mental illnesses such as schizophrenia (Hakak et al., 2001) and major depression 
(Tkachev et al., 2003). 
 
1.1.4  The impact of ageing on white matter integrity 
In the absence of neurological disease the greatest risk factor which has been 
linked to a loss of myelin integrity and the development of cognitive deficits is 
ageing.   Myelination in the human brain occurs in a heterochronological pattern 
(Bartzokis, 2004).   At birth myelin is only found in a few brain regions.   
Myelination occurs in developmental spurts in a posterior to anterior pattern with 
axons in the prefrontal cortical areas and the temporal and parietal lobes myelinating 
last (as late as the 5th decade) (Bartzokis, 2004).   Studies utilising various methods 
have shown that it is myelinated fibres within these later myelinating regions which 
are lost first with ageing (Marner et al., 2003). 
Some of the most compelling evidence linking the development of age-
related cognitive deficits and a loss of white matter integrity comes from large, long- 
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term epidemiological studies (e.g. The Rotterdam Study, The Honolulu-Asia Ageing 
and The Lothian Birth Cohort 1936).   Studies such as these have utilised 
neuroimaging to investigate how white matter changes with age in large human 
cohorts.   Their findings indicate that the development of white matter lesions, which 
are visible as hyperintensities on MRI scans (Fig 1.2), are a common feature of the 
normal ageing process and are present in the brains of upwards of 50% of individuals 
over the age of 65 (Enzinger et al., 2006).   They ave also shown that the number of 
these hyperintensities correlates with levels of cognitive ability in aged individuals 
(Deary et al., 2006; Bucur et al., 2008; Kennedy and Raz, 2009). 
Further evidence which supports these findings comes from stereological 
studies conducted in aged human brains (Tang et al., 1997; Pakkenberg et al., 2003) 
and in the brains of aged non-human primates (O'Donnell et al., 1999; Peters, 2002). 
For example, results published by Tang et. al. (1997) indicate that the total volume of 
white matter is reduced in young (mean age 37.4 +/-14.8 years) as compared to old 
(mean age 74+/-11 years) subjects.  Additionally the total calculated end to end 
length of myelinated fibres was found to be reduced (86,000km versus 114,000km) 
in old as compared to young individuals.   This was attributed to a loss of small 
myelinated fibres.  MRI data from studies performed on humans (Guttmann et al., 
1998) and non-human primates (Lai et. al. 1995) support these findings.  A loss of 
white matter integrity in older individuals, as demonstrated using MRI has also been 
associated with impaired performance on behavioural tasks (O'Sullivan et al., 2001; 
Deary, 2003).   Electron microscopy (EM) studies have confirmed that, at the 
ultrastructural level, abnormalities of the myelin sheath are a common feature in 
brain tissue from aged humans and non human primates and that the frequency of 
these abnormalities increases with age (Peters, 2002, 20 9).   
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Whilst it is unclear what pathological mechanisms underlie a loss of white 
matter integrity and the development of white matter damage with ageing, a large 











Figure 1.2  CT scan of a human brain  
Image of a CT scan of a human brain displaying evidnce of white matter hyperintensities. (Image 
courtesy of Centre for Human Genetic Research J. Philip Kistler Stroke Research Centre, Dept. of 
Neurology, Massachusettes General Hospital (http://www.strokegenomics.org)) 
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1.2  Chronic cerebral hypoperfusion 
 
1.2.1  Cerebral blood flow and its regulation 
The brain is critically dependent on a steady uninterrupted blood supply for 
normal function.   In higher mammals blood supply to the brain is facilitated by the 
internal carotid arteries which supply the forebrain nd the basilar artery which 
supplies the hind brain.   Each of these arteries fe ds into an anatomical structure 
named the Circle of Willis (Fig. 1.3).   The Circle of Willis is vital to maintaining 
CBF uniformity throughout the brain.   The circular st ucture of the Circle of Willis 
means that if an artery becomes occluded then the distal arteries which it supplies, 
may receive blood from another artery, this is termed collateral circulation 
(Liebeskind, 2003).   Put simply, an example of collateral circulation would be a 
situation where blood supply to the forebrain is reduced, say due to the presence of 
atherosclerotic plaques in the internal carotid arteries, which is then compensated for 
via recruitment of blood flow from the basilar artery.   The Circle of Willis is 
complete in most mammals, one notable exception beig the gerbil (discussed 
below).   
To highlight how crucial uninterrupted CBF actually is, it is worth 
considering the ratio of tissue weight in the CNS to the volume of oxygen/glucose 
use compared to the rest of the body (table 1.1).   However, unlike the peripheral 
organs (e.g. lungs, heart, liver kidneys), the brain has no glucose or oxygen reserves, 
meaning that any interruption or reduction in CBF may result in disastrous and 









Figure 1.3  Circle of Willis anatomy  
Schematic drawing of Circle of Willis anatomy.  Blood is supplied to the forebrain via the internal 
carotid artery and to the hind brain by the basilar rtery.  Because these two distinct supplies are 
linked (blue arrow) via the posterior communicating artery any reduction in flow through one may be 
compensated for by the other.  (Image taken from http://vetsci.wordpress.com)   
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Table 1.1  Oxygen/ glucose use of the CNS 
(Edvinson, et. al (1993) 
The Central Nervous System 
Accounts for • 2-3% of body weight 
Requires • 15% of cardiac output 
• 20% oxygen 
• 25% glucose 
 
Average CBF in humans is 50ml/ 100g of brain tissue/ min. (Brain, 1993).   
CBF is regulated (under normal physiological conditions) by the brain’s metabolic 
needs due to neuronal activity i.e. as a region becom s functionally active, its 
demand for oxygen and glucose will increase.   In order to meet this increased 
demand CBF must also increase.   This is termed flow-metabolism coupling, or, 
functional hyperaemia.   Functional hyperaemia is achieved via vasodilatory 
responses of the arterioles e.g. if metabolic demand increases then arterioles will 
dilate, cerebral blood volume will increase and metabolic demand will be met 
(Edvznsson, 1993). 
Uninterrupted CBF is maintained via a combination of cerebral perfusion 
pressure and vascular resistance.   In other words, in order to maintain a constant 
CBF, the cerebrovasculature must compensate for fluctuations in perfusion pressure 
via vasodilatory responses e.g. as perfusion pressur  falls then vascular resistance 
must also fall (via vessel dilation) this leads to an increase in cerebral blood volume 
and therefore steady state CBF.   Under normal physiological conditions this is 
facilitated by a mechanism which is dependent upon myogenic, neurogenic, 
endothelial derived, metabolic and chemical/ hormonal factors (Farkas and Luiten, 
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2001) known as autoregulation.   Normally, autoregulation is able to maintain a 
constant CBF provided that blood pressure remains within the range of 60-
160mmHg.  
Autoregulation and the ability to compensate for transient changes in cerebral 
perfusion pressure are due to what is termed the vascul r reserve.   Once this reserve 
is used up i.e. when arterioles are fully dilated and cerebral blood volume has 
reached its maximal point, if metabolic demand increases or perfusion pressure 
drops, then autoregulation fails, rendering the brain vulnerable to ischaemia.   Under 
these conditions, the brain enters a phase known as misery perfusion, also termed 
oligaemia, or, cerebral hypoperfusion, where it attempts to extract more oxygen from 
the blood (Brain, 1993).   Normally the brain extrac s 40% oxygen from the blood 
(Leenders et al., 1990);  this figure is termed the oxygen extraction fraction (OEF).   
Misery perfusion is synonymous with an increased OEF as measured using positron 
emission tomography (PET) scanning (Gibbs et al., 1984).   Eventually the OEF 
reaches its limit and CBF is no longer able to meet th  brains metabolic demands.  
This is defined as ischaemia (Derdeyn et al., 2002).    
In addition to failure of autoregulation, chronic cerebral hypoperfusion may 
occur as a result of changes in blood flow dynamics.   For example the development 
of local areas of microturbulent flow in the microvasculature, as a result of vascular 
alterations associated with either ageing or a vascul r risk factor such as 
atherosclerosis, can alter detrimentally the transport of nutrients across the blood 
brain barrier (BBB) (Farkas and Luiten, 2001).   This may lead to the development of 
microenvironments throughout the vasculature where cerebral metabolism is 
impaired.   Blood viscosity is a second rheological f ctor which may impact 
negatively on cerebral metabolism.   Haematocrit value (Harrison, 1989) and 
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erythrocyte aggregation (Schmid-SchÃ¶nbein, 1983) have been identified as two 
features which impact on blood viscosity.   In particular, haematocrit value has been 
shown to increase in conjunction with carotid artery occlusion, leading to increased 
blood viscosity and in turn lower CBF (Harrison, 1989).   Furthermore, studies in 
both humans (Thomas et al., 1977) and animals (Lin et al., 1995) have shown that a 
lower haematocrit value correlates with reduced blood viscosity and improved CBF. 
Following the development of chronic cerebral hypoperfusion, it is the brain 
regions where CBF is lowest which are rendered most at risk (de Reuck, 1971; 
Pantoni and Garcia, 1997). 
Chronic cerebral hypoperfusion is most often observed in the elderly, where 
CBF, cerebral blood volume and the cerebral metabolic rate of oxygen has been 
shown to reduce by approximately 0.5% per year (Leend rs et al., 1990) in 
conjunction with age related changes to cerebrovascul ture, in particular the 
microvasculature (Farkas and Luiten, 2001).   These changes are detrimental to 
vascular integrity and include increased arteriolar tortuosity, fibrohyalinosis, vascular 
wall thickening and arteriosclerosis (often as a result of hypertension) (Farkas et al., 
2006).   Chronic cerebral hypoperfusion may also occur as a secondary condition 
linked to a primary disease state, for example heart failure.   
 
1.2.2  The impact of chronic cerebral hypoperfusion on white matter integrity 
White matter has been shown to be particularly vulnerable to reductions in 
cerebral blood flow (Pantoni et al., 1996), with large scale epidemiological studies 
highlighting the link between vascular disorders and risk factors for cerebrovascular 
disease, reduced CBF and the development of white ma ter damage.   This has been 
achieved through the application of neuroimaging technology such as CT and MRI 
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scanning in conjunction with post-mortem studies (Breteler et al., 1994; van Dijk et 
al., 2004).   This approach has confirmed that hyperintensities on scans correlate with 
areas of white matter damage (characterised histologically by demyelination, loss of 
oligodendrocytes and vacuolation (Brun and Englund, 1986; Brown and Thore, 
2011) and increased expression of hypoxia related proteins.   Further support for the 
role of hypoperfusion in the development of white matter damage comes from 
studies utilising animal models (see below) where components of white matter have 
been shown to be lost prior to the development of ischaemic damage to neuronal 
perikarya (Wakita et al., 1994; Shibata et al., 2004).  
 
1.2.3  Vascular architecture of the cerebral white matter 
The likely reason for the heightened sensitivity of white matter to CBF 
reduction lies in its vascular architecture.   It is the pattern of this vascular network 
which is thought to leave white matter particularly vulnerable to reductions in CBF 
(Pantoni and Garcia, 1997).   As outlined in section 1.1.1.4, the penetrating arterioles 
in the deep sub-cortical white matter do not arborise but instead give off short 
branches which create metabolic units.   Around these metabolic units border zones 
are created, in other words, because each metabolic unit is fed by only one branch 
from one penetrating artery, this means there are no other surrounding vessels which 
may compensate for a reduction in nutrient delivery should CBF in the branch 
servicing that metabolic unit be reduced (Rowbotham and Little, 1965).   Essentially, 
as far as blood supply is concerned, white matter is the end of the line.   
1.2.4  Animal models of hypoperfusion 
A wide range of conditions may lead to the onset of chronic cerebral 
hypoperfusion in humans and these often occur concomitantly and have overlapping 
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pathologies.   For this reason, the most appropriate way to examine the pathological 
impact of hypoperfusion on brain white matter and how this in turn affects cognition, 
in isolation, is through the utilisation of animal models.  
The first animal model of cerebrovascular disease was the stroke prone 
spontaneously hypertensive rat (SHRSP) (Okamoto, 1973).   These rats develop 
abnormally high blood pressure by age 4-5 months and neurological deficits at 
approximately 6 months and their average life span is greatly reduced (approximately 
12 months).   Pathological studies conducted on this strain have revealed that 
fibrinoid necrosis occurs in intracerebral arterial walls in conjunction with 
rarefaction of the white matter and the neuropil (Ogata et al., 1982).   Since the 
SHRSP, a wide range of cerebrovascular disease models, including models of 
cerebral hypoperfusion have been developed using several different species including 
rodent, cat, dog and non-human primate.   Of these, the most consistently used has 
been rodent (rat, gerbil and mouse), due to economic and ethical acceptability issues 
(Sarti et al., 2002). 
The most often used and well characterised animal model of hypoperfusion is 
the bilateral common carotid artery occlusion (BCCAO) or 2 vessel occlusion (2VO) 
model in the rat.   Following ligation of the bilateral common carotid arteries an 
immediate reduction in CBF (to as low as 25% of baseline levels) is seen in the 
forebrain (Farkas and Luiten, 2007).   Over a period of months CBF in experimental 
animals returns to normal, initially due to collater l stabilisation (Liebeskind, 2003) 
which is then followed by a period of vascular remodelling (Choy et al., 2006).   This 
is accompanied by progressive neuronal cell loss, particularly in the striatum and 
CA1 region of the hippocampus and also moderate to s vere white matter rarefaction 
and gliosis.   White matter regions most affected are the corpus callosum and the 
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optic tract (Wakita et al., 1994).   Cognitive testing in this model has revealed a 
number of cognitive deficits which become more pronounced over time; including 
visiospatial learning, fear conditioning and other aspects of non-spatial memory 
(Farkas et al., 2007).   Whilst it is clear that white matter damage occurs following 
2VO in the rat, it has not been possible to conclude that white matter damage alone is 
responsible for the observed changes in cognition.   This is due to the fact that 
ischaemic damage to neuronal perikarya is often observed and secondly because the 
most vulnerable region to CBF reduction is the optic tract which raises questions as 
to the validity of results from tests which rely onvisual cues.  
The gerbil has also been used in an attempt investigate the impact of 
hypoperfusion on white matter.   In this model, coiled clips termed microcoils, were 
used to induce hypoperfusion.   The main advantage of using microcoils to induce 
hypoperfusion is that they cause a stenosis of the vessel to which they are attached as 
opposed to a complete ligation as seen in the 2VO rat model, thus causing a more 
modest CBF reduction (Kato and Kogure, 1990).   A further advantage of microcoils 
is that the pitch and diameter of the coils may be modulated to permit more or less 
blood to flow along the artery allowing conditions of varying severity to be 
modelled.   A disadvantage of the gerbil as a species for this type of study is its 
inability to tolerate CBF reductions due to species variability in its cerebrovascular 
architecture.   Unlike other rodents, the gerbil has an incomplete Circle of Willis 
owing to the absence of a posterior communicating artery; consequently there is no 
collateral circulation available to compensate for sudden CBF reductions, therefore 
damage caused by bilateral carotid artery stenosis (BCAS) is severe (global 
ischaemia) (Hattori et al., 1992). 
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More recently microcoils have been used to develop a mouse model of 
hypoperfusion (Shibata et al., 2004) using C57Bl/6J mice.   The C57Bl/6J strain is 
considered particularly suited to studies investigatin  cerebral hypoperfusion because 
of its cerebrovascular architecture, where collateral flow within the Circle of Willis is 
compromised due to underdevelopment of the posterior communicating artery 
(Kitagawa et al., 1998; Shibata et al., 2004).   Itis also the most commonly used 
inbred strain of laboratory mouse when generating transgenic mouse models of 
human disease.   Optimisation of this model was conducted such that the diameter of 
microcoils used was sufficient to induce wide spread d mage exclusively to white 
matter.   Using 0.18mm diameter coils, modest damage was apparent in 
hypoperfused mice 14 days following induction of hypoperfusion;  this had become 
severe by the 30 day time point.   This occurred in co junction with initial reductions 
in CBF, measured at two hours to 67.3 ± 18.5% baseline levels, a considerably more 
modest reduction than that seen in the 2VO model.   CBF was still significantly 
lower than baseline at day 14 and was approximately 10-15% below baseline at 30 
days (Fig 1.4) (Shibata et al., 2004; Shibata et al., 2007).   Behavioural testing in this 
model revealed a deficit in working memory 8 weeks following hypoperfusion in the 
absence of any changes in spatial reference memory.   No other behavioural deficits 
were observed (Shibata et.al. 2007). 
The mouse model of hypoperfusion described above repres nts an excellent 
tool with which to study hypoperfusion induced white matter pathology in detail and 
also how hypoperfusion may impact on cognition.   It may also be applied to 
transgenic mouse strains in an effort to understand how chronic hypoperfusion may 










Figure 1.4 CBF reductions in the mouse following microcoil application 
Using a 0.18mm microcoil (diamond symbol) CBF reductions are initially reduced to ~70% of 
baseline and recover to ~90% of baseline by 30 days.  Data shown published by Shibata et al. 2004. 
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1.3  Alzheimer’s disease 
Alzheimer’s disease (AD) is a neurodegenerative disease and is the most 
frequently diagnosed form of dementia in the elderly in the developed world.   It is 
estimated that currently 35 million people are affected by AD worldwide (Querfurth 
and LaFerla, 2010) and that this figure is set to double every 20 years as average life 
expectancy increases (Qiu, 2007).   In the UK it isestimated that there are currently 
over 750,000 dementia sufferers and that by 2025 this number will have risen to over 
2 million.   The current financial cost of dementia o the UK is over £20 billion 
annually (Jonsson and Wimo, 2009).   The single most important risk factor for the 
development of AD is age (Bartzokis, 2004);  people ov r the age of 65 are much 
more likely to display clinical symptoms.   The incidence of the disease increases 
with age, doubling every 5 years after age 65, until by age 85, more than one in three 
individuals receive a clinical diagnosis (Querfurth and LaFerla, 2010). 
1.3.1  The clinical and pathological characterisation of AD 
Clinically, AD is characterised in its earliest stages by the development of 
deficits in episodic memory, followed by a noticeable deterioration in other elements 
of cognition.   Onset of these symptoms may occur up to 2-3 years prior to AD 
diagnosis (Fox et al., 1998).   Mean survival time is 6-8 years following diagnosis.   
The latter stages of the disease are characterised by behavioural changes, manifest as 
depression and aggressive behaviour and eventually a loss of language and motor 
skills and finally death (Hope et al., 1997).   A point of note is that AD itself does not 
cause death.   IIn AD patients death occurs most often due to an underlying or co-
existing condition such as an opportunistic infection e.g. pneumonia or due to 
choking, or due to malnutrition and/ or dehydration (Castellani et. al. 2010;  
26 
AD diagnosis may only be confirmed post-mortem although regional 
hypoperfusion on brain imaging scans has been identified as a strong predictor of 
disease development (Luckhaus et al., 2008) (discussed later).   Pathologically AD is 
characterised by the abnormal accumulation of Αβ protein sequestered within 
extracellular amyloid plaques and the presence of intraneuronal neurofibrillary 
tangles comprised of hyperphosphorylated tau protein (Selkoe and Podlisny, 2002).   
These plaques and tangles are predominantly found in regions that play important 
roles in learning and memory formation such as the hippocampus, frontal cortex, 
amygdala and entorhinal cortex.   Other key features of the disease include 
widespread neuronal cell loss and atrophy in affected brain regions, inflammation 
and oxidative stress (Castellani et al., 2010). 
 
1.3.2  Generation of Aβ 
Amyloid precursor protein (APP) is a transmembrane protein with three 
major isoforms (695kDa, 751kDa and 770kDa) (Turner et al., 2003) which are 
expressed throughout the body in different tissue specific, isoform ratios (Selkoe et 
al., 1988).   Within the brain the most abundant APP isoform is 695kDa.   The 
functional role of APP is unknown however various studies have implicated a role 
for APP in axonal transport, cell adhesion, cholesterol metabolism, gene 
transcription, synaptic plasticity and synaptogenesis (Turner et al., 2003; Gralle and 
Ferreira, 2007). 
Generation of Aβ is achieved via sequential cleavage of full length APP 
(Glenner and Wong, 1984a, 1984b) by a series of enzymes or enzyme complexes 
(α−, β− and γ− secretases).   Cleavage of APP by α−secretase results in non-
pathological, or, non-amyloidogenic processing of APP as cleavage of APP occurs 
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within the region containing β− amyloid.   Two fragments are generated, a C-
terminal fragment 83 amino acids long (C83) and a large N-terminal fragment; 
sAPPα.   sAPPα is secreted  extracellularly whilst C83 undergoes further cleavage 
by γ−secretase to produce a short fragment termed p3.   Pathological or, 
amyloidogenic processing of APP occurs when the APPparent protein is cleaved by 
β−secretase (BACE-1) in the first instance, generating fragments sAPPβ and the c-
terminal fragment C99.   C99 undergoes further cleavage by γ−secretase resulting in 
the production of the 4kDa Aβ protein (Fig. 1.5) (LaFerla et al., 2007a).   Under 
normal physiological conditions it is estimated that the majority of Aβ protein 
produced is 40 amino acids (Aβ1−40) in length whilst approximately 10% is 42 
residues in length (Aβ1−42).   Aβ1−42 is more hydrophobic and more prone to 
aggregation and fibril (insoluble species) formation and is also the principal form 
found in extracellular plaques whilst the vascular deposits of Aβ seen in cerebral 
amyloid angiopathy (CAA) are comprised mainly of Aβ1−40 (Jarrett et al., 1993).   
Changes in the APP processing pathway, leading to increased Aβ production and 
also changes in the Aβ1−40: Aβ1−42 ratio, are known to underlie the development of 















Figure 1.5 The APP processing pathway 
APP is cleaved via either the non-amyloidogenic pathw y (left) or the Aβ forming, amyloidogenic 
pathway (right).   (Image from http://www.fbs.leeds.ac.uk/staff/Hooper_N/alzheimers.htm) 
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1.3.3  Assembly states of Aβ protein and the amyloid cascade hypothesis 
The biggest advance in the field of AD research in nearly 100 years was the 
identification of Aβ as the major protein component of amyloid plaques and the 
discovery that it was the proteolytically derived product of APP cleavage (Glenner 
and Wong, 1984a, 1984b).   The subsequent cloning of the APP gene (Kang et al., 
1987) led to the identification of several mutations linked to the development of 
familial AD (Levy et al., 1990; Goate et al., 1991; St George-Hyslop, 2000) and the 
formulation of the amyloid cascade hypothesis (Hardy and Allsop, 1991; Selkoe, 
1991) which states that ‘accumulation of Aβ in the brain is the primary influence 
driving AD pathogenesis’ and that ‘the rest of the disease process, including 
formation of neurofibrillary tangles containing tau protein, results from an imbalance 
between Aβ production and Aβ clearance’ (Hardy and Selkoe, 2002).   Significant 
weight was lent to the amyloid cascade hypothesis with the discovery of mutations in 
the genes Presenelin 1 (PS1) (Sherrington et al., 1995) and Presenelin 2 (PS2) 
(Rogaev et al., 1995; Levy-Lahad et al., 1995a; Levy-Lahad et al., 1995b) which 
form part of the γ-secretase complex in the APP processing pathway.   These 
mutations have been demonstrated to cause increased production and oligomerisation 
of Aβ1-42 (Scheuner et al., 1996; Xia et al., 1997).   A major criticism of the amyloid 
cascade hypothesis however, is that plaque load is known not to correlate well with 
severity of dementia (Giannakopoulos et al., 2003).   This has led to various studies 
examining the neurotoxicity of different Aβ species.  
Following amyloidogenic cleavage of APP, the Aβ protein is prone to 
aggregation and may exist in a number of different assembly states.   These include 
monomers, oligomers, protofibrils and fibrils (Fig. 1.6).   Monomers, oligomers and 
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protofibrils are soluble species whilst fibrils, whic  aggregate to form extracellular 
plaques, are insoluble (Walsh et al., 2002).   
Studies examining the toxicity of the various species of Aβ indicate that it is 
the intermediate species which are most harmful, particularly oligomers (Lesne et al., 
2006; Shankar et al., 2008).   These are thought to cause synaptic dysfunction, which 
may be the cause of early cognitive deficits observed in both animal models and 
humans (Oddo et al., 2003b; LaFerla et al., 2007b).   It has also been suggested that 
oligomeric Aβ causes neuronal cell death (Cizas et al., 2010);  the method by which 
this occurs however, is unknown.   Several mechanisms of Aβ toxicity have been 
proposed.   These include Aβ induced mitochondrial dysfunction, production of 
reactive oxygen species and oxidative stress, impair ent of synaptic transmission, 
membrane disruption, upregulation of the inflammatory response, calcium 
dysregulation and also direct activation of the apoptotic pathway (Cotman and 
Anderson, 1995; Griffin et al., 1995; Huang et al., 1998; Billings et al., 2005; 
Caspersen et al., 2005; Lau et al., 2006). 
Aβ Oligomers Protofibrils Fibrils
 
Figure 1.6  Assembly states of Aβ  
Studies examining Aβ have found that it aggregates readily to form a number of soluble and insoluble 
species, monomers, oligomers (toxic), protofibrils and fibrils. (Image based on Laferla (2007)) 
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1.3.4  Tau protein and neurofibrillary tangle pathology in AD 
Tau is a microtubule associated protein found within neurons of the CNS.   Its 
primary role is the stabilisation of microtubules, this is achieved via differential 
isoform expression (tau has six isoforms which differ rom one another in the 
number of tubulin binding repeats they contain and lso the amino acid sequence of 
their N-terminal domain) and also tau phosphorylation (Ballatore et al., 2007).   In 
AD, tau becomes hyperphosphorylated which causes its detachment from 
microtubules.   Hyperphosphorylated tau is functionally inactive however it can 
cause the disassembly of microtubules; this is thoug t to occur due to its competing 
with tubulin for the binding of normal tau.   This is because hyperphosphorylated tau 
acts as a nucleation centre to which normal tau binds, causing aggregation and the 
development of neurofibrillary tangles within neurons (Alonso et al., 2001).   
Hyperphosphorylated tau has been shown to be neurotoxic and unlike 
extracellular plaque load, the number of neurofibrillary tangles present in AD brains 
has been shown to correlate with severity of cognitive decline observed in patients 
(Arriagada et al., 1992).   Proposed mechanisms of tau toxicity in AD include 
disruption of axonal transport leading to synaptic dysfunction and ultimately 
neurodegeneration (Roy et al., 2005), or potentially,  toxic gain of function where 
the neurofibrillary tangles become large enough to pose a physical barrier to normal 
cellular functioning (Ballatore et al., 2007).   
Results from studies conducted in animal models have shown that a 
relationship between Aβ and tau exists and that this is in agreement with the 
relationship predicted by the amyloid cascade hypothesis to some degree.   Tau 
transgenic mice do not develop Aβ pathology however; introduction of Aβ1-42 fibrils 
into the brains of tau overexpressing transgenic mie has been shown to cause a 5- 
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fold increase in levels of neurofibrillary tangles (Gotz et al., 2001).   Also when tau 
transgenic mice (JNPL3) are crossed with APP overexpressing mice (Tg2576), their 
offspring have higher levels of neurofibrillary tangle pathology as compared to 
JNPL3/ JNPL3 mice (Lewis et al., 2001).   The mechanism by which Aβ influences 
the development of neurofibrillary tangles is unknow , however several studies have 
shown that in the presence of Aβ, tau phosphorylation is modulated.   This is thought 
to be either via the upregulation of tau kinases (e.g. GSK-3β or CDK-5) or the down 
regulation of protein phosphatases which regulate tu phosphorylation (e.g. PP2A) 
(Iqbal and Grundke-Iqbal, 2008) or, indirectly via upregulation of the inflammatory 
response (Metcalfe and Figueiredo-Pereira, 2010). 
Much work has been conducted to characterise amyloid and tau pathology in 
AD and their impact on brain function.   More recently however, the research focus 
within the AD field has shifted away from the characteristic disease pathology and 
more towards early events in the AD brain and what potentially may underlie these. 
 
1.3.5  Risk factors for the development of AD 
Despite a significant research effort, both clinical and basic, the underlying 
causes of AD remain unknown.   Mutations in the thre key genes outlined in section 
1.3.3, namely Amyloid Precursor Protein (APP) and Presenilins 1 & 2 (PS1, PS2) 
have been identified as the cause of early onset AD, or familial AD as it is known 
(due to its heritability as an autosomal dominant condition), however, this form of 
the disease accounts for less than 1% of clinical diagnoses (Hardy, 2009).   Several 
risk factors have been implicated in the development of late onset (also known as 
sporadic) AD. 
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For many years the only known major genetic risk factor for the development 
of late onset AD was to be a carrier of the APOE4 allele of the Apolipoprotein E 
gene (Strittmatter et al., 1993; Hardy, 2009).   Carriers homozygous for the APOE4 
allele have an increased risk of up to 30 times as compared to those not carrying the 
APOE4 allele of developing AD in later life.   More cently however, a number of 
other genes have been identified which are thought to confer increased risk of 
developing sporadic AD.   These include, but are not limited to, SORL1 (Rogaeva et 
al., 2007), A2M (Dodel et al., 2000), GSTO1 (Li et al., 2003), Clusterin (Lambert et 
al., 2009).  
In addition to the aforementioned genes, several environmental and lifestyle 
risk factors have been linked via epidemiological studies with the development of 
AD in later life.   These include traumatic brain injury (Lye and Shores, 2000) and 
severe cerebrovascular challenges such as stroke (Sch inberg, 1988).   As well as 
stroke, numerous other factors which lead to a more subtle, long term reduction in 
cerebral perfusion are thought to contribute towards AD development.   Many of 
these are associated with ageing and have a vascular component e.g. smoking, poor 
diet, lack of exercise, atherosclerosis, arteriosclerosis, hypertension, heart failure (for 
review see (de la Torre, 2004)).   Furthermore, specific patterns of cerebral 
hypometabolism and hypoperfusion have been identifid as being a reliable indicator 
as to whether an individual develops AD in later life and these may be detected 






1.3.6  Hypoperfusion in Alzheimer’s disease 
Regional cerebral hypoperfusion has been recognised a  a feature of AD for 
some time.   Initially there was some debate as to whether this was a contributing 
factor to disease development or as a result of disease related brain atrophy. 
Early blood flow studies, conducted in AD patients, utilising the 133Xe 
inhalation CT scanning method identified significant reductions in whole brain 
perfusion in AD patients as compared to healthy agematched controls and also 
disease specific reductions within the temporopariet l cortex (Prohovnik et al., 
1988).   These findings were recapitulated using more s phisticated and less invasive 
neuroimaging methods e.g. arterial spin labelling MRI and single photon emission 
CT (SPECT) scanning, which were also able to identify specific patterns of regional 
hypoperfusion which strongly indicated that AD development in later life was likely 
(Hirao et al., 2005; Matsuda, 2007).   Many studies conducted to examine the 
correlation between regional hypoperfusion and degre  of cognitive decline in AD 
patients, have shown that a strong proportional relationship exists (Farkas and 
Luiten, 2001). 
Functional MRI (fMRI) studies have shown that task ssociated increases in 
CBF are delayed in patients with mild cognitive impairment (MCI) during 
performance of episodic memory tasks and that these d lays become more prominent 
in AD patients (Rombouts et al., 2005).   This is of particular importance as MCI is 
thought to be a transitional condition between normal health and the development of 
AD thus implying hypoperfusion and altered CBF regulation are early events in AD 
as opposed to a result of brain atrophy following disease progression. 
Several hypotheses have been proposed to account for reductions in CBF 
during AD pathogenesis.   These include observed atherosclerotic changes to vessels 
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within the Circle of Willis (Kalback, 2004), or, disease associated microvascular 
pathology e.g. arteriole and capillary atrophy, microvascular collagen deposition, the 
presence of endothelial cell abnormalities and damage, reduced microvascular 
density and altered basement membrane composition (Kalaria and Pax, 1995; Berzin 
et al., 2000; Farkas and Luiten, 2001; Grammas, 2002).   CBF reductions in AD have 
also been attributed to a loss or dysfunction of cholinergic innervation (Bell et al., 
2006).   It is well established that a loss of cholinergic neurotransmission due to the 
loss or shrinkage of cholinergic neurons in the basal forebrain is an early event in AD 
pathogenesis.   These neurons have been shown to project to the microvasculature of 
the frontoparietal cortex where they act to cause acetylcholine (ACh) mediated vessel 
dilation, thus their loss in AD has a pathophysiological impact on CBF (Farkas and 
Luiten, 2001).   
A more recent study conducted by (Wu et al., 2005) has shown that in AD 
patients, endothelial expression of the MEOX2 gene is significantly lower than in 
age-matched healthy controls.   MEOX2 has been identified as being important for 
vascular differentiation, further more it has also been shown to mediate expression of 
the LRP1 receptor which plays a prominent role in Aβ clearance (Tanzi et al., 2004).   
This has led researchers to hypothesise that its down regulation in AD may lead to 
aberrant angiogenesis and hence reductions in CBF as well as impaired Aβ 
clearance.   A further cause of hypoperfusion in AD is the presence of CAA which is 
present in >80% of AD patients (Bell and Zlokovic, 2009).   Imaging studies have 
shown that patients with CAA display significantly reduced levels of CBF in brain 
regions where pathology is present as compared to age matched controls (Chung et 
al., 2009).  
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Whilst much of the work discussed above refers to neuroimaging studies 
conducted in conjunction with post-mortem studies in humans, evidence has also 
been gathered from studies utilising ex-vivo and in-vivo animal models which 
supports a role for altered CBF in AD.   Interestingly, this work has demonstrated 
that Aβ1-40 in particular impacts detrimentally on neurovascular CBF regulation. 
The first study implicating a role for Αβ in cerebrovascular dysfunction was 
conducted in 1996 (Thomas et al., 1996).   In this study, conducted ex-vivo, it was 
shown that Aβ caused damage to vascular endothelial cells and that this impacted on 
vasoactivity.   A number of in-vivo studies soon followed.   In 1999 Iadecola et al. 
showed that endothelial vascular regulation was attenuated in APP transgenic mice 
(Iadecola et al., 1999) and in 2000, Niwa et al. showed that somatosensory induced 
functional hyperaemia was impaired in a transgenic mouse model of AD as 
compared to non transgenic controls and that this impa rment correlated with total 
levels of brain Aβ (Niwa et al., 2000).   They also produced a similar effect in wild 
type mice by addition of exogenous Aβ1-40 to the cortex.   In a separate study (Niwa 
et al., 2001) it was shown that addition of exogenous Aβ to the brains of wild type 
mice was sufficient to cause regional reductions in resting CBF.   In all of these 
studies the Aβ induced CBF alterations were rescued by the superoxide scavenging 
enzyme superoxide dismutase (SOD) thus implicating a role for superoxide radicals 
and oxidative stress in AD related vascular alterations. 
Higher levels of the vasoconstrictor endothelin-1 in the AD brain have also 
been suggested as a potential candidate underlying CBF reduction (Palmer et al., 
2009; Palmer et al., 2010).  It is well established that endothelin converting enzymes 
1 and 2 (ECE-1, ECE-2), in addition to cleaving endothelin to produce endothelin-1 
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(ET-1), also degrade Aβ (Εckman et al., 2001).  Higher levels of ET-1 have been 
shown to be present in the human AD brain and also in mice over-expressing mutant 
human APP. Furthermore in ECE-2 null mice, and in ECE-1 heterozygotes, levels of 
endogenous Aβ were found to be higher than in litter mate controls (Eckman et al., 
2003).  Preserved endothelial function has been demonstrated in the presence Aβ 
following administration of an ET-1 antagonist (Elesb r et al., 2006) thus 
demonstrating a potential role for ET-1 in endothelial cell dysfunction in AD which 
may underlie CBF reductions associated with the early stages of the disease (Palmer 
et al., 2010).  
 In addition to the impact of Aβ on CBF regulation, other work utilising APP 
transgenic mice has shown that as well as regional reductions in brain metabolism 
APP transgenics are more susceptible to ischaemic damage (Zhang et al., 1997).   
More recently, through the use of both autoradiography (Niwa et al., 2002) and more 
sophisticated MRI techniques (Wu et al., 2004; Weidensteiner et al., 2009) regional 
alterations in CBF have been identified in various APP over-expressing transgenic 
animals.   The fact that these alterations occur prior to overt CAA or amyloid plaque 
pathology in these models lends significant weight to the argument that altered CBF 
is an early rather than late event in AD pathogenesis. 
 
1.3.7  White matter integrity and Alzheimer’s disease 
Given the large number of vascular risk factors linked to the development of 
AD and also the identification of hypoperfusion as n early feature in AD 
development, it could be argued that, it is of little surprise a prominent feature of the 
AD brain is the presence of white matter abnormalities (Brun and Englund, 1986; 
Bartzokis et al., 2003; Riekse et al., 2004).   Increasingly, changes to brain white 
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matter are being recognised as an early event in AD (de la Monte, 1989) prior to the 
development of characteristic plaque and tangle pathology, this has been shown in 
humans (Stokin et al., 2005; deToledo-Morrell et al., 2007) and animal models 
(Wirths et al., 2007; Desai et al., 2009).   Furthermore as many as 66% of AD brains 
exhibit evidence of white matter pathology post-mortem in addition to plaques and 
tangles (Roher et al., 2002).    
Neuroimaging is being used with increasing frequency to detect early 
changes to brain white matter in AD.   Many studies have been conducted examining 
individuals with MCI prior to AD conversion (DeCarli et al., 2001) and also in 
individuals exhibiting clinical symptoms of AD (Stout et al., 1996), where white 
matter abnormalities are found to be present with even greater frequency.   A number 
of these studies have identified the splenium of the corpus callosum and the frontal 
and temporal lobes as being the initial areas where white matter damage is detected 
in AD (Duan et al., 2006; Naggara et al., 2006; Ukmar et al., 2008), and that this 
damage becomes more severe with disease progression (Dua  et al., 2006; Di Paola 
et al., 2010). 
Evidence from pathology studies has also been used to demonstrate that white 
matter changes are an early feature of AD.   De la Monte (1989) reported that 
regional white matter shrinkage, in the absence of cortical pathology was a common 
feature observed in the pre clinical AD brain.   Ina  earlier, more detailed study, 
Brun and Englund (1986) described pathological changes to white matter in AD.   
These were characterised by myelin loss, axonal degeneration and damage to 
oligodendrocytes and also activation of inflammatory cells, all in conjunction with 
microvascular pathology.   Interestingly the authors hypothesised that this damage 
was due to hypoperfusion due to the fact that many of the subjects exhibited signs of 
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cardiovascular disease coupled with hypotension.   Other white matter changes 
occurring in AD include abnormalities of the myelin sheath, detectable at the ultra 
structural level and also disruption of the axonal cytoskeleton and in turn axonal 
transport (Stokin et al., 2005; Wirths et al., 2006).   
Why white matter pathology is exacerbated in AD is unknown, however, Aβ 
has been shown to be toxic to oligodendrocytes (Guela et al., 1998; Xu et al., 2001; 
Roth et al., 2005) and Aβ toxicity is known to be exacerbated with ageing (Guela et 
al., 1998).   Interestingly oligodendrocytes in-vitro have recently been identified as a 
source of Aβ (Skaper et al., 2009).   Several studies have hypothesised that Aβ 
toxicity is via the production of reactive oxygen species due to mitochondrial 
dysfunction which in turn leads to the activation of the sphingomyelinase-ceramide 
pathway and apoptosis (Lee et al., 2004; Hsu et al., 2010).   Abnormally 
phosphorylated tau protein has also been shown to be neurotoxic.   The 
hyperphosphorylation of tau is thought to cause destabilisation of the axonal 
cytoskeleton (Roy et al., 2005) which in turn may lead to disruption of axonal 
transport.   However, whilst disruption of axonal tr nsport in AD is known to occur 
early in the disease process, whether this is a cause or a consequence of the disease 
remains to be elucidated (Stolin et. al. 2005). 
1.3.8  Animal models of AD 
Numerous transgenic mouse models of AD have been crated since the 
identification of mutations in three genes (APP, PS1 and PS2) which are linked to the 
development of familial AD.   A large number of models now exist which 
recapitulate a range of AD related pathologies.   Despite the fact that none of the 
models fully replicates the disease they have been extremely useful in determining 
40 
how Aβ and tau pathology develop and also how these pathologies interact and how 
they impact on normal brain function.  
The most commonly utilised method by which transgenic mice are created is 
via pronuclear injection (Elder et al., 2010), where foreign DNA (transgene of 
interest) coupled to a promoter which drives expression is injected into a freshly 
fertilised embryo.   The transgene is then integrated (randomly and often at multiple 
sites) into the mouse genome.   This technique is efficient, ~80% of mice created in 
this manner are true transgenics (every cell has a copy of the transgene) however due 
to the random nature of transgene integration different founder mice display different 
levels of protein expression (Evans, 1994).   Almost all transgenic mice created in 
this manner are hemizygous for the gene of interest; al o because the promoters used 
to drive transgene expression are typically strong, the transgenic protein tends to be 
expressed at much higher levels than would be present physiologically (Elder et al., 
2010). 
The earliest successful transgenic models of AD were based on over 
expression of human APP transgenes containing mutations identified as underlying 
early onset AD e.g. the PDAPP (Games et al., 1995) and the Tg2576 (Hsiao et al., 
1996) mouse strains.   These mice develop extracellular plaque pathology, synaptic 
dysfunction and cognitive deficits in an age dependent manner.   Around the same 
time transgenic mice over-expressing human PS1 genes containing AD related 
mutations were also created (Duff et al., 1996).   Whilst endogenous Aβ1-42 levels 
were increased in these PS1 transgenic animals, extrac llular pathology was lacking, 
this has been attributed to the fact that endogenous mouse Aβ is less prone to 
aggregation than human Aβ (Jankowsky et al., 2007).   However, when these mice 
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were crossed with plaque forming APP over-expressing a imals, earlier and more 
extensive plaque formation occurred (Holcomb et al., 1998). 
One of the major issues facing researchers attempting to model AD in mice 
has been that despite the evidence of overt Aβ pathology in many of the transgenic 
lines created, neurofibrillary tangle pathology is almost always absent.   This has 
been overcome by the discovery of a mutation in the human tau gene (P301L) 
(Hutton et al., 1998) which underlies the development of another distinct type of 
dementia, known as frontotemporal dementia and parkinsonism linked to 
chromosome 17 (FTDP-17).   Mice transgenic for human P301L tau readily develop 
neurofibrillary tangle pathology which correlates with levels of cognitive decline 
(Lewis et al., 2000).  
The first transgenic line to successfully model both plaque and tangle 
pathology was created in 2001 by Lewis et al. (Lewis et al., 2001).   This was 
achieved by crossing APPSwe over-expressing APP Tg2576 mice with JNPL3 
transgenic mice expressing mutant P301L tau.   Shortly after this in 2003, Oddo et al 
derived a triple transgenic (3xTg-AD) mouse strain by utilising a novel co 
microinjection technique where two transgenes (APPSwe and tauP301L) were injected 
into single cell embryos from homozygous PS1M146V knockin mice (Oddo et al., 
2003b).   The resulting 3xTg-AD strain was suggested by many to be the most 
accurate mouse model of human AD as cognitive changes occur prior to the 
development of overt AD pathology and also the emergence of amyloid and tau 
pathology follow a similar temporal pattern to that seen in the human form of the 
disease.  
In 3xTg-AD mice Oddo et al. initially reported that intraneuronal Aβ was 
present from 3-4 months of age in the cortex and by 6 months in the hippocampus, 
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this was followed by the development of extracellular cortical Aβ deposits in some 
animals from 6 months which became readily visible and also evident in the 
hippocampus by 12 months of age in all animals.   Tau pathology was first apparent 
in the hippocampus at 12 months and progressed to cortical structures with age.  
Hyperphosphorylated forms of tau were evident in neurons from 12-15 months.   
This pathology was accompanied by deficits in synaptic dysfunction and long term 
potentiation (LTP) from six months onwards (Oddo et al., 2003b).  
Other work utilising 3xTg-AD mice has shown that in addition to deficits in 
LTP and synaptic function these animals develop cognitive deficits in accordance 
with the emergence of intraneuronal (oligomeric) Aβ pathology; furthermore these 
cognitive changes are rescued by Aβ immunotherapy which causes a reduction in 
intraneuronal Aβ  levels.   Following this, re-emergence of intraneuronal Aβ 
pathology again leads to cognitive deficits (Billings et al., 2005).   This finding was 
key in establishing a role in toxicity for oligomeric Aβ species.   Another interesting 
finding from a separate study utilising immunotherapy in 3xTg-AD mice has shown 
that clearance of Aβ leads to a reduction in levels of early forming 
hyperphosphorylated tau aggregates thus providing further support for the amyloid 
cascade hypothesis (Oddo et al., 2004). 
More recently, work employing the 3xTg-AD model has provided further 
evidence for white matter changes as an early event in the pathogenesis of AD.   In 
animals where intraneuronal pathology but not plaque or tangle pathology was 
present regional reductions in white matter protein l vels (MBP and CNPase) and 
alterations in the myelin sheath at the ultra structural level were observed in 
conjunction with a reduction in levels of oligodendrocyte markers (Desai et al., 2009; 
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Desai et al., 2010).   In addition to the 3xTg-AD model, white matter damage has 
been identified as being present in other AD models.   Wirths et al. (2006) reported 
the presence of progressive axonal damage in APP/PS1 transgenic mice whilst other 
groups have utilised diffusion tensor imaging to identify axonal and myelin damage 
in APP transgenic strains (Song et al., 2004; Sun et al., 2005).  
Despite the identification of a number of vascular risk factors which underlie 
the development of both white matter damage and AD, and also the identification of 
reduced CBF and white matter damage in several AD models, few studies have been 
conducted utilising animal models to investigate how these may be linked to AD 
pathogenesis. 
 
1.4  Aims of thesis 
The creation of a mouse model of chronic cerebral hypoperfusion, which 
allows CBF to be modulated such that selective white matter damage may be 
induced, has provided a powerful tool which can be us d to investigate how white 
matter damage impacts on cognition in the absence of other confounding factors.   
This model may also be utilised in 3xTg-AD mice to investigate how hypoperfusion 
impacts on the development of Aβ pathology.   This thesis set out to test the 
hypothesis that chronic cerebral hypoperfusion underlies the development of white 
matter pathology and cognitive decline and additionally that chronic cerebral 
hypoperfusion causes the development of Aβ pathology in AD. 
 
The specific aims of this thesis were- 
1. To investigate the temporal evolution of white and grey matter pathology in a 
mouse model of chronic cerebral hypoperfusion. 
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2. To characterise in detail which components of white matter are selectively 
damaged following hypoperfusion and to investigate the impact of 
hypoperfusion induced white matter damage on different elements of 
cognition. 
3. To investigate how varying severities of hypoperfusion may impact on the 
development of white matter and intraneuronal Aβ pathology in 3xTg-AD 
mice. 
4. To investigate how ageing may impact on white matter protein composition 
and also how ageing may confer increased vulnerability of white matter to 
hypoperfusion in 3xTg-AD mice.   
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Chapter 2:  Materials and Methods 
2.1  Mice 
All animals used in studies reported were housed in the animal housing unit 
within The Centre for Cognitive and Neural Systems (CCNS), University of 
Edinburgh.   The unit was on a 12h light/dark cycle with a regulated environment 
(temperature, humidity).   All mice were given access to food and water ad libitum 
upon arrival in the facility.   All experiments were conducted under a project and 
personal licence issued by the UK Home Office under the Animals (Scientific 
Procedures) Act 1986.   
 
2.1.1  C57Bl/6J Mice 
C57Bl/6J male mice weighing 25-30g were purchased from Charles River 
UK.   
 
2.1.2 3xTg-AD Mice 
The 3xTg-AD mouse strain used in studies reported in this thesis was 
originally generated by Oddo et al. in 2003 (Oddo et al., 2003a).   Briefly, single cell 
embryos were harvested from homozygous mutant PS1M146V knockin mice (PS1-KI).  
The PS1-KI mice were created on a C57/Bl6J/ SV-129 mixed background by 
exchanging a homologous exon from the mouse PS-1 gene with one which encoded 
an AD-linked PS-1 mutation (Guo et al 1999).   Two human transgenes were 
comicroinjected into the embryos (human APPSwe and human tauP301L).   See Fig 2.1. 
Both transgenes were under transcriptional control of the mouse Thy1.2 
regulatory element which drives transgene expression pecifically within the CNS 
from early in post natal development through to adulthood (Caroni, 1997).   Founder 
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lines harbouring all three transgenes were identifid and back crossed to PS1-KI 
mice to maintain the M146V mutation.   Subsequent aalysis of transgene 
inheritance pattern showed that both the mutant human transgenes were inherited 
with 100% frequency suggesting that both had co-integrated at the same locus and 
would be consequently passed onto offspring as a pair at a single genetic locus 
(Oddo et al., 2003b). 
Breeding pairs of 3xTg-AD mice were obtained via a collaboration with 
Frank LaFerla and a homozygous colony established and maintained.   Transgene 
expression was initially determined via PCR genotyping.  All 3xTg mice utilised in 




Figure 2.1  Generation of 3xTg-AD mice 
3xTg-AD mice were generated via comicroinjection of transgenes into single cell embryos. (Image 







2.2  Surgery 
2.2.1  Induction of Hypoperfusion 
Hypoperfusion was induced via the placement of microcoils around the 
common carotid arteries of mice (Fig 2.2).   0.18mm and 0.16mm diameter 
microcoils, constructed from piano wire were obtained from the Sawane Spring Co., 
Japan.   All surgery relating to studies reported in this thesis was performed by Dr 
Karen Horsburgh with the exception of the initial investigation into temporal 
pathological changes in response to hypoperfusion (Chapter 3) where surgery was 
performed by Dr Catherine Gliddon.  
Surgery was performed as follows.   Animals were anaesthetised with 
isoflurane and their common carotid arteries (CCA) exposed via midline cervical 
incision.   Microcoils were applied to each CCA.   A period of 30 mins was left 
between the insertion of each coil.   Post surgery, animals were given soft food and 
closely monitored for the following 48hrs, and then twice daily for the following 5 
days.   
Any mice displaying a poor recovery from surgery were culled, notably, an 
ischaemic phenotype (spontaneous circling) which was often accompanied by a poor 
appetite and severe weight loss (greater than 20% pre surgical weight).   Sham 
animals underwent an identical procedure except that microcoils were not applied to 
each CCA.   
 
2.3  Behavioural testing 
Prior to undergoing surgery all animals which were selected for behavioural 
testing were handled for 5 mins per day for 5 days in order to minimise stress caused 






Figure 2.2  Induction of hypoperfusion 
A. Schematic of microcoil (ID-internal diameter, d-wire diameter of 0.18 mm) B. Schematic of coil in 
place around common carotid artery below the carotid bifurcation C. Image of microcoil in situ, note 
sutures are placed at the proximal and distal end of the CCA and used to gently lift the artery to 
enable application of the coil. (Adapted from Shibata et al (2004)). 
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2.3.1  Morris water maze 
All water maze testing was carried out in a 2m diameter fibre glass pool filled 
with water (Fig 2.3).   Liquid latex was added to render the water opaque to prevent 
the use of pool features for navigation (e.g. outlet pipe).   Water was maintained at a 
temperature of 25 ± 1°C.   A camera fixed directly above the pool allowed 
monitoring of the animals’ swimming behaviour (latency to platform, swim patterns) 
by a Water maze video tracking system (ActiMetrics Software, v 2.6, Willmet, IL, 
U.S.A.).   3D and 2D extramaze visual cues were placed around the room to allow 
spatial navigation. 
 
2.3.1.1  Cued version of the water maze 
In order to ensure animals were able to swim and that they did not exhibit an 
abnormal stress response, training was conducted on a cued version of the water 
maze task prior to animals undergoing surgery.   Upon entering the pool animals 
were placed facing the wall and allowed to swim until finding the cued platform or 
until 90 secs had elapsed.   Any animals unable to complete the task were excluded at 
this time.   Following surgery, animals were allowed a period of 7 days to recover.   
Cued training on the water maze task was undertaken for a period of 4 days to ensure 










2m diameter fibre glass pool
 
Figure 2.3  The Morris Watermaze 
Image of water maze with 2D and 3D extramaze cues highlighted. 
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Each animal underwent 4 trials per day with a period of 20 mins between trials.   To 
prevent the use of extramaze cues in finding the platform a white curtain was drawn 
around the pool, the platform (20cm diameter) was mde visible by placement of a 
20cm high cue at its location.   The quadrant in which the platform was located was 
changed each day of training.   For each trial the start position was changed (north, 
south, east or west) so that no start position was repeated in any one day.   
 
2.3.1.2  Spatial reference learning and memory testing 
Training in the spatial reference memory task was initiated 3 days after 
completion of the cued platform task.   In this task the platform (13cm diameter) was 
submerged 1cm below the surface of the water and was not cued.   Training lasted 5 
days and 4 trials were undertaken per day with a period of 20 mins between each 
trial.   As in the cued task starting positions were different for each trial however 
throughout the trial the location of the platform did not change for each animal.   
Platform locations and start positions were counter balanced across groups.  In this 
task the use of extra maze cues was allowed.   
 
2.3.1.3  Serial spatial reference learning and memory testing 
A trials to criterion protocol was utilised to test erial spatial reference 
learning and memory, also termed episodic memory, as previously described (Chen 
et al., 2000).   Testing commenced 3 days after the end of the cued water maze task.   
In this task animals were required to learn a serie of hidden platform locations.   
Each animal was trained for up to eight trials per day (inter trial interval was 10 
mins) up to a maximum of 32 trials (with the exception of the first trial where the 
maximum no. of trial allowed was 40), until a performance criterion of three 
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successive trials with an escape latency of less than 20s was reached.   Once criterion 
or the maximum no. of trials was reached, training ended and probe tests were 
conducted to assess memory for the platform location at 10 mins and 3 hours as 
outlined in section 2.3.1.3.   The following day training on a new platform location 
began.   Animals were tested for a minimum of ten days or until 5 platform locations 
were learned.   Counterbalancing of platform locations and start positions was 
employed across groups. 
 
2.3.1.4  Probe testing in the water maze 
Probe testing was conducted at 10 mins and 24 hours after the final trial of 
the spatial reference learning and memory task and at 10 mins and 3 hours following 
animals reaching criterion in the serial spatial lerning and memory task.   Probe tests 
were conducted to test spatial reference memory retention.   During probe trials the 
platform was fully submerged at the bottom of the pool.   Animals were allowed to 
search for the platform for a period of 60 secs, during which, time spent in each 
quadrant was recorded.   After 60 secs the platform was made accessible at its former 
location in the preceding training period and animals were allowed a further 30 
seconds in which to locate it, in order to preserve platform finding behaviour. 
 
2.3.2  Radial arm maze 
All radial arm maze testing was conducted in an 8 arm radial arm maze 
constructed of white plastic with 20cm high transparent Plexiglas walls (Stoelting 
Co. Europe, Dublin, Ireland), (Fig.2.4).   The maze consisted of an octagonal centre 
platform (20cm in diameter) with arms (47cm long, 7cm wide) leading off and a 
plastic food well (3.5cm diameter, 2cm deep) situated at the distal end of each arm.   
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Gates leading to each arm in the maze were controlled by a remote computer using 
the Any-Maze software package (Stoelting Co. Europe, Dublin, Ireland).   A camera 
fixed directly above the maze and connected to the remote computer allowed 
monitoring of the animals’ behaviour (arm choices) within the maze and automatic 
control of gate opening/ closing based on animals’ po ition.   A remote operator also 
manually recorded arm choices.   3D and 2D extramaze visual cues were placed 
around the room to allow spatial navigation. 
 
2.3.2.1  Radial arm maze pretraining 
Animals were food deprived beginning four weeks after surgery to reduce 
their initial body weight by 10-15%, once this weight was reached feeding remained 
restricted until the end of testing in order to maint in this.   In order to habituate 
animals to the maze, and the task, two days of pretraining were undertaken.   On day 
1, mice were placed on the central platform and allowed to explore the maze 
consuming food pellets (Bio-Serv, Frenchtown, NJ, U.S.A.) scattered throughout for 
a period of 5 mins.   On day 2 each arm was baited with a single food pellet.   Gates 
were used to control access to arms, only one arm was open at any one time;  















Perspex wall (20cm high)
Food well (3.5cm dia.)
Arm of maze (47cm long)
Remote operated door 
to arm
 
Figure 2.4  The 8 Arm radial arm maze 
The maze was situated on a raised platform (1m fromthe floor) 
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2.3.2.2  Spatial working memory testing in the radial arm maze 
Each animal undertook one trial per day for 20 days.   Prior to starting the 
trial each arm of the maze was baited with one food pellet.   At the start the trial 
animals were placed on the central platform and all g tes were open allowing 
animals to make any arm choice.   An arm choice was recorded when the animal had 
proceeded 5cm into an arm (as tracked by the Any-Maze software).   Following entry 
into an arm, gates on the other 7 arms closed automatically.   When an animal 
subsequently left the arm, the remaining door closed and the animal was restricted to 
the central platform for a period of 5 secs, following the 5 secs delay all gates opened 
and the animal was allowed to make another arm choice.   Trials were halted 
immediately after the successful retrieval of all 8 pellets or after a period of 25 mins.   
had elapsed.   The number of correct (novel) arm entries in the first eight visits, the 
total number of revisiting (working memory) errors and length of time to task 
completion were recorded for each trial. 
 
2.4  Generation of tissue and tissue processing 
2.4.1  Perfusion fixation 
Mice were weighed and then deeply anaesthetised with 5% isoflurane in 
oxygen (30%).   A midline incision was made and a sternotomy performed to expose 
the heart, 20ml of heparinised (0.9%) saline was perfus d through the left ventricle 
and an incision was made in the right atria to allow blood to flow out.   Following 
removal of blood, tissue fixation was achieved by perfusion of a further 20ml of 4% 
paraformaldehyde (PAM) (Sigma Aldrich Company, Gillingham, U.K.) in phosphate 
buffered solution (pH 7.4) through the vasculature.   Stiffening of the extremities, 
forelimbs, hind limbs and tail, was taken as an indication that adequate perfusion had 
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been achieved.   Subsequent to perfusion mice were decapitated and the brain left in 
the skull and post fixed in PAM for a period of 24 hours, after which brains were 
removed from skulls and immersed in PAM for a furthe  24 hours.   Where hemi 
brains were taken for biochemical analysis, brains were immediately removed from 
skulls following saline perfusion and bisected along the longitudinal fissure.   The 
right hemibrain was taken for immunohistochemistry and post fixed in PAM for a 
period of 48 hours and the left brain was dissected.   The cerebellum and olfactory 
bulb were removed and the remaining portion divided coronally, into two equal 
parts, forebrain and hind brain.   Brain portions were placed in 1.5ml Eppendorf 
tubes and snap frozen in liquid nitrogen immediately, before being transferred to a    
–80oC storage facility for long term storage until required. 
 
2.4.2  Paraffin processing and embedding 
Following fixation in PAM brains were coronally dissected into 3 x 3mm 
slices, striatal, hippocampal and hindbrain (Fig. 2.5) using a mouse brain matrix.   
Sliced brains/ hemi brains were placed into labelled plastic embedding cassettes and 
washed in running water for 30 minutes prior to being dehydrated through a series of 
alcohols and liquid paraffin (table 2.1).   Following processing, each 3mm slice was 
























Figure 2.5  Brain dissection 
A. Mouse brain matrix used for dissection of tissue, channels for coronal slicing are situated at 1mm 
intervals.  Image provided courtesy of www.zivic-miller.com.  B. Diagram illustrating dissection 
procedure.  Numbers on the left indicate order of blade insertion.  Where hemi brains were taken for 
biochemistry brains were bisected along the longitudinal fissure.  Image adapted from (Airey et al., 
2001). 
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Table 2.1  Tissue processing prior to paraffin embedding 
Sequence of solutions brains were processed through prior to paraffin embedding. 
 
Stage Solution Temperature Time in 
Solution 
1 Running water ~ 15oC 30 mins 
2 70% Ethanol Room Temp. 30 mins. 
3 70% Ethanol Room Temp. 30 mins. 
4 90% Ethanol Room Temp. 30 mins. 
5 90% Ethanol Room Temp. 30 mins. 
6 100% Ethanol Room Temp. 30 mins. 
7 100% Ethanol Room Temp. 30 mins. 
8 Xylene Room Temp. 30 mins. 
9 Xylene Room Temp. 30 mins. 
10 Liquid paraffin 65oC 30 mins. 
11 Liquid paraffin 65oC 30 mins. 
12 Liquid paraffin 65oC 30 mins. 
13 Liquid paraffin 65oC Overnight 
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2.4.3  Cutting 
Serial sections (6µm) were cut from paraffin blocks at the level of the 
striatum and the hippocampus at the level of the lat ral habenula on a microtome.   
Levels were defined as corresponding to 0.38mm and -1.70mm from bregma 
according to Franklin and Paxinos (1997).   Sections were floated on a water bath 
maintained at 40oC to remove any creases and then mounted on poly-l-lysine coated 
slides (WVR International, Lutterworth, U.K.).   To ensure lateral and ventro-dorsal 
symmetry fresh cut sections were examined using a li ht microscope.   Sections were 
dried on a hotplate (80oC) and then stored in slide storage boxes until requi d. 
 
2.5  Histology 
Haematoxylin and eosin (H&E) staining was used to identify areas of 
ischaemic damage to neuronal perikarya.   H&E was also used to assess quality of 
tissue fixation/ processing. 
 
2.5.1  Haematoxylin and Eosin staining 
Sections mounted on poly-l-lysine slides were heated in an oven maintained 
at 60oC for 30 mins then de-waxed in xylene for 15 mins before being rehydrated 
through a series of alcohols, 100% (2 x 5 mins) > 90% (2 mins) > 70% (2 mins), and 
running tap water (5 mins).   Sections were immersed in a water based haematoxylin 
solution (Thermo Scientific, Loughborough, U.K.) for 35 secs and then quickly 
washed in running tap water.   To achieve differentiation, sections were immersed in 
acid alcohol solution (1%HCl in 70% EtOH) for 8 sec.   Following differentiation 
sections were rinsed in running tap water for 2 mins prior to ‘blueing’ in Scott’s tap 
water (2% MgSO4, 0.35% NaHCO3) for 2 mins and then a further 2 min wash in 
60 
running tap water.   At this point slides were asses ed to ensure adequate nuclear 
staining had been achieved using a light microscope, where staining was too dark 
sections were re-immersed in acid alcohol, and where to light haematoxylin.   Slides 
were then submerged in undiluted alcoholic Eosin Y solution (Surgipath, 
Cambridgeshire, UK) for 2 mins followed by a rinse in running tap water and then 
dehydrated through a series of alcohols, 70% (2 mins) > 90% (2 mins) > 100% (2 x 5 
mins) and xylene (15 mins) before being mounted with coverslips using DPX. 
 
2.5.2  Counterstaining with haematoxylin 
Where immunostained sections were counterstained with haematoxylin to aid 
delineation of anatomical features following DAB visualisation, sections were rinsed 
for 10 mins and then immersed in haematoxylin, differentiated and ‘blued’, then 
dehydrated through alcohols and xylene and mounted with coverslips using DPX as 
above. 
 
2.5.3  Identification of areas of ischaemic damage to neuronal perikarya 
Areas of ischaemic damage were identified within H&E sections as regions 
where loss of staining and vacuolation of the neuropil had occurred in conjunction 
with changes in neuronal cell morphology (shrunken pyknotic nuclei and 
eosinophilic cytoplasm) and/or the presence of eosinophilic ghost cells (a dead cell 
where the outline remains identifiable in the neuropil but the nucleus or cytoplasmic 
structures are not stained by haematoxylin).   These were easily delineated from 
undamaged tissue where neuropil remained intact and u iformly stained and 
neuronal cell morphology was consistent with the prsence of healthy cells;  large 
round nuclei and cell bodies and visible cytoplasmic structures.   
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2.6  Immunohistochemistry 
All sections used for immunostaining were adjacent to those which had 
undergone histological analysis.   All immunostaining was conducted by the author 
unless otherwise stated. 
 
2.6.1  General principle 
Immunohistochemistry is a commonly used technique to investigate cell 
structure and organisation of tissue.   It exploits the basic principles of immunology 
i.e. the specific interaction of an antibody with is antigen, to allow the visualisation 
of specific cell or tissue constituents.   All immunohistochemistry conducted in 
studies reported in this thesis utilised the immunoper xidase method of staining.  
  
2.6.1.1  Avidin-biotin-peroxidase Complex (ABC) immunostaining 
 
The ABC method of staining was used for all immunohistochemistry 
experiments reported in this thesis.   The method was first reported by Hsu et al. in 
1981 (Hsu et al., 1981) and is based on the high affinity of the protein avidin to bind 
biotin.   Briefly, sections are incubated with a primary antibody to the antigen of 
interest.   A secondary biotin-conjugated antibody is then introduced which binds the 
primary antibody and causes the localisation of many biotin molecules to the site of 
the antigen.   Following this, an avidin/ biotinylated peroxidase complex is added to 
the section which binds to the biotinylated secondary antibody thus amplifying the 
signal.   Finally a chromogen (diaminobenzidene) is added to the section which 




2.6.1.2  Immunohistochemistry method 
Day1:  Sections were heated in an oven maintained at 60oC for 30 mins then 
dewaxed in xylene for 10 mins followed by submersion n 100% alcohol (2 x 5 
mins).   Sections were then immersed in 3% H2O2 methanol solution for 30 mins to 
block any endogenous peroxidase activity then washed in running water for 10 mins.   
Where heat mediated or formic acid mediated antigen retrieval was performed 
sections were microwaved on full power (2 x 5 mins) i  pH 6 citric acid buffer or 
submerged in 80% formic acid for a period of 10 mins.   Slides were then rinsed in 
PBS and blocking of non-specific binding sites was achieved by incubation for 1 
hour at room temp with 10% normal serum and 0.5% bovine serum albumin in PBS.   
The appropriate concentration of primary antibody solution (made in blocking 
solution) was added to sections which were then incubated overnight at 4oC.  
Day 2:  Sections were washed in PBS (2 x 10 mins) and then incubated with 
biotinylated secondary antibody (1:100) for one hour at room temp.   Following this, 
sections were washed in PBS and then incubated with an avidin-biotin-peroxidase 
complex solution (Vector Laboratories, UK) at room temp for a period of one hour.   
Sections were washed in PBS (2 x 10 mins) and then incubated with 3’3’-
diaminobenzidene solution to visualise antibody binding.   The colour reaction was 
stopped after 3 mins by immersion of sections in running water (10 mins).   Sections 
were then dehydrated through a series of alcohols; 70% (2 mins), 90% (2 mins.), 
100% (2 x 5 mins) and then xylene (10 mins) before being mounted and cover 
slipped in DPX. 
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2.6.1.3  Optimisation of antibodies 
Prior to conducting immunostaining on full studies a dilution curve was set 
up to establish the optimal concentration for each ntibody and also to establish 
whether heat mediated, or in the case of Aβ, formic acid mediated retrieval was 
required.   Secondary antibodies against the species in which the primary antibody 
was raised were used; these in turn determined the species of normal sera which was 
added to the blocking solution.   All immunohistochemistry experiments conducted 
included a negative control which received identical treatment with the exception of 
addition of primary antibody.  This ruled out the possibility of non-specific binding 
causing the generation of false positive results.  When setting up the dilution curves 
in C57Bl/6 tissue, positive control tissue was also included.  Tissue obtained from a 
pilot study utilising microcoil induced hypoperfusion (conducted by Dr. Karen 
Horsburgh) was used.  Additionally, tissue from a previous study investigating the 
impact of global ischaemia on white matter (conducted by Dr. Jill Fowler) was also 
utilised.  Tissue from 6 month old sham operated 3xTg animals was used to construct 
dilution curves for antibodies described in chapters 5 and 6, tissue from the 0.18mm 





















Mouse 10% Horse 
serum, 0.5% 
BSA in PBS 
22C11 Millipore 1:1000 
Αβ Mouse 10% Horse 
serum, 0.5% 




MAG Goat 10% Horse 
serum, 0.5% 
BSA in PBS 
Polyclonal Santa Cruz 
Biotechnology 
1:250 
MBP Rat 10% Rabbit 
serum, 0.5% 




dMBP Rabbit 10% Goat 
serum, 0.5% 
BSA in PBS 
Polyclonal Millipore 1:300 
 
Iba-1 Rabbit 10% Goat 
serum, 0.5% 
BSA in PBS 






2.6.2  Quantification of immunohistochemistry 
All analysis of immunohistochemistry was conducted by a blinded observer 
(the author unless otherwise stated).   Sections were examined by conventional light 
microscopy.   All analysis (grading and cell counting) was conducted over two days, 
sections were scored on both days.   To ensure reproducibility, scores for each region 
were compared and the Kappa coefficient calculated (Haley and Osberg, 1989; 
Holland et al., 2010).   This was done for each antibody in a different cohort.   For 
each antibody in all regions κ ≥ 0.77 which may be interpreted as excellent 
reproducibility (Landis, 1977). 
Where grading scores were different regions were scored again on day three.   
For cell counts, where regional counts differed by greater than 10% between days 
one and two, a third count was conducted on day three.    
 
2.6.2.1 Quantification of intraneuronal APP expression and intraneuronal  
Aβ levels in the hippocampus and cortex 
Intraneuronal Aβ and APP deposits were identified based on the typical 
morphology observed.  In the case of APP this constituted large intracellular deposits 
of immunoreactive material in pyramidal cells within the cortex and hippocampus, 
Aβ was visible as granular deposits of immunoreactive material, also visible within 
cortical and hippocampal pyramidal cells.  Photomicrographs were taken of 
immunostained sections using MCID imaging software (MCID, Cambridge, UK) 
attached to a Leica microscope (Leica Microsystems (UK) Ltd., Milton Keynes, 
UK).   For analysis of immunostaining in the CA1 hippocampal subregion, 4 
consecutive images at 400x magnification were taken from each section.   For 
cortical immunostaining analysis 8 consecutive images at 200x magnification were 
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taken.   Using ImageJ software (V1.41), images were converted to greyscale and 
cropped to size for analysis (200 x 800 pixels for hippocampal images and 250 x 900 
pixels for cortical images), mean gray values for each image were measured and then 
averaged to give a mean gray value per section for each region.   Mean gray values 
were converted to relative optical density (Lazic, 2009) for comparison of sham and 
hypoperfused groups.   Relative optical density levels were used as an index of levels 
of immunostaining. 
In order to ensure reliable reproducibility slides from three animals were 
chosen at random from each group of animals to be examined and analysed as 
described three times.   The measure was deemed reproducible when the 3 
measurements fell within 10% of the median value. 
 
2.6.2.2  Quantification of MAG immunohistochemistry 
Loss of myelin integrity in response to hypoperfusion was assessed via MAG 
immunostaining.   A semi quantitative grading scale (0-3) was devised for analysis of 
MAG immunohistochemistry.   The scale was as follows; normal (grade 0), minimal 
myelin debris, vacuolation, and disorganisation of fibres (grade 1), modest myelin 
debris, vacuolation, and disorganisation of fibres (grade 2), and extensive myelin 
debris, vacuolation, and disorganisation of fibres (grade 3) (See Fig 2.6). 
 
2.6.2.3  Quantification of APP immunohistochemistry in white matter 
Axonal damage was visualised using anti amyloid precursor protein (APP) 
antibody which is a well established marker for axonal damage (McKenzie et al., 
1996).   Axonal damage is visualised by the presence of APP stained axonal bulbs.  
Using this marker a semi quantitative grading scale was devised for analysis of levels 
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of APP staining as an index of axonal pathology (see Fig. 2.7).   Axonal damage was 
identified as intense APP immunoreactivity in swollen or bulbous axons and graded 
as normal (grade 0), minimal axonal damage (grade 1), moderate areas of axonal 
damage (grade 2) and extensive areas of axonal damage (grade 3). 
 
2.6.2.4  Quantification of Iba-1 immunohistochemistry 
Ionized calcium binding adaptor molecule 1 (Iba-1) is the protein product of 
upregulation of the Aif1 gene (allograft inhibitory factor) and is specifically 
expressed in brain tissue by microglia following their activation.   Activated 
microglia were quantified in chapter 4, by placing a box grid of defined size in 
randomly selected fields within each region of interest and then calculating the 
number of activated microglial cells per mm2.   In chapters 5 & 6 activated 
microglial were quantified using a grading scale (Fig. 2.9) which was as follows.   
Grade 0- no activated microglia, grade 1- modest microglial activation, grade 2- 




















Figure 2.6  MAG immunostaining grading scale  
Individual brain regions were scored as (A) normal (grade 0), (B) minimal myelin debris, 
vacuolation, and disorganisation of fibres (grade 1), (C) modest myelin debris, vacuolation, and 
disorganisation of fibres (grade 2), (D) extensive myelin debris, vacuolation, and disorganisation of 









Figure 2.7  APP immunostaining grading scale 
Individual brain regions were scored as (A) normal, grade (0), (B) minimal axonal damage (grade 1), 
(C) moderate areas of axonal damage (grade 2), (D) extensive areas of axonal damage (grade 3).   










Figure 2.8  Iba-1 immunostaining grading scale 
Individual brain regions were scored as (A) no microglial activation (grade 0);  (B) minimal 
microglial activation (grade 1);  (C) moderate microglial activation (grade 2);  (D) extensive 
microglial activation (grade 3).   Images taken from the internal capsule.   Scale bar = 25µm. 
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2.7  Western Blotting 
2.7.1  Antibodies and optimisation 
Western blot analysis was utilised to investigate protein levels in whole brain 
homogenate.   For a list of antibodies and the concentration at which they were used 
see table 2.3.   Prior to running studies blots were conducted in control tissue (male 
3xTg 10 months of age) to ascertain optimal antibody concentration and also to 
ascertain antibody specificity.   Negative controls were also run, where blots received 
the same treatment in every aspect with the exception of the addition of primary 
antibody.  
Whilst Western blotting may be considered a relatively cheap, reliable and 
time economic method of protein quantification a potential caveat which must be 
taken into considertation and one which can prove problematic when attempting to 
interpret results, is the presence of non-specific binding (N.S.B.).  This can lead to 
false positive results and also issues with blot quantification.  This highlights the 
importance of negative controls.  It also highlights the importance of incubation with 
an appropriate blocking buffer following protein transfer (section 2.7.5). 
An advantage of using the Western blotting method utilised in this thesis lies 
in the quantification of blots.  Previously Western blotting was only considered 
sensitive enough to detect changes in protein levels of > 20%.  However the Odyssey 
infra red imaging system and Odyssey imaging software V3.0 (Li-Cor Biotechnology 



















Rabbit Polyclonal Merck 1:1000 Goat anti-
rabbit 680 










CNPase Mouse 11-5B Abcam 1:5000 Goat anti-
mouse 680 











2.7.2  Tissue homogenisation and preparation  
Hemi brain sections (3 mm) taken at the level of the hippocampus as 
described in section 2.4.2 were removed from -80oC storage, weighed and kept on 
dry ice.   Homogenisation was conducted in 10x volume (e.g. 750µl in 75mg) of total 
homogenisation buffer (250mM sucrose, 20mM tris base, 1mM EDTA, 1mM 
EGTA) to which protease and phosphatase inhibitors had been added (Merck, 
Nottingham, UK).   Tissue was homogenised in a 1ml glass-glass Dounce hand held 
homogeniser using 15 strokes of the pestle and then pulse spun (the centrifuge was 
allowed to reach full speed and then stopped) in a bench top centrifuge.   Supernatant 
was aspirated off, transferred to a fresh 1.5ml Eppendorf tube and refrozen at -80oC. 
 
2.7.3  Assessment of protein concentration of samples 
Protein concentration of samples was determined using the bicinchoninic acid 
(BCA) protein assay method (Thermo Scientific, Loughborough, UK).   This assay is 
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based on the reduction of Cu2+ ions to Cu+ by protein in an alkaline medium (known 
as the biuret reaction) and the subsequent reaction of the reduced copper cation with 
BCA to produce a quantifiable colourimetric reaction.   The colour intensity may be 
measured via spectrophotometry (wavelength 562nm); colour intensity is 
proportional to protein concentration allowing accurate determination of sample 
protein concentration between a range of 20 to 2000 µg/ml. 
The BCA assay was conducted in a 96 well plate.   Aseries of protein 
(bovine serum albumin (BSA)) standards 25-2000 µg/ml were made from 2000 
µg/ml stock diluted in total homogenisation buffer.   1:15 dilutions of total 
homogenate were prepared, 50 parts of BCA reagent A (Sodium carbonate, sodium 
bicarbonate, bicinchoninic acid and sodium tartrate in 0.1M sodium hydroxide) was 
added to 1 part BCA reagent B (4% cupric sulphate) to form the BCA working 
reagent.   10µl of diluted total homogenate sample was added to the microplate in 
triplicate, 200µl of BCA working reagent was then added to each well and plates 
were covered and incubated at 370C.   Plates were read on a plate reader (Dynex 
Technologies, Worthing, UK) and results recorded.   Triplicates were examined and 
any values greater than +/- 10% were excluded, the value for each sample was taken 
as the average of each triplicate (or duplicate where a value had been excluded).   A 
standard curve was constructed from the values of the known standards and then the 
protein content of samples was determined via linear r gression analysis (Fig. 2.9). 
 
2.7.4  SDS-Page electrophoresis 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
separates polypeptides based on their electrophoretic mobility.   SDS binds proteins 
denaturing their polypeptide back bone and causes th  dissociation of hydrogen 
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bonds which results in an unfolding of tertiary and secondary structures, SDS also 
confers an overall net negative charge on proteins meaning that they are separated 
solely on size.   Samples are prepared in Laemeli buffer which contains 2-
mercaptoethanol, dithiothreitol (DTT), bromophenol blue and glycerol.   2-
mercaptoethanol and DTT are reducing agents which reduce inter and intramolecular 
di-sulphide bonds ensuring proteins remain as linear structures, bromophenol blue is 
added as an indicator dye allowing observation of pr tein migration through the gel, 
it also makes gel loading easier, glycerol is added to increase the density of the 
sample ensuring it will sink to the bottom of the wll when loaded.   All SDS-Page 
electrophoresis and Western blotting in studies report d in this thesis were conducted 
































Figure 2.9  Example of standard curve for determining protein concentration 
The relative absorbancy of BSA standards at 562nm increases with increasing concentration of BSA.   
Linear regression was used to calculate the protein co centration of samples of total homogenate 
utilised for Western blotting experiments. 
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  Following determination of protein concentration f homogenates, samples 
containing equal amounts of protein were prepared for Western blot analysis.   4x 
laemmli buffer and distilled water were added to each sample to make up to the 
required volume (for 10 well gels this was 25µl and for 15 well gels 10µl).   Samples 
were heated at 70oC in a water bath for 10 mins to denature proteins a d then 
vortexed prior to gel loading.   Protein was separated by SDS-polyacrylamide gel 
electrophoresis on 4-12% Bis/ Tris gels using 2-(N-morpholino)ethanesulfonic acid 
(MES) running buffer (Invitrogen, Paisley, UK), gels were run for 1.5 – 2 hours at 
150V unless otherwise stated. 
 
2.7.5  Protein transfer 
Following separation of proteins, gels were removed from chambers and 
opened ready for protein transfer.   The section of the gel containing stacking gel and 
wells was trimmed off and a sheet of blotting paper (6cm x 4cm) soaked in transfer 
buffer placed over the gel.   Gels were then flipped over and  polyvinylidene fluoride 
(PVDF) membrane (6cm x 4cm) (GE Healthcare, Amersham, UK) which had 
previously been activated in 100% methanol for 5 mins then rinsed in dH2O was 
placed over the gel and another piece of blotting paper placed on top.   Blotting 
paper, gel and membrane ‘sandwiches’ (Fig 2.10) were placed into XCell Surelock 
blot modules (Invitrogen, Paisley, UK) between sponges soaked in transfer buffer 
(see appendix 1).   Where possible two transfers wee conducted per blot module, in 
the event of an odd number of gels, extra sponges were added to the blot modules to 
ensure flow of current between electrodes.   Following securing of the blot module 
with the gel tension wedge blot modules were filled with transfer buffer, the chamber 
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around the blot module was filled with dH2O.   Protein transfer was conducted at 






Figure 2.10  Protein transfer 
Schematic of a blotting paper, gel and membrane ‘sandwich’.   These were placed between sponges 
soaked in transfer buffer and into a blot module, a current was then passed through to facilitate 
protein transfer.   Image adapted from www.invitrogen.com  
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Following protein transfer, membranes were incubated in Ponceau S solution (Sigma 
Aldrich Company Ltd., Dorset, UK) to ensure equal loading of protein. Membranes 
were then blocked in 10ml Odyssey blocking buffer (Li-Cor Biotechnology UK Ltd., 
Cambridge, UK) / PBS (1:1) in a light proof box at room temp for a period of one 
hour.   Membranes were incubated with primary antibody in blocking buffer/PBS 
(1:1), 0.1% Tween20 (Sigma Aldrich Company Ltd., Dorset, UK) solution (10ml) 
overnight at 4oC.   In all Western blotting experiments Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) (1:100000, Sigma Aldrich Company Ltd., Dorset, UK) 
was used as a loading control.   On day two membranes were washed 6 times in PBS 
0.1% Tween solution for 5 mins each wash, then incubated with appropriate 
secondary fluorescent antibody (1:3000 Li-Cor Biotechnology UK Ltd., Cambridge, 
UK) in blocking buffer/ PBS (1:1), 0.1% Tween20, 0.01%SDS solution for 45 mins 
at room temp.   Following incubation membranes were washed 6 times in PBS 0.1% 
Tween20 solution for 5 mins per wash and then twice for 2 mins in PBS solution.   
Membranes were then allowed to dry prior to quantification of protein levels.  
 
2.7.6  Coomassie blue staining 
Coomassie blue staining was used to assess whether prot in transfer had been 
successful.   Following western blotting gels were incubated in coomassie blue stain 
(Biorad, Herts., UK) at room temp for a period of one hour then washed in dH2O for 
6 x 5 min washes. 
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2.7.7  Quantification of protein levels 
Once dry, blots were scanned using an Odyssey infra red imaging system and 
protein levels quantified using Odyssey imaging software V3.0 (Li-Cor 
Biotechnology UK Ltd., Cambridge, UK).   GAPDH was utilised as a loading control 
for all Western blotting experiments.   The intensity value (measured in arbitrary 
units (A.U.)) for the protein of interest was express d as a ratio of the intensity value 
of GAPDH for each lane on each gel.   In most cases each Western blot was run 
twice and the values from each gel were averaged for analysis.   To ensure 
reproducibility of gels, images of blots and protein concentration values were 
compared by eye. 
To ensure the suitability of GAPDH as a loading contr l and that GAPDH 
levels were not affected by either hypoperfusion or ageing, GAPDH values were 
compared for each group i.e. sham vs hypoperfused, or, young vs old.   In all cases 
GAPDH levels did not change in response to either hypoperfusion or ageing (p > 
























































Figure 2.11  GAPDH is unaffected by hypoperfusion or ageing 
Data are expressed as GAPDH intensity value ± SEM.   A. Comparison of GAPDH levels in sham (n 
= 7) and hypoperfused animals (n = 8) where hypoperfusion was induced using 0.16mm dia 
microcoils (p=0.557).   B. Comparison of GAPDH levels in young (n = 6) and aged animals (n = 12 
p=0.352).   In each case GAPDH levels were unchanged.   Two-way Student’s t-test. 
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2.8  Comparison of Circle of Willis anatomy 
Circle of Willis anatomy was compared between adult male C57Bl/6J and 
adult 3xTg-AD mice.   Mice were transcardially perfused with 0.9% saline solution 
in PB as outlined in section 2.4.1.   Following this, 5ml of Carbon Black ink were 
perfused at the same rate.   Animals were taken to be adequately perfused when their 
extremities turned black.   Animals were decapitated and the brains removed from 
skulls.   Circle of Willis anatomy was visualised using a dissecting microscope 
(magnification x10).   Circle of Willis anatomy was scored as either complete or 
incomplete, based on the presence or absence of both posterior communicating 
arteries.   Brains were then frozen and scored for a second time by an independent 
blinded observer. 
 
2.9  Statistical analysis 
2.9.1  Behaviour 
Behavioural data were analysed using 2-way ANOVA with the Greenhouse-
Geisser correction.   Student’s t-test with Bonferroni adjustment for multiple 
comparisons was used post hoc.   
 
2.9.2  Pathology 
Loss of myelin integrity, levels of degraded myelin a d axonal damage were 
compared between sham and hypoperfused animals.  The statistical design 
employed, initially determined whether the probability of damage ocurring to the 
aforementioned white matter components was higher following hypoperfusion.  This 
was tested using Fisher’s exact test.  Latterly a Mann-Whitney U test was employed 
to assess whether levels of damage were higher in animals following hypoperfusion 
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as compared to shams.   The grading score for regions of interest were summated to 
give an overall score per animal and then scores were compared.   Microglial 
activation was compared using Student’s t-test unless otherwise stated.   Number of 
activated microglia in regions of interest were summated to give the number of 
activated microglia/animal/mm2.   Relative optical density values obtained via imge 
analysis were compared using Student’s t-test. 
 
2.9.3  Western blot analysis 
All Western blot data are presented as mean of two blots unless otherwise 
stated.   Order of samples on gels was changed between run 1 and run 2 to ensure 
loading pattern had no impact on results.   All data re expressed as mean protein of 
interest/ GAPDH ± SEM.   Groups were compared using Student’s t-test.  
 
2.9.4  Statistical analysis package 
Statistical analysis of data from all studies was performed using Graph Pad 
Prism v5.0 (Graphpad Software Inc. El Camino Real, U.S.A.). 
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Chapter 3:  The temporal development of pathology following 
hypoperfusion in C57Bl/6J mice 
3.1  Introduction 
Chronic reductions in cerebral blood flow may impact on the integrity of 
brain white matter and could underlie the development of cognitive deficits 
(Kawamura et al., 1991; Breteler, 2000; Raz et al., 2007).   To date several 
experimental animal models have been developed to investigate this (Kudo et al., 
1993; Farkas et al., 2007).   The most often used and well characterised is the 2VO 
rat model where CBF is attenuated via ligation of the common carotid arteries 
resulting in reductions of CBF of up to ~35% of baseline levels (Farkas et al., 2007).   
Whist this model has proven useful, one of its major drawbacks is the development 
of ischaemic damage to neuronal perikarya in many experimental animals, making it 
impossible to differentiate the independent role of white matter disruption in any 
cognitive deficit observed during behavioural testing. 
More recently a mouse model of chronic cerebral hypoperfusion has been 
developed, in which CBF is attenuated via the application of microcoils of a fixed 
diameter to the common carotid artery (Shibata et al., 2004).   The ability to vary the 
internal diameter of the coils means that more modest r ductions in CBF may be 
induced. 
This mouse model provides a powerful tool to examine the impact of 
hypoperfusion on the development of white and grey matter pathology and also how 
different types of pathology may impact on different cognitive domains.   However, 
prior to conducting behavioural testing to investiga e cognitive changes, a necessity 
arises to establish firstly, when following induction of hypoperfusion pathology 
becomes detectable and secondly what the extent and severity of this pathology is.   
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This study will test the hypothesis that hypoperfusion will cause a temporal 
progression of white and grey matter pathology. 
 
3.1.1  Aims of study 
This study sought to investigate the temporal development of white matter 
pathology following chronic cerebral hypoperfusion at, 7, 14, 28 and 56 days post 
surgery, in C57Bl/6J wild type mice. 
 
3.2  Methods 
3.2.1  Animals and group sizes 
In four cohorts of C57Bl/6J male mice (aged 3-4 months;  table 3.1) 
hypoperfusion was induced as described in section 2.2 using 0.18mm diameter 
microcoils.   
To investigate the development of pathological changes to white matter 
following hypoperfusion, animals were culled via perfusion fixation as outlined in 
section 2.4 at 7, 14, 28 and 56 days post surgery.  All surgeries conducted on animals 
described in this chapter were performed by Dr. Cath Gliddon. 
Table 3.1  Initial cohort sizes 
                    Treatment 
Time point 
Sham Hypoperfusion 
7 days n=6 n=17 
14 days n=6 n=12 
28 days n=6 n=16 
56 days n=5 n=8 
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3.2.2  Histology 
Haematoxylin and eosin (H&E) staining, as described in section 2.5, was 
used to identify areas of ischaemic damage to neuroal perikarya. 
 
3.2.3  Immunostaining 
MAG immunostaining was used to investigate changes in myelin integrity in 
response to hypoperfusion.   APP immunostaining wasused to investigate the 
development of axonal pathology in response to hypoperfusion.   Immunostaining 
and quantification was conducted as described in section 2.6.  Initially Fisher’s exact 
test was used to determine whether the probability of damage ocurring to white 
matter components was increased following hypoperfusion. Mann-Whitney U tests 
were used to compare loss of myelin integrity and levels of axonal pathology 
between sham and hypoperfused animals. 
 
3.2.4  Regions of interest 
In this study hemi brain sections were stained and alysed (the other hemi 
brains were utilised in a biochemical study not repo ted in this body of work).   
White matter regions of interest examined were external capsule, internal capsule, 
hippocampal fimbria, optic tract and white matter fib e bundles of the striatum (Fig. 
3.1).  Initial attempts were made to analyse myelin/ axonal integrity in the corpus 
callosum however this was not possible due to the presence of artefacts in the tissue 
in all animals examined.  The likely cause of these i  the shrinking back of 
hydrophobic white matter during tissue processing.  This may be considered a 
weakness of attempting to conduct both immunohistochemical and biochemical 









Figure 3.1  White matter regions of interest 
Pathology was examined in the external capsule, internal capsule (area assessed circled), 
hippocampal fimbria, optic tract and white matter fibre bundles of the striatum. Images adapted from 





Fibre bundles of the
striatum
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3.3  Results 
3.3.1 Recovery after surgery 
All animals recovered well from surgery with the exc ption of two 
hypoperfused animals from the 28 day cohort which were culled due to poor 
recovery.   This gave final group numbers for this cohort of n = 6 sham and n = 
14 hypoperfusion.   
 
3.3.2  Pathology 
3.3.2.1 Histological examination of grey matter following hypoperfusion 
There was no evidence of ischaemic damage (as describ d in section 2.5.3) to 
neuronal perikarya in any brain region in any of the sham operated animals.   
Ischaemic neuronal perikaryal damage was seen in 5 out of 17 hypoperfused animals 
in the 7 day cohort, in 4 out of 12 hypoperfused anim ls in the 14 day cohort, in 4 out 
of 14 hypoperfused animals in the 28 day cohort and 3 out of 8 animals in the 56 day 
cohort.   Areas where ischaemic damage was observed were striatum, hippocampus 
and cortex, (table 3.2 & Fig. 3.2), severity of damage varied between animals.   
Table 3.2  Animals displaying evidence of ischaemic damage 
Cohort 
















7 days 5/17  5 4 4 
14 days 4/12 3 4 3 
28 days 4/14  4 3 3 






















Figure 3.2  H&E staining to assess ischaemic damage  
Images from the striatum (A-C), the hippocampus (D-F) and the cortex (G-I) in sham (A, D, G), 
hypoperfused animals where no evidence of ischaemic damage was seen (B, E, H) and hypoperfused 
animals displaying evidence of ischaemic damage to neuronal perikarya (C, F, I).   Scale bar = 
50µm. 
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3.3.2.2  Analysis of MAG immunostaining 
The probability of myelin damage occurring following hypoperfusion was 
increased (7 days, p = 0.003, 14 days p = 0.004, 28 days p<0.001, 56 days p<0.001), 
Fisher’s exact test.  The majority of sham animals displayed no evidence of damage 
to myelinated fibres (Fig. 3.43).   One sham animal from each of the 7, 14 and 28 day 
cohorts displayed minimal evidence of myelin pathology (grading score of 1 in 
regions affected).   Myelin damage was present in hypoperfused animals (Fig. 3.3B) 
from 7 days and was significantly increased as compared to shams at all 4 time 
points;  7 days (p = 0.004), 14 days (p = 0.003), 28 days (p < 0.001), 56 days (p = 
0.004) (Mann Whitney U Test; Fig. 3.4).   Myelin dam ge was anatomically 
widespread and present in all regions examined in the majority of animals.   There 
was no evidence to support a temporal evolution of pathology across the time points.   
Variability within the 4 cohorts of hypoperfused animals was similar. 
In animals where ischaemic damage to neuronal perikarya had occurred 











Figure 3.3  MAG immunostaining 
Representative images of MAG staining in the optic tra t in sham (A), hypoperfused animals where no 
ischaemic damage to neuronal perikarya was evident (B) and hypoperfused animals where ischaemic 
damage was evident (C).  Scale bar = 50µm 
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Figure 3.4  Assessment of myelin damage 
The probability of observing myelin damage following hypoperfusion was increased (7 days, n= 6 
sham, 17 hypoperfused; p = 0.003, 14 days, n= 6 sham, 12 hypoperfused; p = 0.004, 28 days  n= 6 
sham, 16 hypoperfused; p<0.001, 56 days, n= 5 sham, 8 hypoperfused;  p<0.001), Fisher’s exact test. 
Myelin damage was increased in hypoperfused animals at all time points as compared to shams, 
median value for sham animals in all 4 cohorts was 0; 7 days (p=0.004, median value=3.0), 14 days 
(p=0.003, median value=4.5), 28 days (p<0.001, median value=5.0), 56 days (p=0.004, median 
value=4.5).  Mann-Whitney test.  A similar level of variability was present in each experimental 
group.  All animals were included in analyses.  In a imals where ischaemic damage to neuronal 
perikarya had occurred (highlighted in red), myelin pathology was markedly more severe.  
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3.3.2.3  Analysis of APP immunostaining 
The probability of axonal damage occurring following hypoperfusion was not 
increased at 7 days, (p = 0.124), 28 days (p = 0.052) or 56 days (p = 0.231) but was 
increased at 14 days, (p = 0.009)  Fisher’s exact test.  There was no axonal pathology 
present in any brain region of any sham animal (Fig. 3.5A).   Axonal pathology was 
increased in some but not all hypoperfused mice (Fig. 3.5B).   At 7 days axonal 
pathology was present in 7 out of 17 hypoperfused mice, at 14 days axonal pathology 
was present in 9 out of 12 mice, at 28 days axonal pathology was present in 7 out of 
14 mice and at 56 days axonal pathology was present in 3 out of 8 mice.   The 
increase in pathology was significant at 14 days (p = 0.023) but not at 7 days (p = 
0.404), 28 days (p = 0.223) or 56 days (p = 0.739) (Mann Whitney U test; Fig 3.6). 
Notably, the presence of axonal damage was more prominent in mice where 







Figure 3.5  APP immunostaining 
Representative images of APP staining in the internal capsule in sham (A), hypoperfused animals 
where no ischaemic damage to neuronal perikarya was evident (B) and hypoperfused animals where 
ischaemic damage was evident (C).   Arrows denote accumulations of APP, indicative of axonal 
damage.   Scale bar = 50µm 
 





















Figure 3.6  Assessment of axonal damage 
The probability of axonal damage occurring following hypoperfusion was not increased at 7 days, 
(n=6 sham, 17 hypoperfused; p = 0.124), 28 days (n= 6 sham, 16 hypoperfused; p = 0.052) or 56 
days (n= 5 sham, 8 hypoperfused; p = 0.231) but was increased at 14 days, (n= 6 sham, 12 
hypoperfused; p = 0.009) Fisher’s exact test.  . Axonal pathology was increased in hypoperfused 
animals at 14 days as compared to shams (p=0.023, median value 2.0).  There was no difference in 
levels of axonal pathology between sham and hypoperfused animals at any of the other three time 
points examined; 7 days (p=0.0.404, median value 0), 28 days (p=0.223, median value 0.5) or 56 
days (p=0.739, median value 0).  Mann Whitney U test. All animals were included in analyses. The 
median value for sham animals in all 4 cohorts was 0.   In animals where ischaemic damage was 
observed (highlighted red), axonal pathology was markedly increased.  Variability was similar within 
each experimental group.  
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3.4  Discussion 
The results from the study presented in this chapter demonstrate that chronic 
cerebral hypoperfusion as induced by 0.18mm microcoils in C57Bl/6J mice results in 
the development of both white and grey matter pathology which is present from 7 
days.   Contrary to the initial hypothesis there was no clear temporal evolution of 
pathology. 
Previously, (Shibata et al., 2004) conducted a study o characterise pathology 
in the same model of hypoperfusion as described in this chapter.   They reported that 
white matter rarefaction had occurred and was apparent f om 14 days, becoming 
more severe by 30 days.   This was in the absence of any ischaemic damage to grey 
matter.   In the present study, ischaemic damage to n uronal perikarya was present in 
approximately one third of hypoperfused animals thus demonstrating one of the 
biggest disparities between results presented here and those of Shibata et al (2004).   
In both studies ischaemic damage was assessed in the same manner, thus ruling out 
methodological differences in quantification as a re son for this discrepancy.   One 
possible explanation for this difference may be dueto the fact that different surgeons 
were used in each study.   Whilst it would be unfair to question the competency of 
the surgeons the fact that this model was novel to our lab cannot be dismissed.   This 
may have led to surgery taking longer and so the increased likelihood of the 
development of more severe damage or, alternatively th  overall reduction in CBF 
may have been greater in hypoperfused animals.   As CBF was not measured this is 
speculative but must be considered as a possible exp anation.    
Other reasons as to why there was a higher incidence of ischaemic damage 
reported in the present study may be due to differences in animal housing facilities.   
For example, both basic and clinical studies have demonstrated that lower 
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temperatures have been shown to confer neuroprotection against ischaemia (Little, 
1959), hence had the animals utilised in the study by Shibata et al. been housed in a 
unit with a lower ambient temperature this may have influenced outcome after 
surgery.   A further factor which may have influencd the development of ischaemic 
damage is behavioural stress.   In experimental studies investigating the impact of 
behavioural stress, increased psychosocial stress has been associated with 
hypertension, cardiac arrhythmias and sudden death in both humans and animals 
(Lane et al., 2005; Trudel et al., 2010).   Several xperimental studies have shown 
that sensory contact with aggressive mice is associated with an increased stress 
response (Pardon et al., 2004).   In the present study animals were housed 5 or 6 to a 
cage, whilst it is unknown how animals from the Shibata study were housed, had 
they been housed in isolation, then cage aggression and therefore increased 
psychosocial stress would have been avoided potentially lowering the likelihood of 
any stress induced ischaemia.   
A further and arguably more pertinent reason why more ischaemic damage to 
neuronal perikarya was observed in the current study as compared to Shibata et. al. 
(2004) may be due to the different types of anaesthesia utilised during surgery.  In 
the study undertaken by Shibata et. al. mice were anaesthetised using sodium 
pentobarbital (50 mg/kg, intraperitoneal injection), whilst in the present study 
inhalational anaesthesia (isoflurane) was used.  Several studies have been conducted 
which have reported anaesthesia as having a general neuroprotective effect (Kitano et 
al., 2006; Clarkson, 2007; Lasarzik et al., 2011).  Recovery time following 
inhalational anaesthesia is considerably faster than when anaesthesia is induced via 
injection, thus the animals in the study conducted by Shibata et. al. may have had a 
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prolonged period of neuroprotection conferred upon them compared to those 
described in the present study.   
In addition to increased levels of ischaemic damage in hypoperfused animals, 
another notable difference between the study by Shibata et al (2004) and the one 
presented here is the finding that myelin pathology was evident from 7 days.   One 
reason for this temporal difference may be due to the sensitivity of the different 
markers used in each study.   Luxol fast blue (used by Shibata et al) is a general 
histological stain which binds several different myelin components, including 
phospholipids (Kluver and Barrera, 1953; Salthouse, 1962; Lycette et al., 1970) 
which comprise ~70% of myelin.   For this reason Luxol fast blue may be considered 
a suitable marker to identify where damage to white matter has occurred, however, it 
does not provide insight into specifically which components of white matter are 
altered, due to lack sensitivity.   The immunostaining method utilised by the present 
study is much more precise and confers an advantage over Luxol fast blue in that it 
allows specific targeting of selective myelin components.   This is highlighted by the 
use of MAG as a marker for myelin integrity.   As stated in chapter 1, MAG 
comprises < 1% of total myelin however as demonstrated by the results above, 
following hypoperfusion, clear cellular redistribution of MAG may be observed in 
white matter tracts as early as seven days.   Attempts to investigate the impact of 
hypoperfusion on other protein constituents of myelin at 30 days, MBP, PLP and 
CNPase, conducted as part of an earlier immunohistochemical study within the 
Horsburgh group, demonstrated no detectable changes to these protein constituents in 
response to hypoperfusion at this time point.   
The fact that changes in MAG are observed at an early time point, prior to 
gross myelin changes or changes in other myelin components, highlights the 
96 
possibility that MAG is one of the myelin proteins most vulnerable to hypoperfusion.   
This hypothesis is supported by previous work (Aboul-Enein et al., 2003) which 
demonstrated that preferential loss of MAG is observed in hypoxia related tissue 
injury prior to the loss of other myelin proteins and oligodendrocyte apoptosis.   
Given the cellular location of MAG (Fig 3.7) and its function in maintaining the axo-
glial connection (Quarles, 2007) this finding suggests that a loss of normal axo-glial 
integrity/ function is an early event following onset of hypoperfusion.  Further work 
which supports this has been conducted within the Horsburgh group where changes 
in MAG protein levels were evident as early as three days following onset of 























Figure 3.7  Cellular location of MAG 
Electron micrograph coloured to show the cellular location of MAG.  MAG is located periaxonally 
(coloured yellow).  Ax = axon.  Image adapted from Quarles (2007). 
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In addition to the identification of MAG as being particularly vulnerable to 
hypoperfusion another feature of the model identified via immunostaining is that 
axonal pathology is minimal.   The relative lack of axonal pathology observed in the 
present study may be representative of differences in the ability of oligodendrocytes 
and neurons to tolerate reductions in CBF.   Several r asons have been suggested as 
to why this may be the case;  oligodendrocytes have high intracellular iron levels 
which renders them particularly vulnerable to oxidative stress, they also have a very 
large surface area to volume ratio (Bartzokis, 2004) coupled with a relatively low 
metabolic rate as compared to other cell types and, s iscussed in chapter one, blood 
supply to white matter is relatively limited as compared to grey matter (Pantoni and 
Garcia, 1997). 
Previously the most widely used and well characterised model of 
hypoperfusion was the 2VO rat model, where hypoperfusion is induced via complete 
ligation of the bilateral common carotid artery (Farkas et al., 2007).   An advantage 
of the BCAS mouse model described in this thesis is that attenuation of CBF may be 
modulated by varying the internal diameter of the microcoils.   This means that more 
modest reductions in CBF may be induced as compared to the 2VO rat model.   This 
allows investigation of how levels of hypoperfusion, comparable with those observed 
in human ageing may impact on cognition in isolation (see next chapter).   A further 
advantage of the BCAS mouse model, is that it may be applied with relative ease to 
any number of transgenic mouse lines to investigate the role hypoperfusion may 
contribute to a number of neurodegenerative disorders.   This is demonstrated later in 
this thesis. 
Whilst the study presented in this chapter and by others clearly demonstrates 
that an early, prominent pathological feature of this model is damage to white matter, 
99 
more specifically myelin, the mechanisms underlying this pathology remain to be 
elucidated. 
In the mouse model of hypoperfusion described above, using 0.18mm 
microcoils, CBF is reduced to approximately 70% of baseline values immediately 
after surgery and returns to between 10-15% below baseline by 30 days (Shibata et 
al., 2004).   This reduction in itself is too modest to cause ischaemic damage to 
neuronal perikarya (Jones et al., 1981) and should be able to be compensated for via 
auto regulation (Brain, 1993).   However it must be noted that Shibata et al. used 
laser Doppler flowmetery to quantify CBF which measures cortical blood flow and 
not that of the subcortical white matter where flow is known to be lower (Pantoni et 
al., 1996).   Furthermore, the brain is less able to compensate for reductions in blood 
flow in white matter due to the pattern of the white matter vascular network (Pantoni 
and Garcia, 1997).   Hence, whilst cortical flow may be reduced by up to 30% 
initially, the flow reduction in white matter may be even greater and as such, 
sufficient to cause damage.   Alternatively the degre  of stenosis caused by microcoil 
placement on the carotid arteries (greater than 50%) (Shibata et al., 2004) may be 
sufficient to cause alterations in rheological factors such as blood viscosity, or the 
development of microturbulent flow (Brain, 1993).   Each of these factors alone or a 
combination of them may lead to the development of chronic cerebral hypoperfusion 
(Farkas and Luiten, 2001).   However, as yet, no evidence exists to support these 
speculations.   
Other work, which has provided insight into the potential mechanisms 
underlying the development of white matter damage associated with hypoperfusion, 
in the same model utilised by the present study, has implicated a role for matrix 
metalloproteinases (MMPs), specifically MMP2, which was shown to be upregulated 
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in response to hypoperfusion (Nakaji et al., 2006).   Furthermore, inflammation and 
severity of white matter rarefaction was shown to be attenuated in MMP2 KO mice 
(Nakaji et al., 2006).   MMPs belong to a group of endopeptidases which are able to 
degrade numerous pericellular substrates, including the majority of components 
which comprise the extracellular matrix (Sternlicht and Werb, 2001).   MMP2 has 
been shown to be upregulated in the white matter lesions of patients with vascular 
dementia (Rosenberg et al., 2001) and is also known t  be particularly efficient at 
digesting myelin (Chandler et al., 1995) as well as being implicated in BBB 
dysfunction and the subsequent initiation of inflammation (Caplan, 2005). 
A recent study conducted within the Horsburgh group which utilised 
Collagen IV immunohistochemistry to measure vessel diameter in cortical and 
hippocampal vessels, has shown that vessel diameter is increased following 1-2 
months of hypoperfusion (Scullion, unpublished data).   In this study lumen diameter 
was not measured, therefore it is not possible to ascertain whether enlarged vessel 
diameter was due to increased collagen deposition and basement membrane 
thickening or, vessel dilation.   Nonetheless, changes in vascular diameter are known 
to impact on vascular resistance and in turn CBF (Brain, 1993).   If the observed 
changes were due to increased collagen deposition, this may indicate the emergence 
of vascular pathology in response to hypoperfusion, alternatively were it due to 
vessel dilation then this may indicate that vascular reserve has become impaired i.e. 
in response to a reduction in perfusion pressure du to the induction of 
hypoperfusion, the arterioles may have dilated in order to increase cerebral blood 
volume and regulate cerebral blood pressure (autoregulation).  If vascular reserve has 
been used up then this would render the brain vulnerabl  to any additional transient 
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changes in perfusion pressure.   To confirm of reject either of these hypotheses 
further work is required. 
There are several pathologic features which have ben described as 
characterising white matter lesions in the brains of elderly individuals.  These 
include, damage to myelinated fibres and myelin loss, ranging from modest to 
severe, varying severities of axonal damage, infiltrat on of glial cells (microglia and 
astrocytes),  the upregulation of markers of hypoxia e.g. HIF1-α and also blood brain 
barrier dysfunction (Akiguchi et al., 2004; Fernando et al., 2004; Simpson et al., 
2007a; Simpson et al., 2007b).  Selective damage to white matter observed, in the 
majority of animals in the present study, following hypoperfusion was mild and 
limited mainly to the myelin component.   Axonal pathology following 
hypoperfusion was minimal and only present in regions where myelin pathology was 
severe.   This lack of axonal pathology suggests that t e mouse model of chronic 
cerebral hypoperfusion described above may model most accurately early changes 
observed in the pathogenesis of white matter lesions.   The next stage in model 
characterisation will be to investigate pathological changes to white matter in more 





Chapter 4:  Characterisation of cognitive deficits in a mouse model 
of chronic cerebral hypoperfusion   
4.1  Introduction 
In addition to the development of white matter pathology (Kawamura et al., 
1991; Fernando et al., 2006), chronic cerebral hypoperfusion has also been 
associated with the development of cognitive deficits in the elderly (Ruitenberg et 
al., 2005; Tiehuis et al., 2008).   Moreover, it has been hypothesised that white matter 
pathology underlies these changes (Junque et al., 1990; Breteler et al., 1994).   
Several studies conducted in cohorts of aged individuals have demonstrated a 
correlation between deficits in different aspects of c gnition, including processing 
speed, executive function, episodic memory and levels of white matter damage 
(Deary, 2003; Bucur et al., 2008; Kennedy and Raz, 2009).   
A major confounding factor of human studies attempting o investigate how 
chronic cerebral hypoperfusion, white matter pathology and the development of 
cognitive deficits may be linked, is the presence of multiple vascular risk factors, 
each of which may impact detrimentally on white matter integrity e.g. 
atherosclerosis, hypertension or diabetes, thus preventing any observed changes to 
white matter or cognition being attributed solely to hypoperfusion. 
The development of animal models of hypoperfusion has gone some way to 
address this issue.   Following on from the preceding chapter, the aim of the present 
study was to further examine pathological changes and also investigate the impact of 
hypoperfusion on different aspects of cognition in the mouse model previously 
described.   Similar work has already been conducte (Shibata et al., 2007) however; 
the use of separate cohorts for the analysis of pathology and behaviour in this study 
prevent the definite attribution of the observed cognitive changes solely to changes in 
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white matter.   This point is of particular relevance given the findings presented in 
chapter 3 where a spectrum of white and grey matter pathology was observed in 
animals following hypoperfusion.   This caveat will be overcome by the present 
study where parallel analysis of pathology and behaviour will be conducted.   This 
will permit the exclusion of hypoperfused animals di playing any evidence of 
obvious ischaemic damage to grey matter (as describd in chapter 3), thus allowing 
more definite conclusions being drawn as to the rolof white matter pathology in the 
development of cognitive deficits. 
This study tests the hypothesis that in addition to precipitating damage to the 
myelin component of white matter, chronic cerebral hypoperfusion will impact 
detrimentally on cognition. 
 
4.1.1  Aims of study 
This study sought to further investigate and characte ise the selective 
components of white matter which are damaged in response to chronic cerebral 
hypoperfusion in a mouse model and also to investigate how chronic cerebral 
hypoperfusion may impact on different aspects of spatial learning and memory. 
 
4.2  Methods 
4.2.1  Animals, group sizes and experimental design 
For this study three cohorts of C57Bl/6J mice (aged 3-4 months) were set up 
(table 4.1) and hypoperfusion was induced as described in section 2.2.   In cohort 1, 
cued learning and spatial reference memory were assssed using a water maze task 
(Schenk and Morris, 1985);  behavioural testing ended and analysis of pathology was 
undertaken at 1 month post surgery.   In cohort 2, cued learning and serial spatial 
104 
learning and memory (as a measure of episodic memory) were assessed using a trials 
to criterion task (Chen et al., 2000), also in the water maze, behavioural testing ended 
and analysis of pathology was undertaken at two months post surgery.   In cohort 3 
spatial working memory was assessed using an 8-arm radial arm maze (Shibata et al., 
2007), behavioural testing ended and analysis of pathology was undertaken at two 
months post surgery.   All surgery conducted on anim ls described in this chapter 
was performed by Dr. Karen Horsburgh. 
 
Table 4.1  Initial cohort sizes 
                    Treatment 
Cohort/ Task 
Sham Hypoperfusion 
1 (Spatial reference 
memory ) 
n=12 n=14 
2 (Trials to criterion) 
n=12 n=18 




4.2.2 Pathological analysis 
4.2.2.1   Histological assessment of gray matter pathology 
Haematoxylin and eosin (H&E) staining, as described in section 2.5, was 
used to identify areas of ischaemic damage to neuroal perikarya.  Staining of cohort 
1 was conducted by the author, staining of cohorts 2 and 3 were conducted by Miss 
Jess Smith and Miss Yanina Tsenkina.   Assessment of histological staining in 
cohorts 1 and 2 was undertaken by the author.   In cohort 3 this was performed by 




4.2.2.2  Immunohistochemical assessment of white matter pathology 
MAG immunostaining was used to investigate changes in myelin integrity in 
response to hypoperfusion.   dMBP immunostaining was used to investigate levels of 
degraded myelin following hypoperfusion.   APP immunostaining was used to 
investigate the presence of axonal pathology in respon e to hypoperfusion.   Iba-1 
immunostaining was used to investigate microglial upregulation in response to 
hypoperfusion.   Immunostaining and quantification was conducted as described in 
section 2.6 where damage was assessed using a grading score (MAG, dMBP and 
APP) regions were scored bilaterally;  for quantificat on of microglial activation, cell 
counts from each hemisphere were averaged.   Immunostsaining of sections from 
cohort 1 was undertaken by the author, sections from cohorts 2 and 3 were 
immunostained by Mrs Fiona Scott and Mr Tommy Dingwall.   Analysis of sections 
from cohorts 1 and 2 was undertaken by the author.   Immunostained sections from 
cohort 3 were analysed by Miss Yanina Tsenkina. 
 
4.2.2.3  Regions of interest 
Sections adjacent to those used for histological stining were selected for 
immunohistochemical staining.   White matter structures quantified in these sections, 
were, corpus callosum, external capsule, internal capsule, hippocampal fimbria, optic 
tract and the white matter fibre bundles of the striatum (Fig. 4.1).  
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4.2.3  Behaviour: Assessment of spatial reference learning and memory, serial 
spatial learning and memory and spatial working memory 
For full details of behavioural testing see section 2.3.   The spatial reference 
memory task was conducted by the author and Miss Ailing Spain.   The trials to 
criterion task was conducted by Miss Aisling Spain, Miss Yanina Tsenkina and Miss 
Jess Smith.   The radial arm maze task was conducted by the author, Miss Aisling 
Spain and Miss Yanina Tsenkina.    
 
4.2.4  Statistics 
Statistical analysis of behavioural data and data obtained from analysis of 
pathology was conducted as outlined in section 2.9.2.  Pathology was examined as 
follows, initially Fisher’s exact test was used to determine whether the probability of 
damage ocurring to white matter components was increased following 
hypoperfusion. Mann-Whitney U tests were used to compare loss of myelin integrity, 
levels of axonal pathology and levels of degraded myelin between sham and 











Figure 4.1  White matter regions of interest 
Pathology was examined in the corpus callosum, external capsule, internal capsule (area assessed 
circled), hippocampal fimbria, optic tract and the white matter fibre bundles of the striatum. Images 












4.3  Results 
4.3.1  Recovery after surgery 
All animals recovered well from surgery except two hypoperfused animals 
from cohort 1, three hypoperfused animals from cohort 2 and four hypoperfused 
animals from cohort 3 which were culled due to poor recovery.  See table 4.2 for 
cohrt sizes following surgery.     
 
Table 4.2  Cohort sizes following surgery 
 
                    Treatment 
Cohort 
Sham Hypoperfusion 
1 (Spatial reference 
memory) 
n=12 n=12 
2 (Trials to criterion) 
n=12 n=15 






4.3.2  Exclusion criteria 
The specific purpose of this study was to examine th impact of 
hypoperfusion on white matter pathology and how hypoperfusion may impact on 
cognition.  For this reason, prior to analysing data from behavioural testing and 
analysis of pathology, exclusion criteria were set.  
 
4.3.2.1  Exclusion criteria- pathology 
Animals from all three cohorts, where evidence of overt ischaemic damage to 
neuronal perikarya was observed in H&E sections, were excluded from analysis of 
behavioural data and further analysis of white matter pathology.   
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4.3.2.2  Exclusion criteria- behavioural testing 
In cohorts 1 & 2, which were subject to behavioural testing in the water 
maze, animals exhibiting floating behaviour were excluded.   Floating behaviour was 
defined as floating persistently on consecutive trials over consecutive days.   Animals 
exhibiting floating behaviour were also omitted from analysis of pathology.   See 
table 4.3 for excluded animals and final cohort size  for further pathological and 
behavioural analysis.  
Table 4.3  Animals excluded on the basis of exclusion criteria 
 
Cohort 









No. of animals 











































4.3.3  Pathology 
4.3.3.1 Histological examination of grey matter following hypoperfusion 
There was no evidence of ischaemic damage (as define  in section 2.5.3) to 
neuronal perikarya in any sham animals.   In cohort one, 2 of 12 hypoperfused 
animals displayed evidence of overt ischaemic damage to neuronal perikarya in the 
hippocampus and striatum.   In cohort two, 4 of 15 hypoperfused animals displayed 
evidence of overt ischaemic damage to neuronal perikarya in the hippocampus and 
striatum.   One of these animals also displayed evience of a cortical infarction.   In 
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cohort three, 9 of 12 animals displayed evidence of overt ischaemic damage to 
neuronal perikarya in the hippocampus and striatum.   As stated above, animals 
displaying evidence of ischaemic damage to neuronal perikarya were initially 
excluded from further analysis (table 4.3). 
 
4.3.3.2  Detailed analysis of white matter following hypoperfusion  
Detailed analysis of white matter pathology was conducted in cohorts 1, 2, 
and 3 following behavioural testing, at one and twom nths following induction of 
hypoperfusion.   There was no difference in the extent of white matter damage 
between the three cohorts (p < 0.05;  Kruksal-Wallis;  Coltman et al (2010)).   All 
pathology data presented in this chapter are from analysis of pathology in cohort 1. 
   
4.3.3.3  Assessment of myelin integrity following hypoperfusion 
The probability of a loss of myelin integrity following hypoperfusion was 
increased (p = 0.015; Fig 4.2B , F, I), Fisher’s exact test. In sham operated animals, 
the majority of animals displayed no evidence of myelin damage as assessed by 
MAG immunostaining (Fig. 4.2B).   In the sham animal where a disruption of myelin 
integrity was observed, this was minimal (grading score 1).   In hypoperfused 
animals, a spectrum of myelin damage was observed, from modest to severe (Fig. 
4.2F).   Disruption of myelin integrity was widespread and apparent in most regions 
of most animals.   Myelin damage was significantly increased in hypoperfused 
animals as compared to shams (p = 0.004;  Fig 4.2I) Mann-Whitney-U test.   
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4.3.3.4 Assessment of dMBP immunostaining following hypoperfusion 
dMBP immunostaining was conducted to assess levels of degraded myelin 
(Fig. A2, B).   The probability of myelin damage occurring following hypoperfusion 
was increased (p < 0.001; Fig A1 A,B,C), Fisher’s exact test.  In one out of nine 
sham animals where degraded myelin was observed, this was at low levels.   
Degraded myelin was present in all hypoperfused mice.   There was a significant 
increase in levels of degraded myelin in hypoperfused mice as compared to shams 
(Fig. A1 C;  p < 0.001) Mann Whitney-U test. 
 
4.3.3.5 Assessment of axonal integrity following hypoperfusion 
Axonal damage was assessed via APP immunostaining.   The probability of 
axonal damage occurring following hypoperfusion was not increased (p = 0.082; Fig 
4.2C, G, J), Fisher’s exact test.  No sham animals displayed any evidence of axonal 
pathology in any region examined (Fig. 4.2C).   Minimal axonal pathology was 
evident in four out of nine hypoperfused animals (Fig. 4.2G).   Axonal pathology was 
not increased in hypoperfused animals as compared to shams (p = 0.094; Fig. 4.2J) 
Mann Whitney-U test.  
 
4.3.3.6 Assessment of microglial activation following hypoperfusion 
Activated microglia were present to varying degrees in all regions assessed in 
all animals, both sham and hypoperfused.   Hypoperfus d animals displayed elevated 
levels of microglial activation as compared to shams, although this difference was 


































































Figure 4.2  Assessment of pathology following hypoperfusion 
Representative images of pathology following hypoperfusion.  Neuronal cell bodies in the CA1 were intact in most hypoperfused animals (A, E) Scale bar = 30µm.  
The probability of myelin disruption occurring follwing hypoperfusion induced using 0.18mm diameter mic ocoils was significantly increased (I; p=0.015).  The 
probability of axonal pathology occurring following hypoperfusion was not increased (J; p= 0.082) Fisher’s exact test. Disruption of myelin (white arrows) was 
significantly increased in hypoperfused animals as compared to shams (B, F, I; p=0.004; median values- sham 0, hypoperfused 5).  There was no significant 
difference in levels of axonal pathology (black arrows) between sham and hypoperfused animals following one month of hypoperfusion (C, G, J; p=0.094; median 
values- sham 0, hypoperfused 0) Mann Whitney-U test.  Microglial activation was noticeably, but not sign ficantly upregulated in hypoperfused mice (D, H, K; 
p=0.509; mean values- sham 116.8 ± 29.78 , hypoperfus d 142.2 ± 22.97 activated microglia mm2).  Two tailed Student’s t-test.  n=9 sham, 9 hypoperfused.  
Images of white matter pathology taken from the optic tract.  Scale bar = 15µm.   
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4.3.4 Behaviour 
4.3.4.1 Assessment of spatial reference learning and memory in the watermaze 
following hypoperfusion 
Of the 24 (n=12 sham/ 12 hypoperfused) animals in cohort one which 
underwent behavioural testing, 6 animals in total were excluded from analysis of 
behaviour based on the exclusion criteria described n section 4.3.2 (n = 3 sham/3 
hypoperfusion).   This gave final group numbers of n = 9 sham/9 hypoperfusion. 
 
4.3.4.2 Cued task 
All mice were able to complete the cued navigation task.   Average swim 
speed for sham animals was 26.41 ± 0.97cms (average ± SEM) whilst hypoperfused 
animals averaged 26.44 ± 0.93 cms.   Swim speeds di not differ significantly 
between sham and hypoperfused animals |t| = 0.024, df = 16, p = 0.981 (Fig. 4.6A).   
A repeated measures ANOVA of the latency to reach the platform across days for 
sham and hypoperfused animals revealed a significant difference over days [F(5,80) 
= 21.961, p < 0.001], but no significant difference between groups [F(1,16) = 0.002, 
p = 0.97] (Fig. 4.6B), neither was there a significant interaction [F(5, 80) = 1.333, p 
= 0.273].   By the last day of the task following surgery (day 5), escape latencies 
averaged less than 10 seconds for animals from both gr ups. 
 
4.3.4.3 Spatial reference learning 
A repeated measures ANOVA conducted to compare escap  latencies over 
the five training days showed a significant effect of day [F(4,64) = 10.327, p < 
0.001], but  no significant effect of group [F(1,16) = 0.206, p = 0.66] (Fig. 4.5C) 
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neither was there a significant group x day interaction [F(4, 64) = 0.412, p = 0.80].    
These data show that the performance of sham and hypoperfused animals improved 
significantly throughout the duration of the task and that hypoperfusion had no 
impact on the ability of experimental animals to learn the task.   
 
4.3.4.4 Spatial reference memory retention 
Following probe trials, % time spent in each quadrant of the maze was 
analysed.   A significant effect of quadrant was found at both the short term (10 
mins) [F(3,48) = 44.996, p < 0.001] (Fig. 4.6D) and long term time points (24 hours) 
[F(3,48) = 22.903, p < 0.001] (Fig. 4.6E).   No significant group effect was found 
(10mins:  [F(1,16) = 0.105, p = 0.75];  24 hours:  [F(1,16) = 1.8, p = 0.199]).   There 
was no significant group x quadrant interaction (10 min:  [F(3,48) = 0.088, p = 0.97];  
24 hours [F(3,48) = 0.664, p = 0.53]. 
Compared to chance, both hypoperfused and sham animals spent significantly 
more time in the training quadrant during each probe trial (10 mins: hypoperfused t = 
5.894, p < 0.001, df = 8; sham t = 6.56, p < 0.001, df = 8;  24 hours:  hypoperfused t 

































































































Figure 4.3  Spatial reference memory testing in the water maze 
Data are expressed ± SEM.  Sham n = 9; hypoperfused n = 9 (A) Swim speeds did not differ between 
sham and hypoperfused animals (p = 0.981 mean values- sham= 26.41 ± 0.97cm/s, hypoperfused= 
26.44 ± 0.93cm/s);  two-tailed Student’s t-test.   (B) Performance of both groups on the cued task 
improved significantly over training days (p < 0.001).   Hypoperfused animals performed as well as 
shams (p = 0.97);  two-way ANOVA.   (C) Spatial refe nce learning was unaffected by hypoperfusion 
(p = 0.66), the performance of both groups improved significantly across days (p < 0.001);  two-way 
ANOVA.   Sham and hypoperfused animals performed equally well during probe tests conducted at 
(D) 10 mins. (p = 0.75) and (E) 24 hours (p = 0.199) following spatial reference learning; two-way 
ANOVA.   In both probe tests sham and hypoperfused animals spent significantly more time in the 
training quadrant compared to chance (dashed line); 10 mins. (p < 0.001);  24 hours (p < 0.002);  
one sample Student’s t-test. 
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4.3.4.5 Assessment of serial spatial learning and memory 
Of the 27 (n = 12 sham/15 hypoperfused) animals in cohort two which 
underwent behavioural testing, 6 animals in total were excluded from analysis of 
behaviour based on the exclusion criteria described n section 4.3.2 (n = 1 sham/5 
hypoperfusion).   This gave final group numbers of n = 11 sham/ 10 hypoperfusion. 
 
4.3.4.6 Cued task 
All mice were able to complete the cued navigation task.   Average swim 
speed for sham animals was 25.25 ± 1.04cm/s (average ± SEM) whilst hypoperfused 
animals averaged 26.44 ± 0.76 cm/s.  Swim speeds di not differ significantly 
between sham and hypoperfused animals |t| = 0.901, df = 19, p = 0.379 (Fig. 4.7A).  
A repeated measures ANOVA of the latency to reach the platform across days for 
sham and hypoperfused animals revealed a significant difference over days [F(4,76) 
= 34.538, p < 0.001], but no significant difference between groups [F(1,19) = 0.054, 
p = 0.82] (Fig 4.7B).   There was no significant group x day interaction [F(4,76) = 
0.16, p = 0.958].   By the last day of the task (day 5), escape l tencies averaged less 
than 10 seconds for animals from both groups. 
 
4.3.4.7 Serial spatial learning and memory 
A repeated measures ANOVA across the first 5 platform locations revealed 
the number of trials to learn the platform location t  criterion did not change across 
the first five tasks [F(4,76) = 1.57, p = 0.192] and also that hypoperfusion did not 
impact on rate of learning across the tasks [F(1,19) = 0.04, p = 0.853] (Fig 4.7C).   
Neither was there a significant group x task interaction [F(4,76) = 0.52, p = 0.718].   
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Analysis of % time spent in the training quadrant in he probe tests at 10 mins and 3 
hours for the first five platform locations revealed that there was no difference in the 
amount of time that sham and hypoperfused animals spent in the training quadrant; 
10 mins [F(1,18) =0.02, p = 0.894] Fig. 4.7D;  3 hours [F(1,19) = 0.15, p = 0.702] 
(Fig. 4.7E).   Sham and hypoperfused animals were able to learn the same number of 






























































































































Figure 4.4  Serial spatial reference memory testing in the water maze 
Data are expressed ± SEM.  Sham n=11; Hypoperfused n=10   (A) Swim speeds did not differ 
between sham and hypoperfused animals (p = 0.379 mean values- sham= 25.25 ± 1.04cm/s, 
hypoperfused= 26.44 ± 0.76cm/s); two-way Student’s t-test.  (B)  Both groups improved significantly 
on the cued task over training days (p<0.001).  Hypoperfused animals performed as well as shams 
(p=0.82).  (C)  Serial spatial reference learning was unaffected by hypoperfusion (p=0.853), there 
was no change in number of trials to learn platform location across tasks (p=0.192).  Sham and 
hypoperfused animals performed equally well during probe tests conducted at (D) 10 mins. (p=0.894) 
and (E) 24 hours (p=0.702) following spatial referenc  learning; two-way ANOVA.  In both probe 
tests sham and hypoperfused animals spent significatly more time in the training quadrant compared 
to chance (dashed line).  (F)  There was no difference in the number of platform locations learned 
across the first 10 days between sham and hypoperfused animals (p=0.459 mean values- sham= 9.55 
± 0.16 tasks, hypoperfused= 9.22 ± 0.43 tasks); two-way student’s t-test. 
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4.3.4.8 Assessment of spatial working memory in the radial arm maze 
Of the 22 (n = 10 sham/12 hypoperfused) animals in cohort three which 
underwent behavioural testing, 9 hypoperfused animals were excluded from analysis 
of behaviour based on the exclusion criteria described in section 4.3.2.   This gave 
final group numbers of n=10 sham/ 3 hypoperfusion. 
In the radial arm maze task, hypoperfused mice made significantly more 
working memory (revisiting) errors as compared to sham operated controls [F(1,11) 
= 7.93; p = 0.017; Fig. 3.3A].   The number of errors committed per trial by both 
sham and hypoperfused animals diminished across the training period [F(7,77) = 
8.94;  p < 0.001] (Fig. 4.8A).   The number of novel arm entries made in the first 
eight entries did not differ between sham and hypoperfused animals [F(1,11) = 1.74;  
p = 0.213].   Over the training period the number of n vel arm entries in the first 

















Figure 4.5  Spatial working memory testing in the 8-arm radial arm maze 
Data are expressed ± SEM.  Sham n=10; Hypoperfused n=3 (A) Sham and hypoperfused animals 
made significantly fewer revisiting errors across trials (p<0.0001).  Hypoperfused animals made 
significantly more revisiting errors as compared to shams (p=0.017); two-way ANOVA.  (B)  Sham 
and hypoperfused animals made significantly more novel arm entries in the first 8 entries as training 
progressed (p=0.019), the number of novel arm entris made in the first eight entries did not differ 
between sham and hypoperfused animals (p=0.213); two-way ANOVA. 


















































4.3.4.9 Assessment of behaviour in animals displaying evidenc  of ischaemic 
neuronal damage 
 Latterly, analysis of behavioural data was conducted to compare animals 
where evidence of ischaemic neuronal damage was observed with sham and 
hypoperfused animals displaying only selective white matter damage.  All figures 
relating to this analysis are contained within appendix two.  In the spatial reference 
memory and trials to criterion tasks swim speeds di not differ between any of the 3 
cohorts (p =0.576 and p =0.227 respectively; one-way ANOVA; Figs. A2.1A, & 
A2.2A).  In both water maze tasks a repeated measurs ANOVA of the latency to 
reach the platform across days for all 3 cohorts revealed a significant difference over 
days (SRM- [F(5,85) = 9.29, p <0.001], Fig A2.1B; TTC- [F(4,88) = 37.5, p < 
0.001], Fig. A2.2B) and also a significant differenc  between the groups where 
ischaemic animals performed significantly worse as compared to the other groups 
(SRM- [F(2,85) = 7.11, p = 0.006]; TTC- [F(2,88) = 3.86, p = 0.037]).  There was no 
significant group x day interaction.  In each case however, by the last day of the task, 
escape latencies averaged less than 10 seconds for all animals. 
 
In the spatial reference learning task a repeated measures ANOVA to compare 
latencies over the five training days showed a significant effect of day [F(4,68) = 
4.33, p = 0.004] but no significant effect of group [F(2,68) = 1.49, p = 0.254] (Fig. 
A2.1C). There was no significant group x day interaction.  Following probe trials a 
significant effect of quadrant was found at both the s ort term (10 mins [F(3,51) = 
32.81 p <0.001]) and long term time points (24 hours [F(3,51) = 11.05, p < 0.001]).  
No significant group effect was found (10 mins: [F(2,51) = 0.81, p = 0.459]; 24 
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hours: [F(2,51) = 0.67, p = 0.526]).  There was no significant group x quadrant 
interaction. Compared to chance, all animals spent sig ificantly more time in the 
training quadrant during each probe trial (10 mins: hypoperfused t = 5.894, p < 
0.001, df = 8; sham t = 6.56, p < 0.001, df = 8;  24 hours:  hypoperfused t = 4.131, p 
< 0.003, df = 8;  sham t = 4.70, p < 0.002, df = 8) (Figs. A2.1 D&E). 
 
In the trials to criterion task a repeated measureas ANOVA across the first 5 platform 
locations revealed that animals displaying evidence of ischaemic damage took 
significantly more trials to learn the platform location across the first five tasks 
[F(4,88) = 4.41, p = 0.003] and also that ischaemic animals did not learn at the same 
rate as animals in the other two cohorts [F(2,88) = 4.07, p = 0.031] (Fig. A2.2C). 
There was no significant group x task interaction [F(8,88) = 1.37, p = 0.222].  
Analysis of time spent in the training quadrant in he probe tests at 10 mins and 3 
hours for the first five platform locations revealed that there was no difference in the 
amount of time that animals from any cohort spent in the training quadrant; 10 mins 
[F(2,84) = 0.03, p = 0.973] (Fig. A2.2D); 3 hours [F(2,88) = 0.99, p = 0.386] (Fig. 
A2.2E). Animals with ischaemic neuronal damamge learn d fewer tasks in the first 
ten days than animals from the other two cohorts (p = 0.013; Fig. A2.2F); one-way 
ANOVA with Tukey’s multiple comparison post-test. 
 
In the radial arm maze task, as well as hypoperfused animals, ischaemic animals also 
made significantly more working memory (revisiting) errors as compared to shams 
[F(2,119) = 10.61, p = 0.001].  The number of errors committed per trial by all 3 
groups diminished across the period [F(7,119) = 11.18, p < 0.001] (Fig. A2.3A).  
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Animals from the ischaemic group also made significantly fewer novel arm entries in 
the first eight as compared to animals from the sham and hypoperfused groups 
[F(2,119) = 4.06, p = 0.036].  Over the training period the number of novel arm 
entries in the first eight entries improved significantly for all three groups [F(7,119) 
= 3.63, p = 0.001](Fig. A2.3B). 
 
4.4  Discussion 
The results from the study presented in this chapter support the hypothesis 
that chronic cerebral hypoperfusion results in the development of diffuse white 
matter pathology and that hypoperfusion is associated with the development of 
cognitive changes.   More specifically, hypoperfusion results in a selective deficit in 
working memory whilst spatial reference learning and memory and episodic memory 
remain intact.  Analysis of data gathered from animals displaying evidence of 
ischaemic damage revealed neuronal cell damage within the hippocampus appeared 
to impact on serial spatial reference learning.    
This is the first study to assess behaviour and pathology in the same cohort of 
animals following hypoperfusion.   This parallel asse sment accounts for the main 
difference between the present study and that of Shibata et al (2007).   The fact that 
Shibata et al did not do this precludes the definite a tribution of any cognitive 
changes observed to the presence of white matter pahology alone.   The importance 
of this is highlighted when the number of animals from the RAM study reported in 
this chapter displaying evidence of ischaemic damage to neuronal perikarya is 
considered.   In the present study 75% of hypoperfus d animals which underwent 
RAM testing displayed evidence of ischaemic damage nd so were excluded from 
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the study, leaving only n = 3 animals for behavioural/pathological analysis.   Even so 
a behavioural deficit was observed thus demonstrating the robustness of this finding.  
This finding has been replicated several times since within the Horsburgh group.   
One reason as to why experimental animals from the RAM study displayed a higher 
incidence of ischaemic damage as compared to the other two cohorts examined may 
have been due to food deprivation (required for the RAM task; see section 2.3.2.1).    
Several hypoperfused animals displayed evidence of s izure activity during the RAM 
task and also in the animal housing facility.   Food deprivation is known to lead to 
altered nutritional status and can lead to abnormally low glucose levels and 
potentially hypoglycaemia.   Hypoglycaemia has been linked to seizure activity and 
in some cases, to the development of ischaemic neuro al cell death in both animals 
(Auer et al., 1984) and humans (Auer, 1986) and also the development of deficits in 
some aspects of spatial memory (Hershey et al., 2005).   This highlights the failure of 
Shibata et al to make a parallel assessment of pathology and behaviour in the same 
animals as a major limitation.   
In addition to their behavioural findings Shibata e al reported that rarefaction 
of the white matter and glial activation had occurred at 30 days following 
hypoperfusion (Shibata et al., 2004; Shibata et al., 2007).   As discussed in chapter 3, 
one of the advantages conferred by the present study over that of Shibata et al is the 
detail with which white matter pathology was examined i.e. via 
immunohistochemical as opposed to histological examin tion.   In the present study 
this advantage is further extended through the use of additional antibodies (dMBP 
and Iba-1).   These provide further information as to the components of white matter 
impacted by hypoperfusion.   In agreement with the findings of Shibata et al 
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hypoperfusion was associated with an upregulated inflammatory response as 
evidenced by the infiltration of activated microglia to regions of interest examined.  
Also, as reported in chapter 3 and by others (Holland et al., 2010), 
immunohistochemical analysis of white matter cellular components confirmed that a 
key pathological feature of this model is myelin damage and a loss of myelin 
integrity, as evidenced by dMBP and MAG immunostaining respectively.   
It is well established that a correlation exists between hippocampal integrity 
and intact spatial reference memory (Pappas et al., 1997; D'Hooge and De Deyn, 
2001).   In the present study selective white matter pathology was found to be present 
in animals which displayed an impairment in spatial working memory, however, 
spatial reference learning and memory were unaffected in animals displaying the 
same levels of pathology.   This finding is consistent with that of Shibata et al. 
(2007).   More recently a study was conducted (Miki et al., 2009) utilising a modified 
version of this model, where BCAS was induced by placing a 0.18mm dia microcoil 
on one common carotid artery and a 0.16mm dia. microcoil on the other, to 
investigate the impact of hypoperfusion on the development of white matter 
pathology and the subsequent impact on cognition.   In contrast to the present study, 
Miki et al. (2009) reported a spatial reference memory deficit in hypoperfused 
animals as tested using the same watermaze task described in this chapter.   This was 
in conjunction with relatively severe myelin pathology, axonal pathology and 
accompanying astroglial and microglial upregulation.   However they also reported 
increased levels of ischaemic damage to neuronal perikarya in the hippocampus in a 
majority of hypoperfused animals.   Miki et al. (2009) also reported that 
hypoperfused animals exhibited less anxiety in an open field test and those 
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hypoperfused animals exhibiting the most severe CBFreductions (< 30% of baseline 
levels at day 6 following surgery) displayed evidenc  of sensorimotor dysfunction 
when assessed with a rotorod test.   The authors attributed this to infarction in the 
motor and somatosensory cortex although no conclusive pathological evidence was 
produced in support of this. 
In a study (Nishio et al., 2010) designed to investigate longer term 
pathological and cognitive changes in this model, Nishio et al (2010) found a spatial 
reference memory deficit using a Barnes maze test at 6 months following 
hypoperfusion, they also reported working memory deficits similar to those reported 
in this chapter following 5 months of hypoperfusion.   Histological and 
immunohistochemical examination of pathology in experimental animals following 8 
months of hypoperfusion revealed apoptotic neuronal cell death had occurred in both 
the hippocampus (CA1 & CA3 sub regions) and cortex.  
Whilst both of the studies described above (Miki et al., 2009; Nishio et al., 
2010) reported a spatial reference memory deficit in response to hypoperfusion, 
unlike the study described in this chapter, damage to hippocampal neuronal perikarya 
was found in the majority of experimental animals.  This is of interest given that 
animals displaying evidence of ischaemic neuronal cell loss in the hippocampus in 
the present study were able to complete the SRM task as successfully as both 
hypoperfused and sham animals.   Of further interes is the fact that in the more 
challenging serial spatial reference memory task (TTC) ischaemic animals performed 
significantly worse than sham and hypoperfused animls; taking more trials to learn 
the platform location across the first five tasks, their rate of learning was slower and 
they learned fewer tasks over the first ten days of training.  The likely reason for this 
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is due to the added complexity of the TTC task as compared to the SRM task 
(discussed below).  It is well known that the hippocampus plays a major role in 
spatial memory formation and retention and that hippocampal damage can cause 
spatial memory impairment (D’Hooge et. al. 2001).  It may be that the levels of 
ischaemic damage observed in animals was not severe nough to impact on spatial 
reference memory but was severe enough to cause a sri l patial memory 
impairment.  An alternative reason as to why no impairment was found in spatial 
learning and memory in the animals displaying evidence of ischaemic damage may 
be due to group size (n=2) and high levels of variance in the data (see appendix A2).  
In order to investigate this fully, further work using a larger cohort needs to be 
undertaken.   
Deficits in episodic memory and task switching are recognised as an early 
feature of dementia in humans and have been linked to a loss of white matter 
integrity (Deary, 2003; Bucur et al., 2008).   The trials to criterion protocol utilised 
by the present study is designed to measure serial spatial learning and memory in 
mice and is considered a measure of ‘episodic like memory’ (Chen et al., 2000).   
This task requires a degree of memory flexibility as successful task performance 
relies on the ability of animals to constantly update successive platform locations in 
relation to fixed visual cues in their environment and also to recall the platform 
location relevant to the current trial (as opposed to previous platform locations).   
Whilst it has been shown that hippocampal integrity is required for intact episodic 
memory (Dickerson and Eichenbaum, 2009) and therefore successful completion of 
this task, the contribution of white matter is unknow .   Results from the current 
study indicate that a loss of white matter integrity did not impact on spatial memory 
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flexibility, memory retention or learning capacity as hypoperfused animals 
performed equally well as compared to shams.   Thissuggests that hypoperfusion 
had no impact on episodic memory in the animals tested, or, alternatively the task is 
not sensitive/ challenging enough to detect subtle changes which may occur as a 
result of the diffuse pathology observed.  
In the present study it has been demonstrated that selective myelin pathology 
is associated with a deficit in spatial working memory whilst other elements of 
spatial memory- spatial reference memory and serial sp tial memory remain intact.   
The underlying reason for this may lie in the degre of behavioural flexibility 
required for successful performance in different behavioural tasks and also the 
neuroanatomical basis for these different aspects of cognition. 
In the RAM task utilised by the present study and also Shibata et al (2007) a 
greater degree of memory flexibility is required than in either the spatial reference 
memory or the trials to criterion water maze tasks.   To perform effectively in the 
spatial reference memory task, animals need to learn only one platform location, 
whilst platform location in the trials to criterion task needs updating only daily.   
However, in the RAM task a greater degree of memory flexibility is required as 
animals are required to constantly update their memory (during the task) with 
information as to which arms food has been retrieved from.   This frequent updating 
and retrieval of information is likely to require input from many different, 
anatomically discrete, brain regions and so will rely heavily on intact white matter 
pathways for successful integration of information (Bucur et al., 2008).   A further 
point of interest is that animals displaying evidenc  of ischaemic damage performed 
significantly worse than sham animals in the RAM task, it could be argued that this 
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would be expected given that white matter damage in this group was likely more 
severe than in hypoperfused animals where no ischaemic damage had occurred 
(based on the findings presented in chapter 3).  Additionally, animals wth ischaemic 
damage made fewer novel arm entries in the first 8, in order to ascertain whether this 
is due to the more severe levels of myelin damage observed in this group or to 
ischaemic neuronal cell damage, further studies need to be conducted.   
Pathology results from this study and also chapter 3 have demonstrated that 
myelin pathology following hypoperfusion is widespread and diffuse in nature, 
affecting all regions assessed.   This prevents the working memory deficit described 
in this chapter being attributed to damage in a specific anatomical region.   It is 
unknown exactly which or how many brain regions underlie functional spatial 
working memory.   However, evidence from research conducted suggests that the 
neuroanatomical basis for functional working memory is considerably more complex 
than other components of spatial memory and is dependent on a number of distinct 
regions and their communication with one another.   These include, fronto-cortical 
circuitry, in particular, subsets of neurons within the prefrontal cortex (Fuster, 1973; 
Funahashi, 2006), posterior parietal and occipital areas (Ricciardi et al., 2006), the 
CA3 sub region of the hippocampus (Kesner, 2007) and also parahippocampal areas 
(Hodges, 1996).   If this is correct then the underlying cause of the working memory 
deficit demonstrated by RAM testing as described above may be attributed to the 
observed loss of myelin integrity and subsequent disconnection of these regions.   
This is supported by work conducted in models of myelin loss e.g. the plp over-
expressing mouse (Kagawa et al., 1994), where working memory deficits have been 
linked to decreased conduction velocities (Tanaka et l., 2009) and also imaging 
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studies where increased fractional anisotropy (the physiological correlate of which is 
thought to be increased myelination and axonal diameter) has been observed within 
the corpus callosum in individuals following training in a working memory task 
(Takeuchi et al., 2010). 
It could be argued that a potential limitation of the study presented in this 
chapter and also the previous chapter was failure to measure CBF as a means to 
providing evidence of hypoperfusion following BCAS had occurred.   However, 
published data exist (Shibata et al., 2004; Shibata et l., 2007) which demonstrates 
hypoperfusion following BCAS occurs in this model, furthermore, the presence of 
ischaemic damage to neuronal perikarya in some BCAS operated animals in the 
present study suggests a reduction in CBF is present following coil placement.  A 
further limitation of this study is that no other physiological correlates of learning 
and memory were examined following induction of hypoperfusion.  These may have 
included synaptic no., acetylcholine levels/ acetylcho ine receptor no., NMDA 
receptor no. or conduction speed of action potentials, f ilure to do so means that the 
deficits in working memory observed following hypoperfusion described above 
cannot unequivocally be attributed to the white matter pathology observed. 
Nonetheless, the findings presented in this chapter represent one of the first 
studies to conduct a parallel assessment of behaviour and pathology in the same 
animals following BCAS induced hypoperfusion.   This has allowed the 
identification of cellular components of white matter which are selectively 
vulnerable to hypoperfusion and to additionally show that modest levels of 
hypoperfusion, in isolation, can be sufficient to induce deficits in spatial working 
memory, whilst other components of spatial memory (spatial reference memory and 
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serial spatial memory) remain intact.   Whilst the mechanisms underlying the 
development of white matter damage following hypoperfusion remain unknown it 
seems likely that this damage directly contributes to the working memory deficit 
observed, possibly through disruption of flow of electrical information and signal 
integration (due to a loss of myelin integrity) as neurons in anatomically distinct 
brain regions communicate with one another.   These findings are clinically relevant 
in that they demonstrate that hypoperfusion alone may precipitate the development of 
white matter damage and changes in cognition in the absence of other confounding 
factors which are often present in elderly individuals presenting with cognitive 
impairment e.g. hypertension, diabetes and atheroscl r is.   The results of the study 
presented in this chapter have now been published (Coltman et al., 2010). 
Once the model of hypoperfusion had been established and characterised the 
next aim was to study the impact of hypoperfusion on white matter pathology and 
amyloid levels in a mouse model of Alzheimer’s diseas . 
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Chapter 5:  The impact of hypoperfusion of varying severities on the 
extent of white matter and Aβ pathology in a mouse model of AD 
5.1  Introduction 
A large body of evidence exists linking vascular risk factors which underlie 
the development of chronic cerebral hypoperfusion and the development of AD in 
later life (for reviews see (de la Torre, 2002; de la Torre, 2004; de la Torre and 
Alireza, 2009).   These risk factors include hypertension, atherosclerosis and heart 
failure.   Furthermore, recent advances in neuroimag ng technology (e.g. SPECT 
scanning) have identified specific patterns of cerebral hypoperfusion which have 
been shown to precede the development of clinical AD symptoms (Matsuda, 2007).   
Another feature which has been recognised as an early vent occurring prior to the 
emergence of clinical symptoms in AD is a loss of white matter integrity (de la 
Monte, 1989; Bartzokis et al., 2003).   Additionally, at post-mortem, white matter 
abnormalities have been shown to exist in the brains of at least 66% of AD patients 
(Roher et al., 2002).   These changes in cerebral pe fusion and white matter, in some 
cases, may occur decades prior to AD diagnosis; however, their contribution to 
disease onset remains unclear. 
At the outset of this thesis studies investigating CBF and white matter 
abnormalities in transgenic models of AD had been co ducted however very few 
have investigated the link between the two.   
This study investigates the hypothesis that hypoperfusion will exacerbate 
white matter pathology in 3xTg-AD mice.   Also, hypoperfusion will induce the 
development of elevated levels of intraneuronal amyloid pathology and will 
precipitate the development of extracellular plaque pathology.   
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5.1.1  Aims of study 
This study sought to investigate how chronic cerebral hypoperfusion of 
varying severities, induced using 0.18mm dia. and 0.16mm dia. microcoils, may 
impact on grey and white matter and intraneuronal amyloid in 3xTg-AD mice. 
 
5.2  Methods 
5.2.1 Animals and experimental design  
Two cohorts of male 3xTg-AD mice (aged 3-4 months) were studied (table 
5.1a).   Hypoperfusion was induced as described in section 2.2.   In cohort 1, 
hypoperfusion was induced for a period of one month using 0.18mm diameter 
microcoils.   In cohort 2, a more severe level of hypoperfusion was induced for a 
period of one month using 0.16mm diameter microcoils.   Sham animals from each 
cohort underwent an identical procedure except that microcoils were not applied.   
Circle of Willis anatomy was compared between C57Bl/6J and 3xTg-AD mice in the 
absence of any surgery in a third cohort of animals (table 5.1b) as described in 
section 2.8. 
Table 5.1a  Initial cohort sizes 
 
                    Treatment 
Cohort 
Sham Hypoperfusion 
1 (0.18mm dia. coil one 
month) 
n=12 n=13 





Table 5.1b  Cohort size for comparison of Circle of Willis anatomy 
 
                    Strain 
Cohort 
C57Bl/6J 3xTg-AD 
3 (Comparison of Circle 
of Willis anatomy) 
n=6 n=7 
 
5.2.2 Pathological analysis 
5.2.2.1 Histological assessment of gray matter pathology 
Haematoxylin and eosin (H&E) staining, as described in section 2.5, was 
used to identify areas of ischaemic damage to neuroal perikarya. 
 
5.2.2.2 Immunohistochemical assessment of white matter pathology  
MAG immunostaining was used to investigate changes in myelin integrity in 
response to hypoperfusion.   APP immunostaining was used to investigate levels of 
axonal pathology in response to hypoperfusion.   Iba-1 immunostaining was used to 
investigate microglial upregulation in response to hypoperfusion.   4G8 
immunostaining was used to investigate changes in white matter Aβ levels in 
response to hypoperfusion.   Immunostaining and quantification was conducted as 
described in section 2.6 other than for quantification of microglial activation where a 
grading scale (0-3) was used.   The scale was as follows; 0- no activated microglia, 
1- baseline activation, few sparsely distributed activ ted cells, 2- marked 
upregulation, many activated cells present throughot region, 3- very dense patches 
of many activated cells.   APP and 4G8 immunostaining was conducted by the 
author, MAG and Iba-1 immunostaining was conducted by Mrs Fiona Scott and Mr 
Tommy Dingwall. 
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5.2.2.3 Immunohistochemical assessment of intraneuronal APP and Aβ levels  
APP immunostaining was used to investigate changes i  intraneuronal levels 
of APP in response to hypoperfusion.  4G8 immunostaining was used to investigate 
changes in intraneuronal Aβ levels in response to hypoperfusion.   Immunostaining 
was conducted as described in section 2.5 and analysed using image analysis as 
described in section 2.6.   For regions of interest see Fig. 5.1.  
 
5.2.2.4 Regions of interest 
In this study hemi brain sections were stained and alysed.   White matter 
regions of interest examined were external capsule, int rnal capsule, hippocampal 
fimbria, and white matter fibre bundles of the striatum.   Intraneuronal APP and 
Αβ levels were examined in the hippocampal and cortical pyramidal neurons (Fig. 
5.1). 
 
5.2.3  Western blot assay of whole brain homogenate 
Protein extracts were prepared from frozen hemi brains and their 
concentrations assessed.   Samples were separated vi  SDS-gel electrophoresis and 
subject to Western blot analysis to investigate protein levels as described in section 
2.7.   For antibodies and concentrations used see tabl 2.3. 
 
5.2.4 Comparison of Circle of Willis anatomy 
A further study was conducted as part of this chapter to compare Circle of 
Willis (CoW) anatomy between C57Bl/6J and 3xTg-AD mice as described in section 
2.8.   This was done following pathological analysis to investigate whether strain 
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specific differences in CoW architecture might underlie the more robust response of 
3xTg-AD mice as compared to C57Bl/6J mice to BCAS. 
 
5.2.5 Statistical analysis 
Results for image analysis of intraneuronal APP, intraneuronal Aβ and 
Western blot analysis were analysed by Student’s t-te t.   Scores following analysis 
of MAG, APP and Iba-1 immunostaining were analysed as described in chapters 2, 3 




Figure 5.1  White and grey matter regions of interest 
White matter regions of interest were the external capsule, internal capsule (area assessed circled, 
hippocampal fimbria, and white matter fibre bundles of the striatum.  Grey matter regions of interest 
were the CA1 hippocampal subregion and layer IV/ V pyramidal neurons in the cortex. Images 




Fibre bundles of the
striatum
Image analysis of 
intracellular APP and Aβ
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5.3 Results 
5.3.1 Recovery from surgery 
All animals recovered well from surgery with the exc ption of one hypoperfused 
animal from cohort one and six hypoperfused animals from cohort two, which were 
culled due to poor recovery.   See table 5.2 for final group sizes. 
 
Table 5.2  Final cohort sizes  
 
                    Treatment 
Cohort 
Sham Hypoperfusion 
1 (0.18mm dia. coil one 
month) 
n=12 n=12 





5.3.2 Histological examination of grey matter following hypoperfusion 
No sham animals from either cohort displayed any evidence of ischaemic 
damage to neuronal perikarya (as defined in section 2.5.3).   In cohort 1, in which 
BCAS was induced by 0.18mm dia. coils, there was no ischaemic damage to 
neuronal perikarya.   In cohort 2, where animals were subjected to a more severe 
level of stenosis using 0.16mm dia. microcoils, ischaemic damage was seen in six of 
eight hypoperfused animals.   Five of these animals showed evidence of ischaemic 
damage in the striatum, three of these also had ischaemic damage in the cortex and 
one displayed evidence of ischaemic damage in the CA1 and CA3 hippocampal 
subregions, the sixth animal displayed evidence of ischaemic damage in the cortex 
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only.   Where cortical damage had occurred this was limited to neurons in the upper 
cortical layers (I, II & III).    
 
5.3.3 Immunohistochemical analysis of white matter pathology following 
hypoperfusion 
5.3.3.1 Assessment of myelin integrity following hypoperfusion 
The probability of a loss of myelin integrity following hypoperfusion induced 
using 0.18mm diameter microcoils was not increased (p = 1.000; Fig 5.2A, B, D), 
Fisher’s exact test.  In cohort 1, there were no alter tions in myelin integrity in the 
majority of sham and hypoperfused animals (Fig. 5.2A, B), however in a small 
subset of animals, 4 sham and 5 hypoperfused animals, inimal myelin damage was 
observed.   This was manifest as disorganisation of myelinated fibres, deposition of 
myelin debris and vacuolation as described in chapters two, three and four of this 
thesis.   In animals where myelin damage was evident it was widespread and diffuse 
in nature.   Overall myelin integrity did not differ between sham and hypoperfused 
animals in this cohort (Fig 5.2D;  p =  0.764) Mann Whitney-U test.  
The probability of a loss of myelin integrity following hypoperfusion induced 
using 0.16mm diameter microcoils was significantly increased (p = 0.026; Fig 
5.2A,C,E), Fisher’s exact test.  In cohort 2, most sham animals displayed no evidence 
of myelin pathology, in those where pathology was evid nt (3 of 7) it was mild to 
moderate.   A spectrum of pathology was seen across all hypoperfused animals from 
cohort 2 (Fig 5.2C).   Despite there being a higher probability of damage to myelin 
occurring following BCAS induced using 0.16mm diameter microcoils, overall, the 
extent of myelin damage was not significantly increas d in hypoperfused animals as 
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compared to shams (Fig 5.2E;  p = 0.159) Mann-Whitney-U test.   In the majority of 
hypoperfused animals where ischaemic damage had occurred, damage to myelinated 
fibres was markedly increased (Fig. 5.E highlighted red).  
 
5.3.3.2 Assessment of axonal pathology following hypoperfusion 
In all animals, modest APP immunostaining was observed in 
oligodendrocytes in white matter regions, this was accompanied by a subtle axonal 
pathology (small swellings/axonal bulbs).   This was particularly prominent in the 
hippocampal fimbria, internal capsule and fibre bundles of the striatum.  
The probability of axonal damage occurring following hypoperfusion induced 
using 0.18mm diameter microcoils was not increased (p = 0.626; Fig 5.2F, G, I), 
Fisher’s exact test.  In cohort 1 hypoperfusion did not exacerbate axonal pathology as 
compared to shams (Fig. 5.2F, G, I;  p = 0.626) Mann-Whitney-U test;  however in 
one hypoperfused animal more severe axonal pathology (large axonal 
bulbs/swellings) was observed in the hippocampal fimbr a.   
The probability of axonal damage occurring following hypoperfusion induced 
using 0.16mm diameter microcoils was not increased (p = 0.214; Fig 5.2F, H, J), 
Fisher’s exact test.   In cohort 2, similarly, hypoperfusion did not exacerbate axonal 
pathology (Fig. 5.2 F, H, J;  p = 0.284) Mann-Whitney-U test.   However, in 5 of 6 
animals from this cohort, where areas of ischaemic damage were observed, localised 
patches of moderate to severe axonal pathology (denoted by frequently occurring 
large axonal bulbs/ swellings) was also evident in white matter (inset Fig. 5.2H).   
This was observed in the striatum of 5 animals, in 3 of these moderate to severe 
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axonal pathology was also observed in areas within the internal capsule, and in one 
of these, severe axonal pathology was also evident n the hippocampal fimbria.   
 
5.3.3.3 Assessment of microglial activation following hypoperfusion 
The presence of activated microglia was evident in all animals, both sham 
and hypoperfused in both grey and white matter.   Generally, more activated 
microglia were present in hypoperfused animals as compared to shams in each cohort 
examined, however, inter animal variability was high and there was no significant 
difference between sham and hypoperfused mice (Fig.5.2 K, L, M, N, O; cohort 1,   
p = 0.652; cohort 2, p = 0.11).   Additionally, microglial activation tende  to be 
higher in hypoperfused animals where a more severe lev l of stenosis had been 
induced (cohort 2) and was highest in those where evidence of ischaemic damage 
was identified (Fig. 5.2O).   In animals where there was evidence of localised areas 
of severe myelin disruption, moderate to severe axon l pathology or altered Aβ 
levels; dense, localised patches of activated microglia were also visible (Fig. 5.2M, 







































































































































Cohort 2: 0.16mm coil Cohort 1: 0.18mm coil Cohort 2: 0.16mm coil 
Figure 5.2  Immunohistochemical examination of white matter following hypoperfusion 
Representative images from the internal capsule of sham (A, D, G) and hypoperfused animals; cohort 1 (n=12 sham, 12 hypoperfused B, E, H) and cohort 2 (n=7 
sham, 8 hypoperfused C, E, I,). The probability of myelin damage occurring was increased following hypoperfusion induced using 0.16mm but not 0.18mm 
diameter micricoils (p= 0.026 and p= 1.000 respectively.  The probability of axonal damage occurring following hypoperfusion was not increased (cohort 1, 
p=0.626, I; cohort 2, p=0.214) Fisher’s exact test.  Animals where ischaemic damage to neuronal perikarya was observed in cohort 2 are highlighted in red(E, J, 
O).  MAG immunostaining (A, B, C) revealed no signif cant difference in levels of myelin damage between sham and hypoperfused animals in cohort 1 (p=0.764, 
median values- sham = 0, hypoperfused=0, D), or cohort 2 (p= 0.159, median values- sham = 0, hypoperfused=4) Mann Whitney-U test. APP immunostaining 
revealed that in all animals, axonal pathology was present (arrowheads D,E,F).  Overall axonal pathology was not increased following hypoperfusion (cohort 1, 
(p=0.626 median values- sham=3, hypoperfused=3.5), I; cohort 2, (p=0.284 median values- sham=3, hypoperfused=3), J) Mann Whitney-U test. In some animals 
subject to more a more severe level of stenosis, localised areas of severe axonal pathology were observed (inset F, open arrowheads).  Iba-1 immunostaining (G, 
H, I) revealed microglial activation was not increased following hypoperfusion (cohort 1, p=0.652 median values- sham=4, hypoperfused=4, N; cohort 2, p=0.11, 
O median values- sham=5, hypoperfused=6).  In some animals, subject to a more severe level of stenosis, patches of densely upregulated microglia were observed.  
Mann-Whitney-U test.  Scale bars = 50µm. 
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5.3.3.4 Investigation of white matter Aβ levels following hypoperfusion 
In all animals 4G8 immunostaining revealed low leve Aβ expression was 
evident in oligodendrocytes in white matter regions.   There was no change in levels 
of white matter Aβ in any region of any sham animal or any hypoperfusd animal 
from cohort 1 (Fig. 5.3A, B).  
In cohort 2 Aβ levels remained unaltered in most regions in the majority of 
animals (Fig 5.3C), however, in 4 of 8 hypoperfused animals, consistent with the 
location of moderate to severe axonal pathology, localised patches of altered Aβ 
levels were also observed.   This was manifest as what appeared to be axonal 
accumulation of Aβ and was of similar appearance to the axonal swellings seen in 
APP stained sections, indicative of axonal pathology (inset Fig. 5.3C).   Evidence of 
altered white matter Αβ levels was observed in the internal capsule of one animal, 
the striatum of another, a third animal displayed evi nce of altered Aβ levels in both 
of these regions whilst abnormal staining was seen in the hippocampal fimbria of the 











Sham Cohort 1: 0.18mm coil Cohort 2: 0.16mm coil
 
Figure 5.3  White matter Aβ levels following hypoperfusion 
Representative images of 4G8 immunostaining in the internal capsule of sham (A) and hypoperfused 
animals from cohort 1 (B) and cohort 2 (C).  White matter Aβ levels were unchanged in response to 
hypoperfusion, other than in 4 of 8 animals in cohort 2 (inset (C), where a more severe level of 
hypoperfusion had been induced.  Areas where accumulations of Aβ (arrows, inset C) were present 
were consistent with focal areas of severe axonal pathology.  Scale bar= 50µm.   
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5.3.4 Western blot analysis of white matter protein levels following 
hypoperfusion 
5.3.4.1 MBP Western blotting 
Western blot analysis of MBP levels in whole brain homogenate detected no 
change between sham and hypoperfused animals in cohort 1 (p = 0.483, Fig. 5.4 B).   
In cohort 2, MBP levels were significantly reduced in hypoperfused animals as 
compared to shams (p = 0.005, Fig. 5.4 C).   
 
5.3.4.2 CNPase Western blotting 
Western blot analysis of CNPase levels in whole brain homogenate detected 
no change in response to hypoperfusion between sham and experimental animals in 
either of the cohorts examined;  cohort 1 (p = 0.412, Fig 5.5 B);  cohort 2 (p = 0.817, 
Fig. 5.5 C). 
 
5.3.4.3 MAG Western blotting 
Western blot analysis of MAG levels in whole brain homogenate detected no 
change in response to hypoperfusion between sham and experimental animals in 










































Cohort 1: 0.18mm coil one month hypoperfusion












Figure 5.4  MBP levels are reduced in response to severe levels of 
hypoperfusion 
Representative image of Western blot of MBP and GAPDH (A).  Data are expressed as mean MBP/ 
GAPDH ± SEM.  Cohort 1, n=12 sham/ n=12 hypoperfused; cohort 2, n=7 sham and 8 hypoperfused.  
No difference was detected in MBP levels between sham and hypoperfused animals in cohort 1 
(p=0.483, mean values- sham= 1.94 ±0.09 hypoperfused= 2.02 ± 0.25,  B).  In cohort 2, MBP levels 
were significantly reduced in experimental animals s compared to shams (p=0.005, mean values- 










































Cohort 1: 0.18mm coil one month hypoperfusion









Figure 5.5  CNPase levels are unchanged in response to hypoperfusion 
Representative image of Western blot of CNPase and GAPDH (A).  Data are expressed as mean 
CNPase/ GAPDH ± SEM.  Cohort 1, n=12 sham/ n=12 hypoperfused; cohort 2, n=7 sham and 8 
hypoperfused.  No difference was detected in CNPase levels between sham and experimental animals 
in either of the cohorts; cohort 1, (p=0.412, mean values- sham= 2.68 ± 0.08 hypoperfused= 2.54 ± 
0.14 B), cohort 2, (p=0.817, mean values- sham= 1.94 ± 0.13 hypoperfused= 1.97 ± 0.09 C).  Two-








































Cohort 1: 0.18mm coil one month hypoperfusion






Sham ShamHypo Sham Hypo Hypo
 
Figure 5.6  MAG levels are unchanged in response tohypoperfusion 
Representative image of Western blot of MAG and GAPDH (A).  Data are expressed as mean MAG/ 
GAPDH ± SEM.  Cohort 1, n=12 sham/ n=12 hypoperfused; cohort 2, n=7 sham and 8 hypoperfused.  
No difference was detected in MAG levels between sham and experimental animals in either of the 
cohorts; cohort 1, (p=0.697, mean values- sham= 1.68 ± 0.13 hypoperfused= 1.60 ± 0.13 B), cohort 
2, (p=0.283, , mean values- sham= 1.35 ± 0.28 hypoperfused= 1.23 ± 0.04  C).  Two-tailed student’s 
t-test. 
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5.3.5 Image analysis of intraneuronal APP levels following hypoperfusion 
Strong cytoplasmic APP expression was observed in layer IV & V pyramidal 
neurons in the cortex and within neurons in the CA1, CA2 and CA3 subregions of 
the hippocampus in all mice.   The pattern of APP immunostaining was not altered in 
response to hypoperfusion.   There was no significat difference in intraneuronal 
APP staining in the CA1 region between shams (Fig. 5.4A) and hypoperfused (Fig. 
5.4B) mice in cohort 1 (p = 0.200, Fig. 5.4I) or cohort 2, (p = 0.215, Fig. 5.4C, J).   
Similar results were obtained from analysis of corti al APP expression (appendix 1).  
In cohort 2, where ischaemic damage to neuronal perikarya was observed 
intraneuronal APP expression was reduced (Fig 5.4D) 
 
5.3.6 Image analysis of intraneuronal Aβ expression following hypoperfusion 
Intraneuronal Aβ was clearly visible in CA1 hippocampal pyramidal neurons 
and layer IV & V cortical pyramidal neurons of all mice.   Staining was confined to 
cell bodies with no extracellular staining present in either region.   There was no 
significant difference in intraneuronal Aβ staining in the CA1 region between sham 
(Fig. 5.4E) and hypoperfused (Fig. 5.4F) mice in cohort 1 (p = 0.876, Fig. 5.4K), or 
cohort 2 (p = 0.918, Fig. 5.4G, L).   Similar results were obtained from image 
analysis of cortical Aβ expression (appendix 2).   In cohort 2 where ischaemic 
damage to neuronal perikarya was observed, intraneuo al Aβ expression was 





















































Cohort 1: 0.18mm coil 
Cohort 1: 0.18mm coil 
Cohort 2: 0.16mm coil 








Figure 5.7  Intraneuronal APP and Aβ  levels are unchanged in response to 
hypoperfusion  
Representative images of CA1 neurons from sections immunostained for APP (A, B, C, D) and Aβ (E, 
F, G, H). Data are expressed as R.O.D. ± SEM.  Cohort 1, n=12 sham/ n=12 hypoperfused; cohort 2, 
n=7 sham/ n=8 hypoperfused. Image analysis detected no difference in intraneuronal APP levels 
between sham and hypoperfused animals in either of the cohorts; cohort 1 (p=0.200, mean values- 
sham= 0.34 ± 0.01 hypoperfused= 0.35 ± 0.01  I), cohort 2 (p=0.215, , mean values- sham= 0.32 ± 
0.13 hypoperfused= 0.30 ± 0.01  J).  Neither was there a difference in leves of intraneuronal Aβ 
between sham and hypoperfused animals in cohort 1 (p=0.876, , mean values- sham= 0.16 ± 0.01 
hypoperfused= 0.16 ± 0.01  K), or cohort 2 (p=0.918, , mean values- sham= 0.09 ± 0.01 
hypoperfused= 0.09 ± 0.01  F).  Two-tailed Student’s t-test.  In animals from cohort 2 where 
ischaemic damage to neuronal perikarya was observed, intraneuronal APP and Aβ levels were 
reduced (D, H).  Scale bar = 50µm. 
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5.3.7 Western blot analysis of APP levels following hypoperfusion 
Western blot analysis of APP levels in whole brain homogenate detected no 
change between sham and hypoperfused animals in either cohort 1, (p = 0.072, Fig. 
5.8B), or cohort 2 (p = 0.530, Fig. 5.8C). 
 
5.3.8 Western blot analysis of APP C-terminal fragment levels following 
hypoperfusion 
There was no difference in levels of APP C-terminal fr gment C99 between 
sham and hypoperfused animals in either cohort 1 (p = 0.664, Fig. 5.9B), or cohort 2, 
(p = 0.386, Fig. 5.9D).   Similarly there was no difference in levels of C-terminal 
fragment C83 between sham and hypoperfused animals n either cohort 1 (p = 0.304 
Fig.5.9C), or cohort 2 (p = 0.365, Fig. 5.9E).   There was no change in the C83/ 99 







































Cohort 1: 0.18mm coil one month hypoperfusion





Figure 5.8  APP levels are unchanged in response to hypoperfusion 
Representative image of Western blot of APP and GAPDH (A).  Data are expressed as mean APP/ 
GAPDH ± SEM.  Cohort 1, n=12 sham/ n=12 hypoperfused; cohort 2, n=7 sham/ n=8 hypoperfused.  
No difference was detected in APP levels between sham and experimental animals in either of the 
cohorts; cohort 1 (p=0.072, mean values- sham= 0.93 ± 0.03 hypoperfused= 0.86 ± 0.02 B), cohort 2 





















































































Cohort 1: 0.18mm coil one month hypoperfusion







Figure 5.9  APP processing is unaffected following hypoperfusion 
Representative images of Western blot of APP C-terminal fragments C83 and C99 and GAPDH (A).  
Data are expressed as mean C terminal fragment/ GAPDH ± SEM.  Cohort 1, n=12 sham/ n=12 
hypoperfused; cohort 2, n=7 sham/ n=8 hypoperfused.  No difference was detected in levels of C-
terminal fragments C99 or C83 between sham and experimental either of the cohorts, C99- cohort 
1(p=0.664, , mean values- sham= 0.2 ± 0.0.02 hypoperfus d= 0.21 ± 0.01  B), cohort 2 (p=0.386, , 
mean values- sham= 0.67 ± 0.07 hypoperfused= 0.75 ± 0.04  D), C83- cohort 1 (p=0.304, , mean 
values- sham= 0.16 ± 0.02 hypoperfused= 0.14 ± 0.0.01 C), cohort 2 (p=0.365, , mean values- sham= 
0.44 ± 0.04 hypoperfused= 0.39 ± 0.03  E).  Two-tailed Student’s t-test. 
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5.3.9 Comparison of Circle of Willis anatomy  
Circle of Willis anatomy was compared between C57Bl/6J and 3xTg-AD 
mice as described in section 2.8.   In C57Bl/6J mice (n = 6), three mice were 
deficient of both posterior communicating arteries (PcomA), in the three remaining 
mice from this group only one PcomA was present.  I 3xTg-AD mice (n = 7), no 
animals were deficient of both PcomAs, in four animals the Circle of Willis was 
complete, in two animals only one PcomA was present and one animal had two 
PcomAs  present on the same side.   Thus none of the C57Bl/6J mice had a complete 
Circle of Willis whilst four of seven 3xTg-AD mice xamined did (Table 5.3).   
Comparison between groups by Fisher’s exact test reveal d that this difference was 
not statistically significant (p = 0.07).   This was verified by another observer. 
 
Table 5.3  Comparison of Circle of Willis anatomy 
 
                    Strain 
No. of PcomAs 








5.4  Discussion 
Results from the present study demonstrate that chronic cerebral 
hypoperfusion, induced using 0.18mm dia. microcoils in 3xTg-AD mice aged 4-5 
months, does not exacerbate white matter pathology;  however, carotid stenosis 
induced with smaller coils causes more extensive white matter pathology (axonal 
damage, myelin disruption/ loss and inflammation) ad  greater extent of ischaemic 
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neuronal damage.   Additionally, a more severe level of hypoperfusion is sufficient to 
induce subtle alterations to white matter Aβ levels in some animals.   Contrary to the 
initial hypothesis, hypoperfusion does not impact on APP processing or on 
intraneuronal levels of APP or Aβ in pyramidal neurons in the hippocampus or 
cortex, other than in the presence of ischaemic damage to neuronal perikarya, when 
levels are reduced.   
At the outset of this thesis no studies had been conducted to investigate how 
hypoperfusion may impact on the development of white matter and amyloid 
pathology in mouse models of AD.   Subsequently there have been three of note 
(Kitaguchi et al., 2009; Koike et al., 2010; Yamada et al., 2011). 
Kitaguchi et al. (2009) utilised the same model of hypoperfusion described in 
this chapter in J9 APPSwd/Ind (Hsia et al., 1999) mice where they found, using 0.18mm 
diameter coils to induce stenosis, that white matter rarefaction and gliosis had 
occurred following coil placement.   This was in conjunction with an overall increase 
in extracellular levels of fibrillar Aβ and the number of cortical neurons staining 
immunopositive for intraneuronal Aβ1−42.   They also reported the presence of Aβ in 
white matter fibres in regions of interest examined, however this was not altered 
following hypoperfusion.   These findings are in contrast to those of the present study 
where exacerbated white matter pathology was not observed in 3xTg-AD mice 
subject to the same level of stenosis, neither were there changes in intraneuronal 
levels of Aβ.   One reason for this difference may be due to the age of animals 
studied 4-5 months in the present study vs 12 months i  the study by Kitaguchi et al.; 
this is discussed below and addressed in the following chapter.   An alternative 
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reason as to why results of the present study do not concur with those of Kitaguchi et 
al. may be due to strain specific differences in cerebrovascular architecture. 
A further reason for the disparity between the results of Kitaguchi et al. 
(2009) and those presented here may be variation in methodology.   A potential 
limitation of the present study is the use of an antibody (4G8) which does not 
differentiate between different forms of Αβ, furthermore recent evidence has been 
published demonstrating cross-reactivity occurring between 4G8 and APP (Winton et 
al., 2011).  Kitaguchi et al only reported an increase in the number of Aβ1−42  positive 
neurons not Aβ1−40.   As well as the possibility of causing a false positive result, the 
use of 4G8 may have masked any subtle alterations in the Aβ1-40/Aβ1-42 ratio which 
would have been detected had antibodies specific to each form been employed.   An 
alternative and more sensitive method of detecting alterations in Aβ levels in 
response to hypoperfusion would have been to use an ELISA.   This would also have 
allowed differences in the Aβ1-40/ Aβ1-42 ratio to be examined. 
Yamada et al (2011) also utilised the BCAS model of hypoperfusion in J20 
APPSwd/Ind (Mucke et al., 2000) to investigate the impact of hypoperfusion on 
cognitive function and Aβ metabolism.   Yamada et al. (2011) found that overall, 
levels of extracellular soluble Aβ were increased in response to BCAS, this was in 
conjunction with decreased levels of Aβ deposition and cored plaque formation thus 
implying, in accordance with the findings of Kitaguchi et al. and in contrast to the 
findings of the present study, that Aβ metabolism is altered in response to 
hypoperfusion.   This finding is also of interest because it lends weight to the 
hypothesis that extracellular amyloid plaques in ADmay be broken down following 
upregulation of the inflammatory response as is typically seen in ischaemia 
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(Akiyama and McGeer, 2004).   Furthermore, results from Yamada et al. 
demonstrated a reference memory impairment which may have been due to the 
increased levels of soluble Aβ, or, alternatively due to neuronal cell loss, which was 
observed in the hippocampus in BCAS operated transgenic mice.   
Koike et al (2010) investigated the impact of mild hypoperfusion in 3xTg-AD 
mice utilising a different model to that described in this chapter.   In their study, 
hypoperfusion was induced via complete ligation of the common carotid artery for a 
period of four minutes and the effects were studied 48 hours, three weeks and three 
months later.   Changes to Aβ levels and levels of normal tau and phosphorylated tau 
were recorded acutely, however these had returned to baseline by three months.   
White matter changes in response to hypoperfusion were not assessed.   Although 
findings from this study clearly indicate a link betw en a CBF reduction and AD 
pathology, it could be argued that the method of induction and duration of 
hypoperfusion when compared to those utilised by the present study, model less 
accurately the longer term, chronic changes in blood flow associated with ageing and 
vascular risk factors linked to AD occurrence in later life.  
In the present study, exacerbated white matter pathology was only observed 
in animals where a more severe level of stenosis had been induced using 0.16mm 
diameter microcoils, furthermore this was only in animals where ischaemic damage 
to neuronal perikarya had occurred (75% of surviving a imals).   Also of note is the 
proportion of animals (~50%) from this cohort which had to be culled following poor 
recovery from surgery.   Whilst no pathological study was undertaken following 
termination of these animals, all displayed an ischaemic phenotype (hunched, 
circling and ptosis) accompanied by a drop in body temperature and body weight 
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prior to culling.   The fact that some 3xTg-AD mice w re able to withstand this level 
of hypoperfusion suggests that collateral circulation in this strain may be more robust 
than in C57Bl/6J mice (discussed below).  
As stated above, almost all animals which were subject to BCAS using 
0.16mm dia. microcoils in the present study displayed evidence of ischaemic damage 
and focal areas of severe white matter pathology.   Of interest, is that in animals 
where no ischaemic damage was observed, levels of myelin damage, axonal 
pathology and inflammation did not appear to be increased as compared to shams 
(Fig 5.3).   Axonal pathology has previously been rported in transgenic models of 
AD (Song et al., 2004; Stokin et al., 2005; Sun et al., 2005; Wirths et al., 2006), as 
has damage to myelinated fibres (Games et al., 1995; Wirths et al., 2006; Desai et al., 
2009; Desai et al., 2010) and also elevated levels of inflammatory cells (Games et al., 
1995).   Both axonal pathology and elevated levels of microglial activation have been 
linked with increased susceptibility to the development of ischaemia in APP 
transgenics (Zhang et al., 1997; Koistinaho et al., 2002).   The presence of axonal 
pathology and also intraneuronal Aβ in the AD brain has been demonstrated to cause 
elevated levels of inflammation and therefore increased metabolic demand.  
Conversely CBF reductions have been observed in the brains of both human AD 
patients and transgenic AD models, in particular, and of note the 3xTg-AD mouse 
model has been demonstrated to have reduced cerebrovascular volume (Bourasset et 
al., 2009) and altered regional cerebral glucose uptake (Nicholson et al., 2009) as 
compared to age matched non-Tg controls.   This is possibly due to the presence of 
Aβ, which as well as being synaptotoxic, has been shown t  impact negatively on 
cerebrovascular reactivity (Zhang et al., 1997) and e othelial cellular function 
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(Thomas et al., 1996).   Additionally 3xTg-AD mice have been demonstrated to have 
higher resting intraneuronal Ca2+ levels as compared to non-transgenic controls 
(Lopez et al., 2008).   Taking these points into account, it could be argued that the 
AD brain is sensitised to the development of ischaemic damage following any 
vascular insult due to an already altered metabolism.   This may be the reason why 
no intermediate group exists where exacerbated white matter pathology is seen in the 
absence of ischaemic damage following induction of stenosis using 0.16mm dia. 
microcoils.  
Findings reported in this chapter also demonstrate hat, in response to a more 
severe level of stenosis, MBP levels in experimental animals were reduced.   A 
possible reason for this is myelin loss following the development of ischaemic 
damage (as seen in 6 of 8 surviving experimental anim ls).   MBP levels have been 
shown to be altered following hypoperfusion in experim ntal animal models where 
CBF reductions are severe enough such that ischaemic damage to neuronal perikarya 
is observed (Kurumatani et al., 1998; Cho et al., 2006).   This raises the question as 
to why reductions were not observed in levels of the other myelin proteins 
investigated, CNPase and MAG.   One potential reason nd one which highlights a 
limitation of the present study is that Western Blotting was conducted in whole brain 
homogenate for all proteins investigated.  The abundance of CNPase and MAG is 
relatively low in whole brain homogenate therefore any subtle changes in these 
proteins may be masked due to their relatively low c ncentrations.  Retrospectively, 
a more robust measure of white matter protein quantification would have been to 
micro-dissect out the visible white matter tracts and conduct Western blotting using 
this tissue instead.  Also, when examining sections f llowing MAG immunostaining, 
a loss of MAG was not observed as such, rather, a cellular redistribution of protein 
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which was evident as accumulations of myelin debris.   Attempts were made to 
measure both MAG and MBP levels in immunostained sections using image analysis 
(data not reported); however no differences were found between sham and 
hypoperfused animals in either cohort examined.   In the case of MAG this is most 
likely due to the reason outlined above i.e. cellular redistribution of protein.   In the 
case of MBP this is possibly due to the sheer abundance of MBP in white matter 
tracts masking any detectable loss, alternatively it may be due to methodological 
differences.   Whilst Western blotting gives a global representation of alterations in 
protein levels, image analysis of immunostaining only allows selected regions to be 
examined.   It may simply be the case that regions where white matter damage had 
occurred were not present in sections examined.   
Nonetheless the fact that MBP levels were altered raises the question of 
whether myelin repair is occurring in animals following hypoperfusion.   Whilst 
there is no direct evidence for this, an interesting point to consider is the ratio of 
MBP isoform expression in 3xTg-AD mice.   As stated in section 1.1.2.1 of this 
thesis the two MBP isoforms preferentially expressed in the adult mouse are 18.5 and 
14kDa (Staugaitis et al., 1990) which play a role in compaction of the myelin sheath 
(Roach et al., 1985).   However, in the 3xTg-AD mice utilised in the present study it 
is the 18.5kDa and 17kDa isoforms which are most abundant (Fig. 5.4).   The 
upregulated expression of the 17kDa isoform, which is thought to play a role in 
myelination/remyelination (Pedraza et al., 1997) may be indicative of a repair 
process.   It seems unlikely that this is in respone to the hypoperfusion itself as other 
studies conducted within the Horsburgh group have shown that MBP isoform 
expression is normal in hypoperfused C57Bl/6J mice (Scullion, unpublished data).  
More importantly, isoform expression did not differ between sham and hypoperfused 
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animals.   This differential MBP isoform expression may instead be linked to the 
presence of Aβ or the expression of human AD related transgenes.   This hypothesis 
is supported by work published by (Desai et al., 2009; Desai et al., 2010), who 
demonstrated that region specific abnormalities in brain myelination exist in 3xTg-
AD mice, possibly due to the presence of Aβ1-42.  Furthermore, a proteomics study 
conducted recently (Martin et al., 2008) demonstrated that MBP gene expression was 
upregulated in 3xTg-AD mice as compared to age matched ontrols.   Clearly further 
work is required to substantiate this.  However, this in itself highlights a limitation of 
this study; the lack of a non-transgenic control (discussed below).   
Severe cerebrovascular challenges such as stroke have been identified as one 
of the leading risk factors for the development of AD in later life.   Studies conducted 
in animals models of stroke have demonstrated that following an acute ischaemic 
insult, levels of amyloid precursor protein (APP) and Aβ are elevated (Kalaria et al., 
1993; Pluta et al., 1994) and that this occurs in co junction with the development of 
white matter pathology (Wakita et al., 2002).   
In the study described in this chapter, changes to white matter Aβ levels were 
only observed in areas where moderate to severe axonal pathology (grading score 2 
or 3) was evident.   The impairment of axonal transport and accumulation of APP, 
due to disruption of the cytoskeleton in damaged axons is a common feature often 
seen following brain injury.   In addition to stroke, this has also been observed 
following traumatic brain injury (McKenzie et al., 1996; Spain et al., 2010).   Some 
studies have reported that APP is co-transported via kinesin I mediated transport 
along axons with the secretases (β & γ) required for its cleavage to produce Αβ 
(Kamal et al., 2000; Kamal et al., 2001) although evid nce contrary to this has also 
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been published (Lazarov et al., 2005).   Nonetheless it is accepted that APP 
containing vesicles accumulate along with amyloidogenic secretases (and other 
organelles) at sites of axonal injury (Stokin et al., 2005).   Taking this into account, it 
is possible that the altered Aβ levels seen following hypoperfusion in the present 
study are a result of amyloidogenic APP processing at sites of axonal injury.  
Contrary to the initial hypothesis set out at the beginning of this chapter, 
hypoperfusion did not impact on overall intraneuronal APP or Aβ levels, nor did 
hypoperfusion precipitate the development of amyloid plaque pathology.   However, 
in pyramidal neurons where ischaemic damage had occurred, APP and Aβ levels 
were reduced, this was in conjunction with marked microglial upregulation.   
Microglia have been shown to express receptors which, early in AD pathogenesis 
promote the phagocytosis and clearance of Aβ (Hickman et al., 2008).   Therefore 
the marked microglial upregulation in areas where ischaemic damage to neuronal 
perikarya was observed may account for reductions in levels of intraneuronal APP/ 
Aβ.   
Microglial activation may also account for why overall levels of 
intraneuronal Aβ were unchanged.   Given the considerably higher baseline levels of 
activated microglia observed in 3xTg-AD mice as compared to the C57Bl/6J mice 
utilised in chapters 3 and 4, it is possible that microglia mediated Aβ clearance is 
sufficient, in 3xTg-AD mice (aged 4-5 months) to prevent excess Αβ accumulation, 
even following the induction of hypoperfusion.   Alternatively, given that 
hypoperfusion did not impact on the APP processing pathway, as evidenced by no 
change to APP C-terminal fragment levels, it is possible that hypoperfusion does not 
contribute to increased levels of AD pathology.   Given the amount of 
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epidemiological evidence to the contrary, this is contentious, however based on 
results presented above this point cannot be dismissed.   An alternative explanation 
may be that hypoperfusion was not present for a sufficient length of time to impact 
on Aβ levels. 
Work conducted within this laboratory (Kelly et al., 2001) and by others 
(Fujii et al., 1997; Yang et al., 1997; Kitagawa et al., 1998; Maeda et al., 1998) has 
demonstrated that variability in cerebrovascular architecture exists between different 
inbred strains of laboratory mice and that this likely underlies varying susceptibility 
to reductions in CBF.   To date, no studies have ben published which have 
investigated cerebrovascular architecture in 3xTg-AD mice.   The study presented in 
this chapter, to compare Circle of Willis anatomy between C57Bl/6J and 3xTg-AD 
mice found notable strain related differences; specifically regarding the presence of 
the PcomA.   
Previous studies to examine the cerebrovascular architecture of C57Bl/6J 
wild type mice, the background strain upon which APPSwe/Ind transgenics are bred, 
and SV-129 mice (3xTg-AD mice are bred on a C57Bl/6J x SV129 background), 
have revealed strain specific differences in Circle of Willis anatomy (Fujii et al., 
1997; Wellons  et al., 2000) similar to those reported here, between C57Bl/6J and 
3xTg-AD mice.   Although differences in Circle of Willis anatomy between the two 
strains in the present study were not statistically significant, observations made 
suggest that 3xTg-AD mice may have a more robust collateral circulation than 
C57Bl/6J mice.    This difference may explain the more robust response of 3xTg-AD 
mice to BCAS and the disparity between the present tudy and those of Kitaguchi et 
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al. (2009) and Yamada et al. (2011).   This also highlights the failure to measure CBF 
as a limitation of the current study. 
As pointed out above, a further limitation of the current study is the lack of a 
non-transgenic control.   The reason no non-transgenic controls were included in the 
study described in this chapter is due to a lack of availability.   The founder animals 
used to establish the 3xTg-AD mouse colony, from which all experimental animals 
described in this study were derived, were homozygous f r the human AD related 
transgenes.   This precluded the generation of non-transgenic animals for use as 
controls.   In light of this, and taking into consideration the differences in 
cerebrovascular architecture between C57Bl/6J and 3xTg-AD mice discussed above, 
were this study to be repeated the use of an alterntive AD mouse model may be 
more appropriate i.e. one where transgenes are exprssed on a C57Bl/6J background 
e.g. the J9 or J20 strain (Hsiao et al., 1996; Mucke et al., 2000) or the Tg2576 strain. 
In summary evidence presented in this chapter demonstrates that BCAS, as 
induced using 0.18mm dia. microcoils for a period of one month, is insufficient to 
influence the development of AD pathology, or to exacerbate pre-existing white 
matter pathology in 3xTg-AD mice.   However, a more severe level of stenosis, as 
induced using 0.16mm dia. microcoils, is sufficient to cause the development of focal 
areas of severe white matter pathology and ischaemic damage to neuronal perikarya 
in a majority of experimental 3xTg-AD animals.   In some animals where severe 
white matter pathology is present altered white matter Aβ levels may be observed, 
possibly due to amyloidogenic APP processing at sites of axonal injury.   
As discussed above a factor which must be considered when interpreting the 
findings outlined in this chapter is the age of animals studied (4-5 months).  When 
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considered retrospectively this may be considered one of the biggest limitations of 
the present study.  In younger animals Aβ clearance mechanisms may be robust 
enough such that Aβ deposits (both intra and extracellular) do not accumulate, this 
has been demonstrated recently in Tg2576 mice (Hawkes et al., 2011).  Where 
perivascular drainage, thought to be a major clearance route for Aβ (Bell and 
Zlokovic, 2009; Weller et al., 2009) was shown to be intact in animals as old as 7 
months.   Similarly, in younger animals the vessels of the cerebrovasculature may be 
plastic enough such that they are able to compensat for BCAS as induced via 
0.18mm dia. microcoils, thus precluding the exacerbation of white matter pathology.   
With this in mind, the following chapter will investigate how white matter protein 
levels change with ageing in 3xTg-AD mice and also whether ageing confers 
increased vulnerability to the development of white matter damage following BCAS. 
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Chapter 6:  Does ageing impact on white matter protein levels or 
confer increased vulnerability to hypoperfusion in 3xTg-AD mice? 
6.1  Introduction 
Results from numerous neuroimaging studies have shown that a reduction in 
brain white matter volume (Guttmann et al., 1998; Resnick et al., 2000) and myelin 
sheath integrity (Peters, 2002, 2009) are characteristic of normal ageing.   This is 
supported by evidence from post-mortem stereological studies conducted on non-
demented elderly subjects (Pakkenberg and Gundersen, 1997; Tang et al., 1997) and 
is consistent across several species including the rhesus monkey (Wisco et al., 2008) 
and the rat (Yang et al., 2009).   In AD patients, white matter loss and damage to the 
myelin sheath have been shown to be exacerbated (Salat et al., 2009).   Despite this, 
few studies have been conducted to examine alterations in white matter component 
proteins with normal ageing, or in AD.    
Reductions in cerebral blood flow are known to occur with normal ageing 
and these have been shown to correlate with increased levels of white matter damage 
(Kawamura et al., 1991).   Several factors have been proposed as an underlying cause 
for this age related development of hypoperfusion, ncluding changes to endothelial 
cells which lead to decreased vascular reactivity (Farkas et al., 2006) and also 
microvascular changes within the capillary network (de Jong, 1991; Brown and 
Thore, 2011).   These changes are thought to confer i creased vulnerability to 
cerebrovascular insults predisposing individuals to further reductions in cerebral 
blood flow, which may occur as a result of the development of an age related disease 
state e.g. hypertension or atherosclerosis.   
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Whilst much work has been successfully conducted to characterise how the 
cerebrovasculature changes with normal ageing and also how age related disorders 
such as hypertension may accelerate these changes (Farkas et al., 2000), the degree 
to which these changes may augment damage to white matt r following further CBF 
reductions remains to be fully elucidated. 
This study investigated the hypothesis that ageing impacts on white matter 
protein levels in 3xTg-AD mice and that aged animals will show increased 
vulnerability to hypoperfusion and the subsequent development of white matter 
damage. 
 
6.1.1 Aims of study 
The aims of this study were to investigate the impact of ageing on white 
matter protein composition in young and old sham and hypoperfused 3xTg-AD mice 
and to investigate, through the utilisation of the ypoperfusion model previously 
described, the impact of hypoperfusion on white matter integrity in a cohort of aged 
3xTg-AD mice. 
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6.2  Materials and Methods 
6.2.1 Mice and group sizes 
Two cohorts of male 3xTg-AD mice were used (table 6.1).   Hypoperfusion 
was induced in experimental animals from each cohort using 0.18mm diameter 
microcoils for a period of one month.   In cohort 1, young animals aged 3-4 months 
at time of surgery were studied (these were the same nimals referred to as cohort 1 
in chapter 5).  The second cohort consisted of older animals aged 13-14 months at 
time of surgery.  Even though greater levels of damage were observed following 
hypoperfusion using a 0.16mm diameter coil in the preceding chapter, hypoperfusion 
was induced using a 0.18mm diameter coil in the present study as there was a 
concern following the relatively high mortality rate observed in young animals 
following BCAS with the narrower coil, that aged animals would be even less able to 
tolerate the CBF reduction due to age related changes in cerebrovascular integrity. 
Table 6.1  Initial cohort sizes 
 
                  Age        
Treatment               
Cohort 1 Cohort 2 
Sham n=12 n=6 
Hypoperfusion n=13 n=12 
 
6.2.2 Western blotting 
Protein extracts were prepared from frozen hemi brains and their 
concentrations assessed.   Samples (5µg) were separated via SDS-gel electrophoresis 
and subject to Western blot analysis to investigate protein levels as described in 
section 2.7.   For antibodies and concentrations used see table 2.3. 
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6.2.3 Pathological analysis 
6.2.3.1 Histological assessment of gray matter pathology 
Haematoxylin and eosin (H&E) staining, as described in section 2.5, was 
used to identify areas of ischaemic damage to neuroal perikarya. 
 
6.2.3.1 Immunohistochemical assessment of white matter pathology  
MAG immunostaining was used to investigate changes in myelin integrity in 
response to hypoperfusion.   APP immunostaining was used to investigate levels of 
axonal pathology in response to hypoperfusion.   Iba-1 immunostaining was used to 
investigate microglial upregulation in response to hypoperfusion.   4G8 
immunostaining was used to investigate changes in white matter Aβ levels in 
response to hypoperfusion.  Immunostaining and quantification was conducted as 
described in section 2.6. other than for quantification of microglial activation where a 
grading scale (0-3) was used.   The scale was as follows; 0- no activated microglia, 
1- baseline activation, few sparsely distributed activ ted cells, 2- marked 
upregulation, many activated cells present throughot region, 3- very dense patches 
of many activated cells.   APP and 4G8 immunostaining was conducted by the 
author, MAG and Iba-1 immunostaining was conducted by Mrs Fiona Scott and Mr 
Tommy Dingwall. 
 
6.2.4 Regions of interest 
In this study hemi brain sections were stained and analysed.  As in chapter 5, 
white matter regions of interest examined were external capsule, internal capsule, 
hippocampal fimbria, and white matter fibre bundles of the striatum (Fig. 6.1).  
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6.2.5 Statistical analysis 
Results for Western blot analysis were analysed by Student’s t-test.  
Pathology was analysed in the same manner as chapters 3, 4 and 5.  Initially Fisher’s 
exact test was used to determine whether the probability of damage ocurring to white 
matter components was increased higher following hypoperfusion. Mann-Whitney U 
tests were used to compare loss of myelin integrity, levels of axonal pathology and 
levels of degraded myelin between sham and hypoperfus d animals. Results were 
considered significant when p < 0.05. 
 
6.3 Results 
6.3.1 Recovery from surgery 
As reported in chapter 5, all animals from the cohort of animals aged 3-4 
months recovered well from surgery with the exception of one hypoperfused animal 
which was culled following poor recovery.   All animals from the aged cohort 
recovered well from surgery.   See table 6.2 for final cohort sizes. 
Table 6.2  Final cohort sizes  
 
                  Age        
Treatment               
Cohort 1 Cohort 2 
Sham n=12 n=6 






6.3.2 Western blotting 
6.3.2.1 Western blot analysis of MBP levels in young vs old 3xTg-AD sham and 
hypoperfused mice 
MBP levels were found to be significantly increased in old sham animals as 
compared to young sham animals (p<0.001, Fig. 6.1A).    similar result was seen 
when levels of MBP were compared in old and young hypoperfused animals (p < 
0.001, Fig. 6.1B).  
 
6.3.2.2 Western blot analysis of CNPase levels in young vs old 3xTg-AD sham and 
hypoperfused mice 
CNPase levels were found to be significantly increased in old sham animals 
as compared to young (p < 0.001, Fig. 6.2A).   A similar result was seen when 
comparing CNPase in old and young hypoperfused animals (p < 0.001, Fig. 6.2B). 
 
6.3.2.3 Western blot analysis of MAG levels in young vs old 3xTg-AD sham and 
hypoperfused mice 
MAG levels were found to be significantly reduced in old sham animals as 
compared to young sham animals (p = 0.036, Fig. 6.3A).   A similar result was seen 
when MAG levels in young and old hypoperfused animals were compared (p = 
















































































Figure 6.1  MBP levels are increased with ageing 
Representative images of Western blot of MBP and GAPDH (A, B).  Data are expressed as mean 
MBP/ GAPDH ± SEM.  Young vs old sham animals n=12 young/ n=6 old; young vs old hypoperfused 
animals n=12 young/ n= 12 old.  MBP levels were signif cantly increased in old as compared to 
young sham (p<0.001; mean values- sham= 1.60 ± 0.09 hypoperfused= 2.88 ± 0.23 A, C) and 
hypoperfused animals (p=0.001; mean values- sham= 3.23 ± 0.18 hypoperfused= 4.73 ± 0.26  B, D).  

















































































Figure 6.2  CNPase levels are increased with ageing 
Representative images of Western blot of CNPase and GAPDH (A, B).  Data are expressed as mean 
CNPase/ GAPDH ± SEM.  Young vs old sham animals n=12 young/ n=6 old; young vs old 
hypoperfused animals n=12 young/ n= 12 old.  CNPase lev ls were significantly increased in old as 
compared to young sham (p<0.001; mean values- sham= 1.24 ± 0.02 hypoperfused= 1.80 ± 0.09  A, 
C) and hypoperfused (p<0.001; mean values- sham= 1.67 ± 0.09 hypoperfused= 2.35 ± 0.09  B, D) 
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Figure 6.3  MAG levels are reduced with ageing 
Representative images of Western blot of MAG and GAPDH (A, B).  Data are expressed as MAG/ 
GAPDH ± SEM.  Young vs old sham animals n=12 young/ n=6 old; young vs old hypoperfused 
animals n=12 young/ n= 12 old.  MAG levels were signif cantly reduced in young and old sham 
(p=0.036; mean values- sham= 1.79 ± 0.08 hypoperfusd= 1.34 ± 0.10  A, C) and young and old 
hypoperfused (p=0.011; mean values- sham= 1.62 ± 0.08 hypoperfused= 1.30 ± 0.08  B, D) animals.  
Two tailed Student’s t-test. 
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6.3.2.4 Western blot analysis of protein levels in response to hypoperfusion in aged 
3xTg-AD mice 
Western blotting was also employed to investigate how ypoperfusion might 
impact on APP, MAG, CNPase and MBP levels in the agd cohort of animals 
described in this study.   No changes were detected in the levels of any of these 
proteins following one month of hypoperfusion induced using 0.18mm diameter 
microcoils (appendix 4). 
 
6.3.3 Histological examination of grey matter following hypoperfusion in aged 
3xTg-AD mice 
H&E sections were examined for evidence of ischaemic damage to neuronal 
perikarya as described in section 2.5.3.   One hypoperfused animal displayed 
evidence of neuronal perikaryal damage.   This was observed in the striatum, the 
hippocampus and the upper layers of the cortex.  Areas of damage were bordered by 
normal appearing healthy cells.   No aged sham 3xTg-AD mice displayed any 
evidence of ischaemic damage. 
 
6.3.4 Evaluation of white matter pathology in aged 3xTg-AD mice following 
hypoperfusion 
6.3.4.1 Assessment of myelin integrity following hypoperfusion 
The probability of a loss of myelin integrity following hypoperfusion was not 
increased in aged animals (p = 0.600; Fig 6.4A, B, C), Fisher’s exact test.  There 
were no alterations in myelin integrity in the majority of aged sham or hypoperfused 
3xTg-AD mice, however in a small subset of animals, 1 sham and 5 hypoperfused 
animals, minimal myelin damage was observed.   Overall myelin integrity did not 
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differ between sham and hypoperfused animals in this cohort (Fig. 6.4 A, B, C; p = 
0.402) Mann Whitney-U test.   In the animal where ischaemic damage to neuronal 
perikarya was observed, highlighted in red (Fig. 6.4C), areas of severe myelin 
pathology, were present. 
 
6.3.4.2 Assessment of axonal pathology following hypoperfusion 
As described in chapter 5, low level APP expression was observed in 
oligodendrocytes.   A baseline level of axonal pathology was also present, however 
in aged 3xTg-AD mice this was more pronounced than in the younger animals 
examined in chapter 5.   Accumulations of APP in axonal swellings/ bulbs were 
present with greater frequency and were larger in size.  The probability of axonal 
damage occurring following hypoperfusion was not increased (Fig. 6.4D, E, F; p = 
0.634) Fisher’s exact test.    Hypoperfusion did not exacerbate axonal pathology as 
compared to shams in aged 3xTg-AD mice (Fig. 6.4 D, E, F; p = 0.634).   In the 
animal where ischaemic damage to neuronal perikarya was observed, highlighted in 
red (Fig. 6.4F), areas of moderate to severe axonal pathology were also present. 
 
6.3.4.3 Assessment of microglial activation following hypoperfusion 
The presence of activated microglia was evident in all regions of all animals 
examined.   In aged 3xTg-AD mice microglial activaton was markedly more 
pronounced, in all brain regions, than in the younger 3xTg-AD animals examined in 
chapter 5.   Analysis of microglial activation in the aged cohort revealed that there 
was no difference in levels of microglial activation following hypoperfusion (p = 
0.122; Fig. 6.4G, H, I).   In the hypoperfused animal where evidence of ischaemic 
damage was observed (marked in red; Fig. 6.4I), dense patches of activated microglia 
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were observed in areas corresponding to those where ischaemic damage to neuronal 
perikarya was evident. 
 
6.3.4.4 Investigation of white matter Aβ levels following hypoperfusion 
Hypoperfusion had no impact on white matter Aβ levels, other than in the 
hypoperfused animal in which ischaemic damage was observed.   In this animal 
altered Aβ levels were visible in the white matter fibre bundles of the striatum 
consistent with the location of severe axonal pathology.   No animals displayed any 









































































Figure 6.4  Immunohistochemical examination of white matter in aged 3xTg-
AD mice following hypoperfusion 
Representative images of MAG, APP and Iba-1 immunostaining in the int rnal capsule of aged 3xTg-
AD sham (A, D, G) and hypoperfused (B, E, H) mice.  The probability of myelin damage occurring 
was not increased following hypoperfusion (p= 0.600).  Neither was the probability of axonal damage 
occurring following hypoperfusion (p=0.634)  Fisher’s exact test.  The hypoperfused animal 
displaying evidence of ischaemic damage is highlighted in red (C, F, I).  Hypoperfusion did not 
impact on myelin integrity in aged animals (p=0.402, median values- sham= 0, hypoperfused= 0, C).  
Axonal pathology (black arrows) was present in all nimals examined but was not exacerbated 
following hypoperfusion (p=0.634, median values- sham=5, hypoperfused= 5, F)).  There was no 
difference in levels of microglial activation in aged 3xTg-AD hypoperfused mice as compared to 
shams (p=0.122, median values- sham=8, hypoperfused=8, I) Mann Whitney-U test.  Scale bar = 
50µm. 
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6.4  Discussion 
Results from the present study demonstrate that white matter protein 
composition is differentially altered in 3xTg-AD mice with normal ageing, levels of 
MBP and CNPase are increased in conjunction with a decrease in levels of MAG.  
However, contrary to the original hypothesis there was no strong evidence that 
ageing increased susceptibility of white matter to hypoperfusion in 3xTg-AD mice. 
Whilst the majority of published data regarding white matter changes with 
ageing and AD has been gathered from studies conducted in either humans or non-
human primates, the study presented in this chapter is one of the first to investigate 
how levels of the white matter proteins, MBP, CNPase nd MAG change with ageing 
in 3xTg-AD mice.   Desai et al. (2009) compared MBP and CNPase levels in 2 
month and 6 month old 3xTg-AD mice and also non-trasgenic controls.   In contrast 
to the results presented in this chapter, they report d reductions in MBP and CNPase 
levels in 6 month old 3xTg-AD mice as compared to younger and control animals.   
One reason for this discrepancy may be due to methodological differences.   The 
present study examined protein levels in whole brain homogenate; Desai et al. 
conducted their Western blot analysis in microdissected tissue samples from the 
entorhinal cortex and hippocampus.   However, it was only following subregion 
specific immunohistochemical analysis that a statistical difference in protein levels 
was observed.   This was in the CA1 subregion of the hippocampus and layer II/ III 
of the entorhinal cortex.   These are both areas associated with the early development 
of pathology in AD, and possibly where one might exp ct to see reductions in myelin 
protein levels due to increased levels of Αβ prior to the development of overt plaque 
pathology (discussed below).   
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Previous studies conducted to examine how white matter changes with 
normal ageing and in patients with AD, have reported that overall white matter 
volume decreases with advancing age and that this is exacerbated in AD (Guttmann 
et al., 1998; Bartzokis et al., 2003).   This has been attributed mainly to a loss of 
myelin lipid as opposed to proteins (Stommel et al., 1989; Svennerholm et al., 1991); 
however, myelin protein composition has also been shown to change (Sloane et al., 
2003; Hinman et al., 2008).    In accordance with results from the present study, 
findings presented by Sloane et al. (2003) demonstrate a loss of MAG in conjunction 
with increased levels of CNPase in a cohort of ageing rhesus monkeys as compared 
to young controls.   These findings were in part, recapitulated by Hinman et al. 
(2008) who also reported an increase in CNPase levels with ageing in the rhesus 
monkey.   Several studies have investigated MBP levels in ageing animals however 
results are conflicting, some report no change (Sloane et al., 2003), some report a 
decrease (Ansari and Loch, 1975), whilst the present tudy, reports an increase.   One 
possible reason for this may be sampling of different brain areas in different studies.  
Irrespective of this, a large range of studies support the hypothesis that in addition to 
overall white matter loss with ageing, the protein profile of white matter also 
changes. 
Reductions in levels of MAG, have also been reported in studies investigating 
pathological conditions such as hypoxia/ ischaemia (Aboul-Enein et al., 2003) where 
MAG is one of the first myelin proteins to be lost, and also MS (Gendelman et al., 
1985) where, in certain types of lesion, MAG loss i prominent.   Furthermore, 
previous work in MAG null mice has shown that reductions in MAG may precede 
the loss of myelin or changes in expression of other myelin proteins (Loers et al., 
2004).    It has been suggested that loss of MAG with normal ageing may be an 
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indicator of damage to oligodendrocytes (Sloane et al., 2003).   As well as playing an 
important role in axo-glial trophic signalling, MAG is thought to play a role in the 
adherence of the myelin sheath to the axon (see section 1.1).   If this trophic 
signalling/ anchoring mechanism is lost, either as a result of age related myelin 
damage, or, in AD, Aβ mediated toxicity, then a loss of normal axonal function (e.g. 
disruption of axonal transport) and the development of axonal pathology might 
occur.   The over production of other myelin proteins e.g. CNPase and MBP is 
possibly due to some compensatory remyelination mechanism attempting to correct 
for this (Peters, 2002; Peters and Sethares, 2002).   Alternatively, increases in 
CNPase and MBP may be due to increased proliferation of oligodendrocytes 
following age related oligodendrocyte degeneration/ l ss (Peters, 2009).   A further 
reason which could explain increased levels of MBP and CNPase with ageing is the 
production of ‘redundant’ myelin.   This has been described in the rhesus monkey 
(Peters and Sethares, 2002), the toad (Rosenbluth, 1966) and also the mouse 
(Sturrock, 1976).   In aged animals the thickness of the myelin sheath has been 
demonstrated to increase; this tends to occur in sheaths which envelope small 
diameter axons however why this occurs is unknown (Peters, 2009).   Finally, 
ultrastructural analysis has shown that in ageing aim ls, myelin malformations are 
present in many myelin sheaths.  These can appear as fluid filled cavities, termed 
balloons, which require the production of excess myelin by the parent 
oligodendrocyte.   It has been suggested that the formation of myelin balloons is 
degenerative (Peters, 2009) as, in addition to ageing, they are observed following 
application of agents known to cause demyelination e.g. cuprizone (Ludwin, 1978) 
 181 
or chronic copper poisoning (Howell et al., 1974) and also in severe diabetes 
(Tamura and Parry, 1994). 
In addition to investigating alterations in white matter protein levels with 
ageing, a further aim of the present study was to examine whether age would confer 
increased vulnerability of white matter to hypoperfusion.   Other studies attempting 
to investigate the impact of hypoperfusion on the development of white matter 
damage have examined pathological changes in young animals (as in previous 
chapters).   It could be argued that one of the drawbacks of using young animals in 
studies such as these is that they do not accurately model the aged brain, where a 
degree of hypoperfusion may already be present due to age related changes to the 
cerebrovasculature (Leenders et al., 1990; Farkas et al., 2006).   Thus creating a 
situation where white matter is rendered even more vulnerable to further reductions 
in CBF.   
Findings from the present study, contrary to the initial hypothesis, indicate 
that white matter pathology (myelin disruption, axonal pathology, microglial 
activation) was not exacerbated in response to hypoperfusion in aged 3xTg-AD mice.   
One possible reason for this may be, as postulated in chapter 5, that hypoperfusion as 
induced using 0.18mm diameter microcoils may be insufficient to induce white 
matter pathology, even in older animals, due to Circle of Willis architecture.   
Alternatively, it may be possible that age related changes to the cerebrovasculature 
may not have begun to occur in the 3xTg-AD mice examined, at least not to the point 
where the animals had become vulnerable to the level of hypoperfusion induced.   
This theory is supported by work in the rat, where age related deterioration of the 
cerebrovasculature was not observed until animals were aged 16 months (de Jong, 
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1991) other than in the presence of an additional confounding factor, hypertension, 
when pathology was observed from ~12 months (Farkas et l., 2000).   
Although unchanged in response to hypoperfusion, axon l pathology was 
observed to increase with ageing in 3xTg-AD mice (as compared to animals 
examined in chapter 5).   Age related increases in axonal pathology have been 
observed and reported in other transgenic mouse models of AD in the absence of 
overt plaque pathology.   The presence of intraneuronal amyloid pathology, similar 
to that observed in 3xTg-AD mice utilised in this thesis, has been proposed as a 
possible causative factor for this (Wirths et al., 2007).   Higher levels of microglial 
activation were also observed in aged 3xTg-AD mice as compared to the younger 
animals utilised in the previous chapter.   Microglial activation is a common feature 
seen in early Alzheimer’s disease where it has been shown to increase with disease 
progression (Mastrangelo and Bowers, 2008) and also normal ageing (Peters, 2002).   
Αβ toxicity has been proposed as a mechanism by which white matter is lost 
in AD.  Work to examine protein levels in human AD brains has shown that levels of 
CNPase (Vlkolinský et al., 2001) and MBP were reduced in conjunction with 
elevated white matter levels of Aβ (Roher et al., 2002).   Again, these results differ 
from those presented in this chapter, where levels of MBP and CNPase were shown 
to be increased.   One reason for this may be due to the lack of Aβ pathology present 
in the 3xTg-AD animals utilised in the present study.   Several studies have shown 
that Aβ is toxic to oligodendrocytes and myelin (Jantaratnotai et al., 2003; Roth et 
al., 2005).   Furthermore white matter changes have been reported as an early event 
occurring in several AD mouse models (Stokin et al., 2005; Wirths et al., 2006; 
Desai et al., 2009; Desai et al., 2010) and in some cases, Aβ mediated toxicity has 
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been demonstrated to underlie this (Desai et al., 2010).     However in the aged 3xTg-
AD mice utilised by the present study, Aβ levels were relatively low (compared to 
levels previously reported (Oddo et al., 2003a) as evidenced by the lack of plaque 
pathology which was expected to be present in most animals from 12 months of age.   
Why levels of Aβ pathology in 3xTg-AD animals examined in this chapter were 
lower than expected is unknown however this finding is not novel and has been 
reported by others (Hirata-Fukae et al., 2008; Mastrangelo and Bowers, 2008).   
Possible reasons may be due to a loss of phenotype relat d to successive breeding, 
founder effects between colonies, or altered expression of transgenes (Kwang-Jin 
Oh, 2010).  
Were this study to be repeated, a remedy to this, and also possibly the 
relatively low levels of Aβ pathology observed, would be to either induce a more 
severe level of stenosis as described in chapter 5, using 0.16mm diameter microcoils 
or, alternatively, as suggested in chapter 5, utilise an AD model which is more 
vulnerable to reductions in CBF.   As suggested above, the use of an alternative AD 
model would also allow for the inclusion of non-transgenic animals, potentially 
providing a clearer understanding as to why white matter protein levels were altered 
with ageing in the present study. 
Including non-transgenic controls would also be advantageous because this 
would allow the attribution of the observed axonal p thology to either the expression 
of AD related mutant transgenes or ageing in 3xTg-AD mice.   Additionally, 
transgene expression cannot be discounted as a reason for the observed changes in 
white matter protein levels.   Several recent studies have implicated a role for BACE-
1 and γ-secretase in the regulation of myelination and myelin thickness (Hu et al., 
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2008; Bartzokis, 2009).   The mutant APPSwe gene which is expressed in 3xTgAD 
mice is known to alter BACE-1 activity (Haass et al., 1995).   Similarly the mutant 
PS1M146V which is also expressed in 3xTg-AD animals is know to alter γ-secretase 
activity.   Expression of these mutant transgenes, in addition to altering APP 
processing, may also impact on other processing/ signall ng pathways in which they 
play a role; including myelination/ remyelination ad in turn levels of white matter 
proteins (Bartzokis, 2009). 
Results presented in this chapter demonstrate that with normal ageing, 
alterations in white matter protein levels occur in 3xTg-AD mice.   Whilst the 
reasons for this remain unclear, a point of interest is how they may impact on 
cognitive function.   Taking into account the result  presented in chapter 4, it seems 
possible a loss of axo-glial integrity due to a reduction in levels of MAG, may impact 
negatively on normal cognitive function.   Additionally formation of sheaths of 
redundant myelin or any alterations in the thickness of the myelin sheath may cause 
altered conduction speed of nerve impulses (Peters, 2002; Bartzokis, 2004; Peters, 
2009).   This could potentially lead to disruption f neuronal circuits and may play a 
role in the development of any age related cognitive deficits.   Clearly further work is 
required to substantiate this.   
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Chapter 7:  General Discussion 
7.1  Summary 
The findings of this thesis clearly demonstrate that chronic cerebral 
hypoperfusion impacts detrimentally on white matter, causing a loss of myelin 
integrity, and that this is associated with a deficit n spatial working memory.  
Additionally, the work conducted in 3xTg-AD mice has shown that hypoperfusion 
does not impact on levels of intraneuronal Aβ pathology, nor does it exacerbate 
white matter pathology in this strain.   It has also been demonstrated that levels of 
some white matter proteins change with ageing in 3xTg-AD mice. 
 
7.2 Limitations and further work 
Whilst several studies described in this body of work have yielded positive 
results which may be considered novel findings, there are limitations, raised briefly 
in the previous chapters which warrant, further discus ion here. 
In addition to the numerous methodological alterations which could be made 
to improve studies e.g. micro-dissection of white matter tracts for use in Western 
blotting experiments or use of an ELISA as a method to quantify changes in Aβ 
levels as mentioned in chapter 5, two major caveats stand out.  The first of these 
relates to the use of the antibody 4G8 as a marker for Aβ whilst the second relates to 
the 3xTg-AD mouse strain utilised in chapters 5 and6.   
Since completion of this body of work results of a study conducted in 3xTg-
AD mice have demonstrated cross-reactivity between antibody 4G8 and full length 
APP (Winton et al., 2011) furthermore the authors concluded that what had 
previously been described as intracellular Aβ in cortical and pyramidal neurons in 
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3xTg-AD brain tissue was in fact intracellular APP.  As suggested in chapter 5, were 
this work to be repeated, then the use of multiple m thods of Aβ quantification 
would need to be employed to avoid mis-interpretation of results and also to 
demonstrate in a more robust fashion any changes which might occur in Aβ levels 
following hypoperfusion. 
Given the findings of Winton et. al. (2011) which suggest that what was 
initially thought to be intracellular amyloid is infact APP and also that pathology in 
the 3xTg-AD strain utilised was different to that first reported i.e. was not present, 
even in older animals, further work investigating the impact of hypoperfusion on Aβ 
levels would best be conducted in a different strain e.g PDAPP (Games et al., 1995), 
Tg2576 (Hsiao et al., 1996) or J9 (Hsia et al., 1999).  These strains are better 
characterised in terms of age of onset of pathology.  Furthermore, they may also be 
back crossed onto the C57Bl/6J strain, thus avoiding the potential issues surrounding 
strain specific differences in response to hypoperfusion due to variations in 
cerebrovascular architecture as described in chapter 5.  Finally, future studies should 
be conducted in older animals, where amyloid pathology has already begun to 
develop, with hindsight, the age of animals used; especially in chapter 5 was too 
young.  As discussed, younger animals are less likely to have developed amyloid 
pathology; additionally their Aβ clearance mechanisms are likely to be functionally 
robust as compared to aged animals, thus even if hypoperfusion does impact on 




Follow up studies to those described in this body of w rk might include an 
investigation as to whether the white matter damage observed following 
hypoperfusion causes a functional deficit.  This could be done using 
electrophysiology to measure conduction velocity and/ or field potentials, 
particularly within the frontal cortex and hippocampus.  Other studies might include 
an electron microscopy study to investigate myelin integrity at the ultra-structural 
level, or alternatively a study utilising con-focal microscopy to image, myelin 
integrity, amyloid deposition or integrity of the crebrovasculature. 
 
7.3 White matter pathology and the development of cognitive deficits 
following hypoperfusion 
In the mouse model of chronic cerebral hypoperfusion described in this 
thesis, hypoperfusion was modelled in a ‘pure’ form i.e. hypoperfusion in the 
absence of any other co-morbidities or confounding factors such as ageing, diabetes 
or hypertension.   For this reason, it may considere  an appropriate model of 
hypoperfusion with ageing in humans, where CBF has been shown to be reduced by 
up to 20% by the age of 65 as compared to age 20 (Leenders et al., 1990).   Whilst 
other models of chronic cerebral hypoperfusion are vailable, none are able to 
recapitulate with the same success as the model utilised here, the subtle reductions in 
cerebral blood flow which are seen to occur with agein  in humans.  
Findings presented in chapters 3 and 4 demonstrate th t chronic cerebral 
hypoperfusion is sufficient to cause damage to the myelin component of white 
matter, resulting in a loss of myelin integrity and potential disruption of neuronal 
communication.   Although this damage is relatively subtle, compared, for example, 
to the characteristic white matter lesions of leukoaraiosis (Fazekas et al., 1993; 
 188 
O'Sullivan, 2008) or to that caused by more severe c brovascular challenges such 
as stroke (Moskowitz et al., 2010), it is sufficient to produce a deficit in spatial 
working memory.   This is possibly due to its diffuse and widespread nature resulting 
from the global reduction in CBF, and the reliance of intact working memory on 
unbroken communication between many distinct brain regions including the 
posterior parietal and occipital areas, and the prefrontal cortex (Ricciardi et al., 
2006).   In order to confirm that the myelin damage observed following 
hypoperfusion leads to a functional deficit, electrophysiological studies could be 
conducted to investigate conduction velocity via intracellular recording (e.g. 
(Crawford et al., 2009) and or signal strength by measuring field inputs (e.g. 
(Stephanova et al., 2005).  
In addition to myelin damage another feature of the hypoperfusion model is 
an upregulation of microglial activation, indicative of an inflammatory response.   
This inflammatory response in itself may cause further damage to white matter, 
possibly leading to subsequent axonal and neuronal i jury, initiating a self 
perpetuating cycle of pathology which, over time, could impact on other aspects of 
cognition.   This hypothesis is supported by results from another study conducted 
within the Horsburgh group, where, following six months of hypoperfusion, a loss of 
white and grey matter integrity was observed, in cojunction with breakdown of the 
penetrating arterioles and fibrinoid necrosis.   Atsix months the working memory 
deficit was found to be more prominent than at two m nths and deficits in spatial 
reference memory were also observed (Holland et al, in preparation).   Although 
work is ongoing to examine white matter pathology in these animals the 
development of a deficit in spatial reference memory suggests the presence of a more 
severe pathology than that seen at one month.   This may be axonal; previous work in 
 189 
this lab has demonstrated an association between axo al injury following TBI and 
spatial reference memory deficits (Spain et al., 2010).   Taken together, these 
findings suggest that hypoperfusion initiates a progressive white matter pathology 
that also leads to vascular disturbances and that tese pathologies impact 
detrimentally on cognition.    
 
7.4  Chronic cerebral hypoperfusion, white matter damage and the 
development of AD 
A large body of evidence exists linking chronic cerebral hypoperfusion 
resulting from vascular disorders with the development of AD in later life e.g. 
(Breteler et al., 1994; Breteler, 2000; Launer et al., 2000; de la Torre, 2002; Altman 
and Rutledge, 2011).   Furthermore specific patterns of regional hypoperfusion have 
been identified as strong predictors of conversion fr m mild cognitive impairment to 
AD (Matsuda, 2007; Yoshiura et al., 2009; Hu et al., 2010; Kume et al., 2011).   The 
findings presented in chapter 5 demonstrated that, in animals where hypoperfusion 
was sufficient to cause focal areas of severe white matter pathology, subtle 
alterations in white matter Aβ levels were also observed.  As discussed this was 
possibly due to amyloidogenic APP processing at the site of axonal injury.   In the 
absence of severe white matter damage, levels of Aβ remained unchanged.   These 
findings are in contrast to other studies conducted in animal models of AD which 
have reported altered levels of AD pathology following less severe levels of BCAS 
induced cerebral hypoperfusion (e.g. Kitaguchi et al. (2009); Koike et al. (2010); 
Yamada et. al (2011)).   Whilst the reason for this, as discussed in chapter 5, may 
have been due to strain related differences in cerebrovascular architecture, this 
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highlights an interesting point regarding the validity of animal models which must be 
considered when attempting to utilise them in the study of human disease. 
Currently available transgenic models of AD are reliant on expression of 
transgenes which underlie the development of the familial form of the disease.  
Bearing in mind that familial AD accounts for less than 1% of cases, the question 
must be asked, how pertinent are these models to the sporadic form of the disease?  
Whilst animal models allow investigation into the factors which may influence AD 
pathology e.g. in the context of this work, hypoperfusion, they have limitations when 
used to investigate the underlying causes of AD.   This is because transgene 
expression will ultimately lead to all animals developing pathology.   This precludes 
their use in the identification of environmental factors which may cause AD 
development.  
Finally, when considering the mechanisms underlying the development of 
sporadic AD, it is important to bear in mind that it is considered to be a multifactorial 
disorder of which there are, arguably, several different phenotypes (Ryan and 
Rossor, 2010).   Many risk factors e.g. stroke, traum tic brain injury, hypertension 
have been identified as being associated with its development however none, as yet 
in isolation, have been identified as a cause.   The reason for this is possibly that in 
order for disease onset to occur, multiple risk factors need to be present for a 
significant length of time (Small and Duff, 2008). 
7.5 Current strategies for white matter repair 
Clinical treatment strategies for risk factors associated with the development 
of hypoperfusion already exist (discussed below).   However investigations into the 
repair/ prevention of white matter damage in general, remain at the preclinical stage.   
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This is, at least in part, due to a lack of understanding of the underlying mechanisms 
involved.   
Currently the majority of studies investigating white matter repair strategies 
are focused on remyelination following demyelination in demyelinating diseases 
(Franklin and ffrench-Constant, 2008).   These diseases include inherited genetic 
disorders (leukodystrophies) and also multiple sclerosis where demyelination occurs 
due to aberrant inflammation (Compston and Coles, 2002).   Two main approaches to 
remyelination are currently being investigated.   These are, cell replacement via cell 
transplant e.g. stem cell therapy and promotion of repair by the endogenous stem and 
precursor cell populations (Franklin and ffrench-Constant, 2008).   Whilst cell 
replacement therapy may be appropriate where demyelination has occurred, given 
the type of white matter pathology observed following hypoperfusion this strategy 
seems inappropriate.   Results presented in this thesis do not demonstrate 
demyelination as a pathological feature occurring following hypoperfusion; instead 
hypoperfusion is associated with a more subtle myelin disruption, where some 
myelin components were identified as being more susceptible to hypoperfusion than 
others e.g. MAG. 
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7.6 Is MAG a critical mediator in the development of white matter damage 
and associated cognitive decline in ageing and follwing hypoperfusion? 
In addition to vulnerability to hypoperfusion, work in this thesis has also 
demonstrated that MAG levels are reduced with ageing in 3xTg-AD mice.   This 
finding has also been observed in other aged animal models (Sloane et al., 2003).   
As yet however, no data has been published concerning MAG levels in aged humans.   
The reason MAG levels are reduced with ageing remains to be elucidated, one 
possible explanation may be as a result of age related hypoperfusion, or alternatively 
age related damage to oligodendrocytes possibly due to increased levels of oxidative 
stress (Squier, 2001; Floyd and Hensley, 2002). 
Why MAG is vulnerable to ageing and hypoperfusion is unclear however one 
reason may be due to its cellular location at the periaxonal membrane (Sloane et al., 
2003).   If normal cellular function becomes impaired due to an imbalance in energy 
delivery or demand, it seems possible that the proteins and cellular functions most 
vulnerable will be those most distally located in relation to the cell body.   Other 
work conducted within the Horsburgh group has demonstrated that changes in MAG 
and some paranodal proteins can be detected as early as three days following 
hypoperfusion (Reimer et al, in preparation).  Other studies have also shown that 
MAG is one of the first proteins lost following hypoxia/ ischaemia (Aboul-Enein et 
al., 2003) and also in some MS lesions (Gendelman et l., 1985; Lassmann, 2003).   
As previously discussed, MAG is thought to play a role in the maintenance of 
axon-glial integrity.   Specifically axon-glia or glia-glia signal transduction and 
adhesion and also myelin maintenance and stabilisation of paranodal loops (Erb et 
al., 2006).   If myelin sheath adherence to the axon is lost then cell-cell signalling 
between oligodendrocytes and axons will be disrupted and action potential 
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propagation will most likely be impacted (Hinman et al., 2006).   Furthermore, loss 
of oligodendrocyte trophic signalling could be the initiating factor in the 
development of axonal pathology eventually leading to neuronal cell loss (Pan et al., 
2005; Fancy et al., 2010).   Taking this into account, loss of MAG function through 
protein loss or cellular redistribution as a result of hypoperfusion and/ or ageing may 
be the initiating factor underlying the development of associated cognitive changes.   
One way to investigate this would be to generate a line of MAG over-expressing 
transgenic mice.    Providing MAG over expression did not impact phenotypically, 
chronic cerebral hypoperfusion could be induced in these animals to investigate if 
MAG over expression would prevent the development of a cognitive deficit.   If a 
study such as this were successful then follow up biochemical studies might include 
attempts to elucidate the signalling pathways involved in maintaining the MAG 
mediated axon-glial connection.   An understanding as to how this becomes disrupted 
with ageing and/ or hypoperfusion may present novel therapeutic opportunities. 
 
7.7  Inflammation as a potential therapeutic target 
In addition to further mechanistic insight into the link between hypoperfusion 
and the development of white matter pathology the BCAS mouse model of 
hypoperfusion may also be applied to investigating how myelin damage following 
hypoperfusion may be reversed or repaired.   As stated bove cell replacement/ 
proliferation therapy may not be the most appropriate treatment strategy for the type 
of subtle damage observed following the development of modest levels of 
hypoperfusion.   However, one pathological feature of the model which does 
represent an interesting target is the upregulated inflammatory response.   
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Cytokines released by activated microglia have been shown to impact 
negatively on oligodendrocytes and myelin causing damage (Schmitz and Chew, 
2008).   Thus attenuation of the inflammatory response following hypoperfusion may 
reduce or even prevent damage to myelin and subsequent cognitive changes.   A 
study such as this would be relatively easy to conduct with many compounds which 
display anti inflammatory properties being currently available e.g. non-steroidal anti 
inflammatory drugs.   
Alternatively, compounds which have previously been demonstrated to 
attenuate white matter damage following ischaemia e.g. melatonin could be 
investigated.   Melatonin has been shown to attenuat  d mage to white matter 
following ischaemia in neonatal (Olivier et al., 2009) and adult rats (Lee et al., 2007).   
It is thought that melatonin impacts negatively on pro inflammatory signalling and 
additionally accelerates oligodendrocyte maturation fr m oligodendrocyte progenitor 
cells (Pappolla et al., 1998; Escames, 2010).    Interestingly, and of note melatonin 
has also been demonstrated to improve pathological outcome in animal models of 
AD (Pappolla et al., 2000).   
 
7.8 Current clinical intervention strategies for the treatment of 
hypoperfusion 
When considering the impact of chronic cerebral hypoperfusion clinically, it 
is important to bear in mind that the development of chronic cerebral hypoperfusion 
does not always lead to the development of white matter damage, nor does the 
presence of abnormalities in brain white matter automatically predispose the patient 
to the development of cognitive deficits.   However, when the findings presented in 
this body of work are considered alongside that of the wider scientific community, a 
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picture begins to emerge which paints chronic cerebral hypoperfusion as a major risk 
factor for the development of white matter damage and cognitive decline, potentially 
leading to more severe forms of dementia such as AD.   
The current clinical implications of this body of work are clear.   In the majority 
of humans, chronic cerebral hypoperfusion occurs as p rt of the ageing process 
(Leenders et al., 1990; Brown and Thore, 2011).   This may be exacerbated in the 
presence of age associated vascular risk factors (de Jong, 1991), leading to the 
development of white matter damage and initially subtle changes in cognition which 
may eventually progress to full blown dementia.   However, it has been demonstrated 
that many individuals remain asymptomatic for years prior to the onset of detectable 
cognitive changes (Drzezga, 2009; Bendlin et al., 2010).   For this reason, intervention 
strategies should be focused on preventing or delaying the onset of hypoperfusion if 
possible, or, endeavouring to slow the progression of hypoperfusion at an earlier stage, 
instead of attempting to treat it once hypoperfusion is established and cognitive changes 
are detectable.   
In agreement with the above, early intervention strategies have already been 
suggested to identify and treat vascular risk factors, in an attempt to reduce the incidence 
of those most at risk going on to develop severe forms of dementia such as AD.   
Recently a two tier screening system was proposed (d  la Torre, 2010) (Fig. 7.1) 
comprising a series of primary screens employed to i entify those at risk of developing 
dementia due to the presence of vascular risk factors.   Following primary screening, 
individuals identified as ‘at risk’ then undergo a further series of secondary screens 
including neuroimaging and cognitive testing to asses  current cognitive status.   The 
appropriate medical treatment to attempt to slow/ prevent the onset of cognitive decline 
may then be prescribed.   This system offers a number of benefits; the primary screening 
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techniques are cost effective, easy to perform, and non-invasive, also during primary 
screening a number of other deleterious conditions may be identified (de la Torre, 2010). 
Currently the appropriate treatment for hypoperfusion very much depends 
upon the risk factor underlying its development.   For example, to promote healthier 
ageing and thereby minimise the probability of developing a risk factor associated 
with hypoperfusion in later life, a number of lifestyle factors may be modified.  
These include smoking cessation, moderation of alcohol intake, under taking regular 
exercise and eating healthily (Flicker, 2010).   Clinical treatment tends to be risk 
factor dependent also, although this is not aimed at alleviating hypoperfusion as 
such, rather at managing the underlying cause of hypoperfusion e.g. treatment of 
hypercholesterolemia with lipid lowering drugs such as statins (Witztum, 1989), the 
appropriate management of diabetes with insulin therapy or treatment of 
hypertension with angiotensin converting enzyme (ACE) inhibitors (Rubin, 1978).    
Implementation of a screening treatment system such as the one outlined 
above and in Fig. 7.1, which could be conducted regularly in patients (say every 3-5 
years, from 35 years of age onwards), in conjunctio with the appropriate treatment 
strategies, would almost certainly decrease the incide e of those with vascular risk 







Figure 7.1  Proposed screening system for vascular risk factors 
Patients undergo a series of cost, effective, non-ivasive, easily conducted procedures as part of a 
primary screen.  Those displaying vascular risk factors undergo a series of in depth secondary 
screens to assess cognitive status prior to commencing an appropriate treatment regime. (Image taken 
from de la Torre (2010))   
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7.9  Concluding remarks 
Based on evidence from work presented in this thesis and elsewhere, the 
development of chronic cerebral hypoperfusion is a major risk factor associated with 
brain white matter damage and cognitive decline.   Further work, using the model of 
hypoperfusion utilised in studies presented in this t esis may help to elucidate 
whether hypoperfusion associated white matter damage may be prevented or even 
repaired.   Work such as this may impact in a significantly positive manner not only 









Aboul-Enein F, Rauschka H, Kornek B, Stadelmann C, Stefferl A, BrÃœCk W, 
Lucchinetti C, Schmidbauer M, Jellinger K, Lassmann H (2003) Preferential Loss of 
Myelin-Associated Glycoprotein Reflects Hypoxia-Like White Matter Damage in 
Stroke and Inflammatory Brain Diseases. Journal of Neuropathology & Experimental 
Neurology 62:25-33. 
 
Airey DC, Lu L, Williams RW (2001) Genetic Control f the Mouse Cerebellum: 
Identification of Quantitative Trait Loci Modulating Size and Architecture. J 
Neurosci 21:5099-5109. 
 
Akiguchi I, Tomimoto H, Wakita H, Kawamoto Y, Matsuo A, Ohnishi K, Watanabe 
T, Budka H (2004) Topographical and cytopathological lesion analysis of the white 
matter in Binswanger's disease brains. Acta Neuropath logica 107:563-570. 
 
Akiyama H, McGeer PL (2004) Specificity of mechanisms for plaque removal after 
A[beta] immunotherapy for Alzheimer disease. Nat Med 10:117-118. 
 
Alonso A, Zaidi T, Novak M, Grundke-Iqbal I, Iqbal K (2001) 
Hyperphosphorylation induces self-assembly of tau into tangles of paired helical 
filaments/straight filaments. Proc Natl Acad Sci U S A 98:6923 - 6928. 
 
Altman R, Rutledge JC (2011) The vascular contribution to Alzheimer's disease. 
Clinical Science 119:407-421. 
 
Ansari KA, Loch J (1975) Decreased myelin basic protein content of the aged human 
brain. Neurology 25:1045. 
 
Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT(1992) Neurofibrillary 
tangles but not senile plaques parallel duration and severity of Alzheimer's disease. 
Neurology 42:631-. 
 
Auer RN (1986) Progress review: hypoglycemic brain damage. Stroke 17:699-708. 
 
Auer RN, Olsson Y, Siesja BK (1984) Hypoglycemic brain injury in the rat. 
Correlation of density of brain damage with the EEG isoelectric time: a quantitative 
study. Diabetes 33:1090-1098. 
 
Ballatore C, Lee VMY, Trojanowski JQ (2007) Tau-mediated neurodegeneration in 
Alzheimer's disease and related disorders. Nat Rev Neurosci 8:663-672. 
 
Bartzokis G (2004) Age-related myelin breakdown: a developmental model of 
cognitive decline and Alzheimer's disease. Neurobiol gy of Aging 25:5-18. 
 
Bartzokis G (2009) Alzheimer's disease as homeostatic responses to age-related 
myelin breakdown. Neurobiology of Aging In Press, Corrected Proof. 
 
 200 
Bartzokis G, Cummings JL, Sultzer D, Henderson VW, Nuechterlein KH, Mintz J 
(2003) White Matter Structural Integrity in Healthy Aging Adults and Patients With 
Alzheimer Disease: A Magnetic Resonance Imaging Study. Arch Neurol 60:393-398. 
 
Baumann N, Pham-Dinh D (2001) Biology of Oligodendrocyte and Myelin in the 
Mammalian Central Nervous System. Physiol Rev 81:871-927. 
 
Bell KFS, Ducatenzeiler A, Ribeiro-da-Silva A, Duff K, Bennett DA, Claudio Cuello 
A (2006) The amyloid pathology progresses in a neurotransmitter-specific manner. 
Neurobiology of Aging 27:1644-1657. 
 
Bell R, Zlokovic B (2009) Neurovascular mechanisms and blood–brain barrier 
disorder in Alzheimer’s disease. Acta Neuropathologica 118:103-113. 
 
Bendlin BB, Ries ML, Canu E, Sodhi A, Lazar M, Alexander AL, Carlsson CM, 
Sager MA, Asthana S, Johnson SC (2010) White matter is altered with parental 
family history of Alzheimer's disease. Alzheimer's and Dementia 6:394-403. 
 
Berzin TM, Zipser BD, Rafii MS, Kuo--Leblanc V, Yancopoulos GD, Glass DJ, 
Fallon JR, Stopa EG (2000) Agrin and microvascular damage in Alzheimer's disease. 
Neurobiology of Aging 21:349-355. 
 
Bifulco M, Laezza C, Aloj SM, Garbi C (1993) Mevalonate controls cytoskeleton 
organization and cell morphology in thyroid epithelial cells. Journal of Cellular 
Physiology 155:340-348. 
 
Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM (2005) Intraneuronal 
Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in 
transgenic mice. Neuron 45:675 - 688. 
 
Blass JP, Hoyer S, Nitsch R (1991) A Translation of Otto Binswanger's Article, 'The 
Delineation of the Generalized Progressive Paralyses'. Arch Neurol 48:961-972. 
 
Bourasset F, Ouellet M, Tremblay C, Julien C, Do TM, Oddo S, LaFerla F, Calon F 
(2009) Reduction of the cerebrovascular volume in a transgenic mouse model of 
Alzheimer's disease. Neuropharmacology 56:808-813. 
 
Brain RW (1993) Brain's Diseases of the Nervous System, 10th Edition. New York: 
Oxford University Press. 
 
Breteler MM (2000) Vascular Involvement in Cognitive Decline and Dementia: 
Epidemiologic Evidence from the Rotterdam Study andthe Rotterdam Scan Study. 
Annals of the New York Academy of Sciences 903:457-65. 
 
Breteler MMB, van Swieten JC, Bots ML, Grobbee DE, Claus JJ, van den Hout 
JHW, van Harskamp F, Tanghe HLJ, de Jong PTVM, van Gij  J, Hofman A (1994) 
Cerebral white matter lesions, vascular risk factors, and cognitive function in a 
population based study. Neurology 44:1246. 
 
 201 
Brown WR, Thore CR (2011) Review: Cerebral microvascular pathology in ageing 
and neurodegeneration. Neuropathology and Applied Nurobiology 37:56-74. 
 
Brun A, Englund E (1986) Brain changes in dementia of Alzheimer's type relevant to 
new imaging diagnostic methods. Progress in Neuro-Psychopharmacology and 
Biological Psychiatry 10:297-308. 
 
Bucur B, Madden DJ, Spaniol J, Provenzale JM, Cabez R, White LE, Huettel SA 
(2008) Age-related slowing of memory retrieval: Contributions of perceptual speed 
and cerebral white matter integrity. Neurobiology of Aging 29:1070-1079. 
 
Butt AM, Ibrahim M, Ruge FM, Berry M (1995) Biochemical subtypes of 
oligodendrocyte in the anterior medullary velum of the rat as revealed by the 
monoclonal antibody rip. Glia 14:185-197. 
 
Campagnoni A, Macklin W (1988) Cellular and molecular aspects of myelin protein 
gene expression. Molecular Neurobiology 2:41-89. 
 
Capello E, Voskuhl RR, McFarland HF, Raine CS (1997) Multiple sclerosis: Re-
expression of a developmental gene in chronic lesions correlates with remyelination. 
Annals of Neurology 41:797-805. 
 
Caplan LR (2005) Dilatative arteriopathy (dolichoectasia): What is known and not 
known. Annals of Neurology 57:469-471. 
 
Caroni P (1997) Overexpression of growth-associated proteins in the neurons of 
adult transgenic mice. Journal of Neuroscience Methods 71:3-9. 
 
Caspersen C, Wang N, Yao J, Sosunov A, Chen X, Lustbader JW, Xu HW, Stern D, 
McKhann G, Yan SD (2005) Mitochondrial Aβετα: a potential focal point for 
neuronal metabolic dysfunction in AlzheimerÂ’s disea . The FASEB Journal 
19:2040-2041. 
 
Castellani RJ, Rolston RK, Smith MA (2010) Alzheimer Disease. Disease-a-Month 
56:484-546. 
 
Chandler S, Coates R, Gearing A, Lury J, Wells G, Bone E (1995) Matrix 
metalloproteinases degrade myelin basic protein. Neuroscience Letters 201:223-226. 
 
Chen G, Chen KS, Knox J, Inglis J, Bernard A, Martin SJ, Justice A, McConlogue L, 
Games D, Freedman SB, Morris RGM (2000) A learning deficit related to age and 
[beta]-amyloid plaques in a mouse model of Alzheimer's disease. Nature 408:975-
979. 
 
Cho K-O, La HO, Cho Y-J, Sung K-W, Kim SY (2006) Minocycline attenuates 
white matter damage in a rat model of chronic cerebral hypoperfusion. Journal of 
Neuroscience Research 83:285-291. 
 
 202 
Choy M, Ganesan V, Thomas DL, Thornton JS, Proctor E, King MD, van der Weerd 
L, Gadian DG, Lythgoe MF (2006) The chronic vascular and haemodynamic 
response after permanent bilateral common carotid occlusion in newborn and adult 
rats. J Cereb Blood Flow Metab 26:1066-1075. 
 
Chung Y-A, Hyun O J, Kim J-Y, Kim K-J, Ahn K-J (2009) Hypoperfusion and 
Ischemia in Cerebral Amyloid Angiopathy Documented by 99mTc-ECD Brain 
Perfusion SPECT. J Nucl Med 50:1969-1974. 
 
Cizas P, Budvytyte R, Morkuniene R, Moldovan R, Brocci  M, Lösche M, Niaura G, 
Valincius G, Borutaite V (2010) Size-dependent neurotoxicity of [beta]-amyloid 
oligomers. Archives of Biochemistry and Biophysics 496:84-92. 
 
Clarkson A (2007) Anesthetic-mediated protection/preconditioning during cerebral 
ischemia. Life Sciences 80:1157-1175. 
 
Coltman R, Spain A, Tsenkina Y, Fowler JH, Smith J, Scullion G, Allerhand M, 
Scott F, Kalaria RN, Ihara M, Daumas S, Deary IJ, Wood E, McCulloch J, 
Horsburgh K (2010) Selective white matter pathology induces a specific impairment 
in spatial working memory. Neurobiology of Aging In Press, Corrected Proof. 
 
Compston A, Coles A (2002) Multiple sclerosis. The Lancet 359:1221-1231. 
 
Cotman C, Anderson A (1995) A potential role for apoptosis in neurodegeneration 
and Alzheimer's disease. Molecular Neurobiology 10:19-45. 
 
Crawford DK, Mangiardi M, Xia X, López-Valdés HE, Tiwari-Woodruff SK (2009) 
Functional recovery of callosal axons following demyelination: a critical window. 
Neuroscience 164:1407-1421. 
 
D'Hooge R, De Deyn PP (2001) Applications of the Morris water maze in the study 
of learning and memory. Brain Research Reviews 36:60-90. 
 
Danton GH, Dietrich WD (2003) Inflammatory Mechanisms after Ischemia and 
Stroke. Journal of Neuropathology & Experimental Neurology 62:127-136. 
 
de Jong G, Jansen AS, Horvath E, Gispen WH, Luiten PG. (1991) Nimodipine 
effects on cerebral microvessels and sciatic nerve in aging rats. Neurobiology of 
Ageing 13:8. 
 
de la Monte SM (1989) Quantitation of cerebral atrophy in preclinical and end-stage 
alzheimer's disease. Annals of Neurology 25:450-459. 
 
de la Torre JC (2002) Vascular Basis of Alzheimer's Pathogenesis. Annals of the 
New York Academy of Sciences 977:196-215. 
 
de la Torre JC (2004) Is Alzheimer's disease a neurodegenerative or a vascular 
disorder? Data, dogma, and dialectics. The Lancet Neurology 3:184-190. 
 
 203 
de la Torre JC (2010) Vascular risk factor detection and control may prevent 
Alzheimer's disease. Ageing Research Reviews 9:218-2 5. 
 
de la Torre JC, Alireza M (2009) Chapter 3 Cerebrovascular and Cardiovascular 
Pathology in Alzheimer's Disease. In: International Review of Neurobiology, pp 35-
48: Academic Press. 
 
de Reuck J (1971) The Human Periventricular Arterial Blood Supply and the 
Anatomy of Cerebral Infarctions. European Neurology 5:321-334. 
 
Deary IJ, Bastin ME, Pattie A, Clayden JD, Whalley LJ, Starr JM, Wardlaw JM 
(2006) White matter integrity and cognition in childhood and old age. Neurology 
66:505-512. 
 
Deary IJ, Leaper S A,  Murray A D,  Staff R T, Whalley L J (2003) Cerebral white 
matter abnormalities and lifetime cognitive change: A 67-year follow-up of the 
Scottish Mental Survey of 1932. Psychology and Aging:140-148. 
 
DeCarli C, Miller BL, Swan GE, Reed T, Wolf PA, Carmelli D (2001) 
Cerebrovascular and Brain Morphologic Correlates of Mild Cognitive Impairment in 
the National Heart, Lung, and Blood Institute Twin Study. Arch Neurol 58:643-647. 
 
Derdeyn CP, Videen TO, Yundt KD, Fritsch SM, Carpenter DA, Grubb RL, Powers 
WJ (2002) Variability of cerebral blood volume and oxygen extraction: stages of 
cerebral haemodynamic impairment revisited. Brain 125:595-607. 
 
Desai MK, Sudol KL, Janelsins MC, Mastrangelo MA, Frazer ME, Bowers WJ 
(2009) Triple-transgenic Alzheimer's disease mice exhibit region-specific 
abnormalities in brain myelination patterns prior t appearance of amyloid and tau 
pathology. Glia 57:54-65. 
 
Desai MK, Mastrangelo MA, Ryan DA, Sudol KL, Narrow WC, Bowers WJ (2010) 
Early Oligodendrocyte/Myelin Pathology in Alzheimer's Disease Mice Constitutes a 
Novel Therapeutic Target. The American Journal of Pathology 177:1422-1435. 
 
deToledo-Morrell L, Stoub TR, Wang C, Helen ES (2007) Hippocampal atrophy and 
disconnection in incipient and mild Alzheimer's disea e. In: Progress in Brain 
Research, pp 741-753, 823: Elsevier. 
 
Di Paola M, Di Iulio F, Cherubini A, Blundo C, Casini AR, Sancesario G, 
Passafiume D, Caltagirone C, Spalletta G (2010) When, where, and how the corpus 
callosum changes in MCI and AD. Neurology 74:1136-1142. 
 
Dickerson BC, Eichenbaum H (2009) The Episodic Memory System: Neurocircuitry 
and Disorders. Neuropsychopharmacology 35:86-104. 
 
Dodel RC, Du Y, Bales KR, Gao F, Eastwood B, Glazier B, Zimmer R, Cordell B, 
Hake A, Evans R, Gallagher-Thompson D, Thompson LW, Tinklenberg JR, 
Pfefferbaum A, Sullivan EV, Yesavage J, Altstiel L, Gasser T, Farlow MR, Murphy 
 204 
GM, Paul SM (2000) Î±2 Macroglobulin and the risk of Alzheimerâ€™s disease. 
Neurology 54:438. 
 
Drzezga A (2009) Diagnosis of Alzheimer's disease with [18F]PET in mild and 
asymptomatic stages. Behavioural Neurology 21:101-115. 
 
Duan J-H, Wang H-Q, Xu J, Lin X, Chen S-Q, Kang Z, Yao Z-B (2006) White 
matter damage of patients with Alzheimer’s disease correlated with the decreased 
cognitive function. Surgical and Radiologic Anatomy 28:150-156. 
 
Duff K, Eckman C, Zehr C, Yu X, Prada C-M, Perez-tur J, Hutton M, Buee L, 
Harigaya Y, Yager D, Morgan D, Gordon MN, Holcomb L, Refolo L, Zenk B, Hardy 
J, Younkin S (1996) Increased amyloid-[beta]42(43) in brains of mice expressing 
mutant presenilin 1. Nature 383:710-713. 
 
Eckman EA, Reed DK, Eckman CB (2001) Degradation of the Alzheimer's Amyloid 
Î² Peptide by Endothelin-converting Enzyme. Journal of Biological Chemistry 
276:24540-24548. 
 
Eckman EA, Watson M, Marlow L, Sambamurti K, Eckman CB (2003) Alzheimer's 
Disease Î²-Amyloid Peptide Is Increased in Mice Defici nt in Endothelin-converting 
Enzyme. Journal of Biological Chemistry 278:2081-2084. 
 
Edgar JM, Nave K-A (2009) The role of CNS glia in preserving axon function. 
Current Opinion in Neurobiology 19:498-504. 
 
Edvznsson MET, McCulloch J. (1993) Cerebral blood flow and metabolism. New 
York: Raven. 
Elder GA, Gama Sosa MA, De Gasperi R (2010) Transgeic Mouse Models of 
Alzheimer's Disease. Mount Sinai Journal of Medicine: A Journal of Translational 
and Personalized Medicine 77:69-81. 
 
Elesber AA, Bonetti PO, Woodrum JE, Zhu X-Y, Lerman LO, Younkin SG, Lerman 
A (2006) Bosentan preserves endothelial function in mice overexpressing APP. 
Neurobiology of Aging 27:446-450. 
 
Enzinger C, Smith S, Fazekas F, Drevin G, Ropele S, Nichols T, Behrens T, Schmidt 
R, Matthews P (2006) Lesion probability maps of white matter hyperintensities in 
elderly individuals. Journal of Neurology 253:1064-1070. 
 
Erb M, Flueck B, Kern F, Erne B, Steck AJ, Schaeren-Wiemers N (2006) Unraveling 
the differential expression of the two isoforms of myelin-associated glycoprotein in a 
mouse expressing GFP-tagged S-MAG specifically regulated and targeted into the 
different myelin compartments. Molecular and Cellular Neuroscience 31:613-627. 
 
Escames G, Lopez A., Garcia JA, .Garcia L., Acuna-Castroviejo D., Garcia JJ, Lopez 
L. (2010) The Role of Mitochondria in Brain Aging and the Effects of Melatonin. 
Current Neuropharmacology 8:182-193. 
 
 205 
Evans M (1994) Transgenic rodents. Animals with novel genes. Cambridge: 
Cambridge University Press. 
 
Fancy SPJ, Kotter MR, Harrington EP, Huang JK, Zhao C, Rowitch DH, Franklin 
RJM (2010) Overcoming remyelination failure in multiple sclerosis and other myelin 
disorders. Experimental Neurology 225:18-23. 
 
Farkas E, Luiten PGM (2001) Cerebral microvascular p thology in aging and 
Alzheimer's disease. Progress in Neurobiology 64:575-611. 
 
Farkas E, Luiten PGM, Bari F (2007) Permanent, bilateral common carotid artery 
occlusion in the rat: A model for chronic cerebral hypoperfusion-related 
neurodegenerative diseases. Brain Research Reviews 54:162-180. 
 
Farkas E, De Jong GI, Apró E, Keuker JIH, Luiten PGM (2000) Calcium antagonists 
decrease capillary wall damage in aging hypertensiv rat brain. Neurobiology of 
Aging 22:299-309. 
 
Farkas E, de Vos R, Donka G, Jansen Steur E, Mihály A, Luiten P (2006) Age-
related microvascular degeneration in the human cerebral periventricular white 
matter. Acta Neuropathologica 111:150-157. 
 
Fazekas F, Kleinert R, Offenbacher H, Schmidt R, Kleinert G, Payer F, Radner H, 
Lechner H (1993) Pathologic correlates of incidental MRI white matter signal 
hyperintensities. Neurology 43:1683. 
Fernando MS, O'Brien JT, Perry RH, English P, Forster G, McMeekin W, Slade JY, 
Golkhar A, Matthews FE, Barber R, Kalaria RN, Ince PG, Neuropathology Group of 
MC (2004) Comparison of the pathology of cerebral white matter with post-mortem 
magnetic resonance imaging (MRI) in the elderly brain. Neuropathology and Applied 
Neurobiology 30:385-395. 
 
Fernando MS, Simpson JE, Matthews F, Brayne C, Lewis CE, Barber R, Kalaria RN, 
Forster G, Esteves F, Wharton SB, Shaw PJ, O'Brien JT, Ince PG, on behalf of the 
MRCCFaANSG (2006) White Matter Lesions in an Unselect d Cohort of the 
Elderly: Molecular Pathology Suggests Origin From Chronic Hypoperfusion Injury * 
Annex - Supplemental Online-Only Content. Stroke 37:1 91-1398. 
 
Fields RD (2008) White matter in learning, cognition and psychiatric disorders. 
Trends in Neurosciences 31:361-370. 
 
Flicker L (2010) Modifiable Lifestyle Risk Factors for Alzheimer's Disease. Journal 
of Alzheimer's Disease 20:803-811. 
 
Floyd RA, Hensley K (2002) Oxidative stress in brain aging: Implications for 
therapeutics of neurodegenerative diseases. Neurobiology of Aging 23:795-807. 
 
Fox NC, Warrington EK, Seiffer AL, Agnew SK, Rossor MN (1998) 
Presymptomatic cognitive deficits in individuals at risk of familial Alzheimer's 
disease. A longitudinal prospective study. Brain 121: 631-1639. 
 206 
 
Franklin RJM, ffrench-Constant C (2008) Remyelination n the CNS: from biology 
to therapy. Nat Rev Neurosci 9:839-855. 
 
Fujii M, Hara H, Meng W, Vonsattel JP, Huang Z, Mosk witz MA (1997) Strain-
Related Differences in Susceptibility to Transient Forebrain Ischemia in SV-129 and 
C57Black/6 Mice. Stroke 28:1805-1811. 
 
Funahashi S (2006) Prefrontal cortex and working memory processes. Neuroscience 
139:251-261. 
 
Fuster JM (1973) Unit activity in prefrontal cortex during delayed-response 
performance: neuronal correlates of transient memory. J Neurophysiol 36:61-78. 
 
Games D, Adams D, Alessandrini R, Barbour R, Borthelett  P, Blackwell C, Carr T, 
Clemens J, Donaldson T, Gillespie F, Guido T, Hagopian S, Johnson-Wood K, Khan 
K, Lee M, Leibowitz P, Lieberburg I, Little S, Masliah E, McConlogue L, Montoya-
Zavala M, Mucke L, Paganini L, Penniman E, Power M, Schenk D, Seubert P, 
Snyder B, Soriano F, Tan H, Vitale J, Wadsworth S, Wolozin B, Zhao J (1995) 
Alzheimer-type neuropathology in transgenic mice overexpressing V717F [beta]-
amyloid precursor protein. Nature 373:523-527. 
 
Garden G, Möller T (2006) Microglia Biology in Health and Disease. Journal of 
Neuroimmune Pharmacology 1:127-137. 
 
Gendelman HE, Pezeshkpour GH, Pressman NJ, Wolinsky JS, Quarles RH, 
Dobersen MJ, Trapp BD, Kitt CA, Aksamit A, Johnson RT (1985) A quantitation of 
myelin-associated glycoprotein and myelin basic protein loss in different 
demyelinating disease. Annals of Neurology 18:324-38. 
 
Giannakopoulos P, Herrmann FR, BussiÃ¨re T, Bouras C, Kavari E, Perl DP, 
Morrison JH, Gold G, Hof PR (2003) Tangle and neuron numbers, but not amyloid 
load, predict cognitive status in Alzheimer's disease. Neurology 60:1495-1500. 
 
Gibbs JM, Leenders KL, Wise RJS, Jones T (1984) EVALU TION OF 
CEREBRAL PERFUSION RESERVE IN PATIENTS WITH CAROTID-ARTERY 
OCCLUSION. The Lancet 323:310-314. 
 
Glenner GG, Wong CW (1984a) Alzheimer's disease: Initial report of the purification 
and characterization of a novel cerebrovascular amyloid protein. Biochemical and 
Biophysical Research Communications 120:885-890. 
 
Glenner GG, Wong CW (1984b) Alzheimer's disease and Down's syndrome: Sharing 
of a unique cerebrovascular amyloid fibril protein. Biochemical and Biophysical 
Research Communications 122:1131-1135. 
 
Goate A, Chartier-Harlin M-C, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, 
Haynes A, Irving N, James L, Mant R, Newton P, Rooke K, Roques P, Talbot C, 
Pericak-Vance M, Roses A, Williamson R, Rossor M, Owen M, Hardy J (1991) 
 207 
Segregation of a missense mutation in the amyloid precursor protein gene with 
familial Alzheimer's disease. Nature 349:704-706. 
 
Gorelick PB, Scuteri A, Black SE, DeCarli C, Greenbrg SM, Iadecola C, Launer LJ, 
Laurent S, Lopez OL, Nyenhuis D, Petersen RC, Schneider JA, Tzourio C, Arnett 
DK, Bennett DA, Chui HC, Higashida RT, Lindquist R,Nilsson PM, Roman GC, 
Sellke FW, Seshadri S (2011) Vascular Contributions to Cognitive Impairment and 
Dementia. Stroke 42:2672-2713. 
 
Gotz J, Chen F, Barmettler R, Nitsch RM (2001) Tau filament formation in 
transgenic mice expressing P301L tau. J Biol Chem 276:529 - 534. 
Gralle M, Ferreira ST (2007) Structure and functions of the human amyloid 
precursor protein: The whole is more than the sum of its parts. Progress in 
Neurobiology 82:11-32. 
 
Grammas P, Yamada M, Zlokovic B (2002) The cerebromicrovasculature: A key 
player in the pathogenesis of Alzheimer's disease Journal of Alzheimer's Disease 
4:217-223. 
 
Gravel M, Peterson J, Yong VW, Kottis V, Trapp B, Braun PE (1996) 
Overexpression of 2',3'-Cyclic Nucleotide 3'-Phosphodiesterase in Transgenic Mice 
Alters Oligodendrocyte Development and Produces Aberrant Myelination. Molecular 
and Cellular Neuroscience 7:453-466. 
 
Griffin TWS, Sheng JG, Roberts GW, Mrak RE (1995) Interleukin-1 Expression in 
Different Plaque Types in Alzheimer's Disease: Significance in Plaque Evalution. 
Journal of Neuropathology & Experimental Neurology 54:276-281. 
 
Guela C, Wu C-K, Saroff D, Lorenzo A, Yuan M, Yankner BA (1998) Aging renders 
the brain vulnerable to amyloid [beta]-protein neurotoxicity. Nat Med 4:827-831. 
 
Guttmann CRG, Jolesz FA, Kikinis R, Killiany RJ, Moss MB, Sandor T, Albert MS 
(1998) White matter changes with normal aging. Neurology 50:972-978. 
 
Haass C, Lemere CA, Capell A, Citron M, Seubert P, Schenk D, Lannfelt L, Selkoe 
DJ (1995) The Swedish mutation causes early-onset Alzheimer's disease by beta-
secretase cleavage within the secretory pathway. Nat Med 1:1291 - 1296. 
 
Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD, Haroutunian V, 
Fienberg AA (2001) Genome-wide expression analysis reveals dysregulation of 
myelination-related genes in chronic schizophrenia. Proceedings of the National 
Academy of Sciences of the United States of America 98:4746-4751. 
 
Haley SM, Osberg JS (1989) Kappa Coefficient Calcultion Using Multiple Ratings 
Per Subject: A Special Communication. Physical Therapy 69:970-974. 
 
Hardy J (2009) The amyloid hypothesis for Alzheimer’s disease: a critical 
reappraisal. Journal of Neurochemistry 110:1129-1134. 
 
 208 
Hardy J, Allsop D (1991) Amyloid deposition as the central event in the aetiology of 
Alzheimer's disease. Trends in Pharmacological Sciences 12:383-388. 
 
Hardy J, Selkoe DJ (2002) The Amyloid Hypothesis of Alzheimer's Disease: 
Progress and Problems on the Road to Therapeutics. Science 297:353-356. 
Harrison MJ (1989) Influence of haematocrit in the cerebral circulation 
Cerebrovascular and Brain Metabolism Reviews 1:55-67. 
 
Hattori H, Takeda M, Kudo T, Nishimura T, Hashimoto S (1992) Cumulative white 
matter changes in the gerbil brain under chronic cerebral hypoperfusion. Acta 
Neuropathologica 84:437-442. 
 
Hawkes C, HÃ¤rtig W, Kacza J, Schliebs R, Weller R, Nicoll J, Carare R (2011) 
Perivascular drainage of solutes is impaired in the ag ing mouse brain and in the 
presence of cerebral amyloid angiopathy. Acta Neuropathologica 121:431-443. 
 
Hershey T, Perantie DC, Warren SL, Zimmerman EC, Sadler M, White NH (2005) 
Frequency and Timing of Severe Hypoglycemia Affects Spatial Memory in Children 
With Type 1 Diabetes. Diabetes Care 28:2372-2377. 
 
Hickman SE, Allison EK, El Khoury J (2008) Microglia  Dysfunction and Defective 
{beta}-Amyloid Clearance Pathways in Aging Alzheimer's Disease Mice. J Neurosci 
28:8354-8360. 
 
Hinman JD, Chen CD, Oh SY, Hollander W, Abraham CR (2008) Age-dependent 
accumulation of ubiquitinated 2′,3′-cyclic nucleotide 3′-phosphodiesterase in myelin 
lipid rafts. Glia 56:118-133. 
 
Hinman JD, Peters A, Cabral H, Rosene DL, Hollander W, Rasband MN, Abraham 
CR (2006) Age-related molecular reorganization at the node of Ranvier. The Journal 
of Comparative Neurology 495:351-362. 
 
Hirao K, Ohnishi T, Hirata Y, Yamashita F, Mori T, Moriguchi Y, Matsuda H, 
Nemoto K, Imabayashi E, Yamada M, Iwamoto T, Arima K, Asada T (2005) The 
prediction of rapid conversion to Alzheimer's disease in mild cognitive impairment 
using regional cerebral blood flow SPECT. NeuroImage 28:1014-1021. 
 
Hirata-Fukae C, Li H-F, Hoe H-S, Gray AJ, Minami SS, Hamada K, Niikura T, Hua 
F, Tsukagoshi-Nagai H, Horikoshi-Sakuraba Y, Mughal M, Rebeck GW, LaFerla 
FM, Mattson MP, Iwata N, Saido TC, Klein WL, Duff KE, Aisen PS, Matsuoka Y 
(2008) Females exhibit more extensive amyloid, but no tau, pathology in an 
Alzheimer transgenic model. Brain Research 1216:92-103. 
 
Hodges H (1996) Maze procedures: the radial-arm and water maze compared. 
Cognitive Brain Research 3:167-181. 
 
Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, 
Saad I, Mueller R, Morgan D, Sanders S, Zehr C, O'Campo K, Hardy J, Prada C-M, 
Eckman C, Younkin S, Hsiao K, Duff K (1998) Accelerated Alzheimer-type 
 209 
phenotype in transgenic mice carrying both mutant amyloid precursor protein and 
presenilin 1 transgenes. Nat Med 4:97-100. 
 
Holland PR, Bastin ME, Jansen MA, Merrifield GD, Coltman RB, Scott F, Nowers 
H, Khallout K, Marshall I, Wardlaw JM, Deary IJ, McCulloch J, Horsburgh K (2010) 
MRI is a sensitive marker of subtle white matter pathology in hypoperfused mice. 
Neurobiology of Aging In Press, Corrected Proof. 
 
Hope T, Keene J, Fairburn C, McShane R, Jacoby R (1997) Behaviour changes in 
dementia 2: Are there behavioural syndromes? Interna io al Journal of Geriatric 
Psychiatry 12:1074-1078. 
 
Howell JM, Blakemore WF, Gopinath C, Hall GA, Parker JH (1974) Chronic copper 
poisoning and changes in the central nervous system of sheep. Acta 
Neuropathologica 29:9-24. 
 
Hsia AY, Masliah E, McConlogue L, Yu G-Q, Tatsuno G, Hu K, Kholodenko D, 
Malenka RC, Nicoll RA, Mucke L (1999) Plaque-independ nt disruption of neural 
circuits in Alzheimer's disease mouse models. Proceedings of the National Academy 
of Sciences of the United States of America 96:3228-3 33. 
 
Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G 
(1996) Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in 
Transgenic Mice. Science 274:99-103. 
 
Hsu M-J, Sheu J-R, Lin C-H, Shen M-Y, Hsu CY (2010) Mitochondrial mechanisms 
in amyloid beta peptide-induced cerebrovascular degen ration. Biochimica et 
Biophysica Acta (BBA) - General Subjects 1800:290-26. 
 
Hsu SM, Raine L, Fanger H (1981) Use of avidin-biotin-peroxidase complex (ABC) 
in immunoperoxidase techniques: a comparison between ABC and unlabeled 
antibody (PAP) procedures. J Histochem Cytochem 29:577-580. 
 
Hu WT, Wang Z, Lee VMY, Trojanowski JQ, Detre JA, Grossman M (2010) 
Distinct cerebral perfusion patterns in FTLD and AD. Neurology 75:881-888. 
 
Hu X, He W, Diaconu C, Tang X, Kidd GJ, Macklin WB, Trapp BD, Yan R (2008) 
Genetic deletion of BACE1 in mice affects remyelination of sciatic nerves. The 
FASEB Journal 22:2970-2980. 
 
Huang H-M, Ou H-C, Hsueh S-J (1998) Amyloid [beta] peptide enhanced 
bradykinin-mediated inositol (1,4,5)trisphosphate formation and cytosolic free 
calcium. Life Sciences 63:195-203. 
 
Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown 
S, Chakraverty S, Isaacs A, Grover A, Hackett J, Adamson J, Lincoln S, Dickson D, 
Davies P, Petersen RC, Stevens M, de Graaff E, Wauters E, van Baren J, Hillebrand 
M, Joosse M, Kwon JM, Nowotny P, Che LK, Norton J, Morris JC, Reed LA, 
Trojanowski J, Basun H, Lannfelt L, Neystat M, Fahn S, Dark F, Tannenberg T, 
 210 
Dodd PR, Hayward N, Kwok JBJ, Schofield PR, Andreadis A, Snowden J, Craufurd 
D, Neary D, Owen F, Oostra BA, Hardy J, Goate A, van Swieten J, Mann D, Lynch 
T, Heutink P (1998) Association of missense and 5[prime]-splice-site mutations in 
tau with the inherited dementia FTDP-17. Nature 393:702-705. 
 
Iadecola C (2010) The overlap between neurodegenerative and vascular factors in the 
pathogenesis of dementia. Acta Neuropathologica 120:287-296. 
 
Iadecola C, Zhang F, Niwa K, Eckman C, Turner SK, Fischer E, Younkin S, 
Borchelt DR, Hsiao KK, Carlson GA (1999) SOD1 rescues cerebral endothelial 
dysfunction in mice overexpressing amyloid precursor pr tein. Nat Neurosci 2:157-
161. 
 
Ihara M, Polvikoski T, Hall R, Slade J, Perry R, Oakley A, Englund E, O’Brien J, 
Ince P, Kalaria R (2010) Quantification of myelin loss in frontal lobe white matter in 
vascular dementia, Alzheimer’s disease, and dementia with Lewy bodies. Acta 
Neuropathologica 119:579-589. 
 
Iqbal K, Grundke-Iqbal I (2008) Alzheimer Review Series: Alzheimer neurofibrillary 
degeneration: significance, etiopathogenesis, therapeutics and prevention. Journal of 
Cellular and Molecular Medicine 12:38-55. 
 
Jankowsky JL, Younkin LH, Gonzales V, Fadale DJ, Slunt HH, Lester HA, Younkin 
SG, Borchelt DR (2007) Rodent Aβ Modulates the Solubility and Distribution of 
Amyloid Deposits in Transgenic Mice. Journal of Biological Chemistry 282:22707-
22720. 
 
Jantaratnotai N, Ryu JK, Kim SU, McLarnon JG (2003) Amyloid [beta] peptide-
induced corpus callosum damage and glial activation in vivo. NeuroReport 14:1429-
1433. 
 
Jarrett JT, Berger EP, Lansbury PT (1993) The carboxy terminus of the .beta. 
amyloid protein is critical for the seeding of amyloid formation: Implications for the 
pathogenesis of Alzheimer's disease. Biochemistry 32:4693-4697. 
 
Jones TH, Morawetz RB, Crowell RM, Marcoux FW, FitzGibbon SJ, DeGirolami U, 
Ojemann RG (1981) Thresholds of focal cerebral ischemia in awake monkeys. 
Journal of Neurosurgery 54:773-782. 
 
Jonsson L, Wimo A (2009) The Cost of Dementia in Europe: A Review of the 
Evidence, and Methodological Considerations. PharmacoEconomics 27:391-403  
Junque C, Pujol J, Vendrell P, Bruna O, Jodar M, Ribas JC, Vinas J, Capdevila A, 
Marti-Vilalta JL (1990) Leuko-Araiosis on Magnetic Resonance Imaging and Speed 
of Mental Processing. Arch Neurol 47:151-156. 
 
Kagawa T, Ikenaka K, Inoue Y, Kuriyama S, Tsujii T, Nakao J, Nakajima K, Aruga 
J, Okano H, Mikoshiba K (1994) Glial cell degeneration and hypomyelination caused 
by overexpression of myelin proteolipid protein gene. Neuron 13:427-442. 
 
 211 
Kalaria RN, Pax AB (1995) Increased collagen content of cerebral microvessels in 
Alzheimer's disease. Brain Research 705:349-352. 
 
Kalaria RN, Bhatti SU, Lust WD, Perry G (1993) The Amyloid Precursor Protein in 
Ischemic Brain Injury and Chronic Hypoperfusiona. Annals of the New York 
Academy of Sciences 695:190-193. 
 
Kalback WE, Chera; Castaño, Eduardo; Rahman, Afroza; Kokjohn, Tyler; Luehrs, 
Dean; Sue, Lucia; Cisneros, Raquel; Gerber, Francoise; Richardson, Claudia; 
Bohrmann, Bernd; Walker, Douglas; Beach, Thomas; Roher, Alex (2004) 
Atherosclerosis, vascular amyloidosis and brain hypoperfusion in the pathogenesis of 
sporadic Alzheimer's disease. Neurological Research 26:525-539. 
 
Kamal A, Stokin GB, Yang Z, Xia C-H, Goldstein LSB (2000) Axonal Transport of 
Amyloid Precursor Protein Is Mediated by Direct Binding to the Kinesin Light Chain 
Subunit of Kinesin-I. Neuron 28:449-459. 
 
Kamal A, Almenar-Queralt A, LeBlanc JF, Roberts EA, Goldstein LSB (2001) 
Kinesin-mediated axonal transport of a membrane compart ent containing [beta]-
secretase and presenilin-1 requires APP. Nature 414:6 3-648. 
 
Kang J, Lemaire H-G, Unterbeck A, Salbaum JM, Masters CL, Grzeschik K-H, 
Multhaup G, Beyreuther K, Muller-Hill B (1987) The precursor of Alzheimer's 
disease amyloid A4 protein resembles a cell-surface re ptor. Nature 325:733-736. 
 
Kato H, Kogure K (1990) Neuronal damage following non-lethal but repeated 
cerebral ischemia in the gerbil. Acta Neuropathologica 79:494-500. 
 
Kawamura J, Meyer JS, Terayama Y, Weathers S (1991) Leukoaraiosis correlates 
with cerebral hypoperfusion in vascular dementia. Stroke 22:609-614. 
 
Kelly S, McCulloch J, Horsburgh K (2001) Minimal ischaemic neuronal damage and 
HSP70 expression in MF1 strain mice following bilater l common carotid artery 
occlusion. Brain Research 914:185-195. 
 
Kennedy KM, Raz N (2009) Aging white matter and cognition: Differential effects 
of regional variations in diffusion properties on me ory, executive functions, and 
speed. Neuropsychologia 47:916-927. 
 
Kesner RP (2007) Behavioral functions of the CA3 subregion of the hippocampus. 
Learning & Memory 14:771-781. 
 
Kim T, Pfeiffer SE (1999) Myelin glycosphingolipid/cholesterol-enriched 
microdomains selectively sequester the non-compact myelin proteins CNP and 
MOG. Journal of Neurocytology 28:281-293. 
 
Kitagawa K, Matsumoto M, Yang G, Mabuchi T, Yagita Y, Hori M, Yanagihara T 
(1998) Cerebral Ischemia After Bilateral Carotid Artery Occlusion and Intraluminal 
 212 
Suture Occlusion in Mice: Evaluation of the Patency of the Posterior Communicating 
Artery. J Cereb Blood Flow Metab 18:570-579. 
 
Kitaguchi H, Tomimoto H, Ihara M, Shibata M, Uemura K, Kalaria RN, Kihara T, 
Asada-Utsugi M, Kinoshita A, Takahashi R (2009) Chronic cerebral hypoperfusion 
accelerates amyloid [beta] deposition in APPSwInd transgenic mice. Brain Research 
1294:202-210. 
 
Kitano H, Kirsch JR, Hurn PD, Murphy SJ (2006) Inhalational anesthetics as 
neuroprotectants or chemical preconditioning agents i  ischemic brain. J Cereb 
Blood Flow Metab 27:1108-1128. 
 
Kluver H, Barrera E (1953) A Method for the Combined Staining of Cells and Fibers 
in the Nervous System *. Journal of Neuropathology & Experimental Neurology 
12:400-403. 
 
Koike MA, Green KN, Blurton-Jones M, LaFerla FM (2010) Oligemic 
Hypoperfusion Differentially Affects Tau and Amyloid-{beta}. Am J Pathol 
177:300-310. 
 
Koistinaho M, Kettunen MI, Goldsteins G, KeinÃ¤nen R, Salminen A, Ort M, Bures 
J, Liu D, Kauppinen RA, Higgins LS, Koistinaho J (200 ) β-Amyloid precursor 
protein transgenic mice that harbor diffuse Aβ deposits but do not form plaques show 
increased ischemic vulnerability: Role of inflammation. Proceedings of the National 
Academy of Sciences of the United States of America 99:1610-1615. 
 
Kudo T, Takeda M, Tanimukai S, Nishimura T (1993) Neuropathologic changes in 
the gerbil brain after chronic hypoperfusion. Stroke 24:259-264. 
 
Kume K, Hanyu H, Sato T, Hirao K, Shimizu S, Kanetaka H, Sakurai H, Iwamoto T 
(2011) Vascular risk factors are associated with faster decline of Alzheimer disease: 
a longitudinal SPECT study. Journal of Neurology:1-9. 
 
Kurihara T, Tsukada Y (1967) THE REGIONAL AND SUBCELLULAR 
DISTRIBUTION OF 2′,3′-CYCLIC NUCLEOTIDE 3′-PHOSPHOHYDROLASE 
IN THE CENTRAL NERVOUS SYSTEM. Journal of Neurochemistry 14:1167-
1174. 
 
Kurumatani T, Kudo T, Ikura Y, Takeda M, Kontos HA (1998) White Matter 
Changes in the Gerbil Brain Under Chronic Cerebral Hypoperfusion • Editorial 
Comment. Stroke 29:1058-1062. 
 
Kwang-Jin Oh SEP, Sarita Lagalwar, Laurel Vana, Lester Binder, and Elliott J. 
Mufson, (2010) Staging of Alzheimer's Pathology in Triple Transgenic Mice: A 




LaFerla FM, Green KN, Oddo S (2007a) Intracellular amyloid-[beta] in Alzheimer's 
disease. Nat Rev Neurosci 8:499-509. 
 
LaFerla FM, Green KN, Oddo S (2007b) Intracellular amyloid-beta in Alzheimer's 
disease. Nat Rev Neurosci 8:499 - 509. 
 
Lambert J-C, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, 
Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, 
Fievet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, 
Helisalmi S, Porcellini E, Hanon O, de Pancorbo MM, Lendon C, Dufouil C, Jaillard 
C, Leveillard T, Alvarez V, Bosco P, Mancuso M, Panz  F, Nacmias B, Bossu P, 
Piccardi P, Annoni G, Seripa D, Galimberti D, Hannequin D, Licastro F, Soininen H, 
Ritchie K, Blanche H, Dartigues J-F, Tzourio C, Gut I, Van Broeckhoven C, 
Alperovitch A, Lathrop M, Amouyel P (2009) Genome-wide association study 
identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 
41:1094-1099. 
 
Landis J, Koch, GG. (1977) The measurement of observer agreement for categorical 
data. Biometrics:16. 
 
Lane RD, Laukes C, Marcus FI, Chesney MA, Sechrest L, Gear K, Fort CL, Priori 
SG, Schwartz PJ, Steptoe A (2005) Psychological Stress Preceding Idiopathic 
Ventricular Fibrillation. Psychosom Med 67:359-365. 
 
Lasarzik I, Noppens Rd, Wolf T, Bauer H, Luh C, Werner C, Engelhard K, Thal S 
(2011) Dose-Dependent Influence of Sevoflurane Anesthesia on Neuronal Survival 
and Cognitive Outcome After Transient Forebrain Ischemia in Sprague-Dawley Rats. 
Neurocritical Care:1-8. 
 
Lassmann H (2003) Hypoxia-like tissue injury as a component of multiple sclerosis 
lesions. Journal of the Neurological Sciences 206:187- 91. 
 
Lassmann H, Bartsch U, Montag D, Schachner M (1997) Dying-back 
oligodendrogliopathy: A late sequel of myelin-associated glycoprotein deficiency. 
Glia 19:104-110. 
 
Lau T-L, Ambroggio EE, Tew DJ, Cappai R, Masters CL, Fidelio GD, Barnham KJ, 
Separovic F (2006) Amyloid-[beta] Peptide Disruption f Lipid Membranes and the 
Effect of Metal Ions. Journal of Molecular Biology 356:759-770. 
 
Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR, Havlik RJ (2000) 
Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiology 
of aging 21:49-55. 
 
Lazarov O, Morfini GA, Lee EB, Farah MH, Szodorai A, DeBoer SR, Koliatsos VE, 
Kins S, Lee VMY, Wong PC, Price DL, Brady ST, Sisodia SS (2005) Axonal 
Transport, Amyloid Precursor Protein, Kinesin-1, and the Processing Apparatus: 
Revisited. J Neurosci 25:2386-2395. 
 
 214 
Lazic S (2009) Statistical evaluation of methods for quantifying gene expression by 
autoradiography in histological sections. BMC Neuroscience 10:5. 
 
Lee J-T, Xu J, Lee J-M, Ku G, Han X, Yang D-I, Chen S, Hsu CY (2004) Amyloid-β 
peptide induces oligodendrocyte death by activating the neutral 
sphingomyelinaseâ€“ceramide pathway. The Journal of Cell Biology 164:123-131. 
 
Lee M-Y, Kuan Y-H, Chen H-Y, Chen T-Y, Chen S-T, Huang C-C, Yang IP, Hsu Y-
S, Wu T-S, Lee EJ (2007) Intravenous administration of melatonin reduces the 
intracerebral cellular inflammatory response following transient focal cerebral 
ischemia in rats. Journal of Pineal Research 42:297-309. 
 
Leenders KL, Perani D, Lammertsma AA, Heather JD, Buckingham P, Jones T, 
Healy MJR, Gibbs JM, Wise RJS, Hatazawa J, Herold S, Beaney RP, Brooks DJ, 
Spinks T, Rhodes C, Frackowiak RSJ (1990) CEREBRAL BLOOD FLOW, BLOOD 
VOLUME AND OXYGEN UTILIZATION. Brain 113:27-47. 
 
Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe 
KH (2006) A specific amyloid-[beta] protein assembly in the brain impairs memory. 
Nature 440:352-357. 
 
Levy-Lahad E, Wijsman EM, Nemens E, Anderson L, Goddar  KA, Weber JL, Bird 
TD, Schellenberg GD (1995b) A familial Alzheimer's di ease locus on chromosome 
1. Science 269:970-973. 
 
Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, Yu 
CE, Jondro PD, Schmidt SD, Wang K, al e (1995a) Candidate gene for the 
chromosome 1 familial Alzheimer's disease locus. Science 269:973-977. 
 
Levy E, Carman MD, Fernandez-Madrid IJ, Power MD, Lieberburg I, van Duinen 
SG, Bots GT, Luyendijk W, Frangione B (1990) Mutation of the Alzheimer's disease 
amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 248:1124-
1126. 
 
Lewis J, Dickson DW, Lin W-L, Chisholm L, Corral A, Jones G, Yen S-H, Sahara 
N, Skipper L, Yager D, Eckman C, Hardy J, Hutton M,cGowan E (2001) 
Enhanced Neurofibrillary Degeneration in Transgenic M e Expressing Mutant Tau 
and APP. Science 293:1487-1491. 
 
Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, 
Gwinn-Hardy K, Murphy MP, Baker M, Yu X, Duff K, Hardy J, Corral A, Lin W-L, 
Yen S-H, Dickson DW, Davies P, Hutton M (2000) Neurofibrillary tangles, 
amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) 
tau protein. Nat Genet 25:402-405. 
 
Li Y-J, Oliveira SA, Xu P, Martin ER, Stenger JE, Scherzer CR, Hauser MA, Scott 
WK, Small GW, Nance MA, Watts RL, Hubble JP, Koller WC, Pahwa R, Stern MB, 
Hiner BC, Jankovic J, Goetz CG, Mastaglia F, Middleton LT, Roses AD, Saunders 
AM, Schmechel DE, Gullans SR, Haines JL, Gilbert JR, Vance JM, Pericak-Vance 
 215 
MA (2003) Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer 
disease and Parkinson disease. Human Molecular Genetics 12:3259-3267. 
 
Liebeskind DS (2003) Collateral Circulation. Stroke 34:2279-2284. 
 
Lin S-Z, Chiou T-L, Chiang Y-H, Song W-S (1995) Hemodilution Accelerates the 
Passage of Plasma (Not Red Cells) Through Cerebral Microvessels in Rats. Stroke 
26:2166-2171. 
 
Little DMJ (1959) Hypothermia. Anesthesiology 20:842-877. 
 
Loers G, Aboul-Enein F, Bartsch U, Lassmann H, Schachner M (2004) Comparison 
of myelin, axon, lipid, and immunopathology in the c ntral nervous system of 
differentially myelin-compromised mutant mice: a morphological and biochemical 
study. Molecular and Cellular Neuroscience 27:175-189. 
 
Lopez JR, Lyckman A, Oddo S, LaFerla FM, Querfurth HW, Shtifman A (2008) 
Increased intraneuronal resting [Ca2+] in adult Alzheimer’s disease mice. Journal of 
Neurochemistry 105:262-271. 
 
Luckhaus C, Flüß MO, Wittsack H-J, Grass-Kapanke B, Jänner M, Khalili-Amiri R, 
Friedrich W, Supprian T, Gaebel W, Mödder U, Cohnen M (2008) Detection of 
changed regional cerebral blood flow in mild cognitive impairment and early 
Alzheimer's dementia by perfusion-weighted magnetic resonance imaging. 
NeuroImage 40:495-503. 
 
Ludwin S (1978) Central nervous system demyelinatio and remyelination in the 
mouse: an ultrastructural study of cuprizone toxicity. Journal of laboratory 
investigation 39:15. 
 
Lycette RM, Danforth WF, Koppel JL, Olwin JH (1970) The Binding of Luxol Fast 
Blue Arn by Various Biological Lipids. Biotechnic &Histochemistry 45:155-160. 
 
Lye TC, Shores EA (2000) Traumatic Brain Injury as a Risk Factor for Alzheimer's 
Disease: A Review. Neuropsychology Review 10:115-129. 
 
Maeda K, Hata R, Hossmann K-A (1998) Differences in the cerebrovascular 
anatomy of C57Black/6 and SV129 mice. NeuroReport 9:1317-1319. 
 
Marner L, Nyengaard JR, Tang Y, Pakkenberg B (2003) Marked loss of myelinated 
nerve fibers in the human brain with age. The Journal of Comparative Neurology 
462:144-152. 
 
Martin B, Brenneman R, Becker KG, Gucek M, Cole RN, Maudsley S (2008) 
iTRAQ Analysis of Complex Proteome Alterations in 3xTgAD Alzheimer's Mice: 
Understanding the Interface between Physiology and Disease. PLoS ONE 3:e2750. 
 
 216 
Mastrangelo M, Bowers W (2008) Detailed immunohistochemical characterization of 
temporal and spatial progression of Alzheimer's disease-related pathologies in male 
triple-transgenic mice. BMC Neuroscience 9:81. 
 
Matsuda H (2007) Role of Neuroimaging in Alzheimer's Disease, with Emphasis on 
Brain Perfusion SPECT. J Nucl Med 48:1289-1300. 
 
McKenzie KJ, McLellan DR, Gentleman SM, Maxwell WL, Gennarelli TA, Graham 
DI (1996) Is β-APP a marker of axonal damage in short-surviving head injury? Acta 
Neuropathologica 92:608-613. 
 
McKerracher L, David S, Jackson DL, Kottis V, Dunn RJ, Braun PE (1994) 
Identification of myelin-associated glycoprotein as a major myelin-derived inhibitor 
of neurite growth. Neuron 13:805-811. 
 
Metcalfe MJ, Figueiredo-Pereira ME (2010) Relationship Between Tau Pathology 
and Neuroinflammation in Alzheimer's Disease. Mount Si ai Journal of Medicine: A 
Journal of Translational and Personalized Medicine 77:50-58. 
 
Miki K, Ishibashi S, Sun L, Xu H, Ohashi W, Kuroiwa T, Mizusawa H (2009) 
Intensity of chronic cerebral hypoperfusion determines white/gray matter injury and 
cognitive/motor dysfunction in mice. Journal of Neuroscience Research 87:1270-
1281. 
 
Miller RH, Raff MC (1984) Fibrous and protoplasmic astrocytes are biochemically 
and developmentally distinct. J Neurosci 4:585-592. 
 
Moskowitz MA, Lo EH, Iadecola C (2010) The Science of Stroke: Mechanisms in 
Search of Treatments. Neuron 67:181-198. 
 
Mucke L, Masliah E, Yu G-Q, Mallory M, Rockenstein EM, Tatsuno G, Hu K, 
Kholodenko D, Johnson-Wood K, McConlogue L (2000) High-Level Neuronal 
Expression of Abeta 1-42 in Wild-Type Human Amyloid Protein Precursor 
Transgenic Mice: Synaptotoxicity without Plaque Formation. J Neurosci 20:4050-
4058. 
 
Naggara O, Oppenheim C, Rieu D, Raoux N, Rodrigo S, Dalla Barba G, Meder J-F 
(2006) Diffusion tensor imaging in early Alzheimer's disease. Psychiatry Research: 
Neuroimaging 146:243-249. 
 
Nakaji K, Ihara M, Takahashi C, Itohara S, Noda M, Takahashi R, Tomimoto H 
(2006) Matrix Metalloproteinase-2 Plays a Critical Role in the Pathogenesis of White 
Matter Lesions After Chronic Cerebral Hypoperfusion n Rodents. Stroke 37:2816-
2823. 
 
Nicholson RM, Kusne Y, Nowak LA, LaFerla FM, Reiman EM, Valla J (2009) 
Regional cerebral glucose uptake in the 3xTG model of Alzheimer's disease 




Nishio K, Ihara M, Yamasaki N, Kalaria RN, Maki T, Fujita Y, Ito H, Oishi N, 
Fukuyama H, Miyakawa T, Takahashi R, Tomimoto H (2010) A Mouse Model 
Characterizing Features of Vascular Dementia With Hippocampal Atrophy * 
Supplemental Methods. Stroke 41:1278-1284. 
 
Niwa K, Kazama K, Younkin SG, Carlson GA, Iadecola C (2002) Alterations in 
Cerebral Blood Flow and Glucose Utilization in Mice Overexpressing the Amyloid 
Precursor Protein. Neurobiology of Disease 9:61-68. 
 
Niwa K, Porter VA, Kazama K, Cornfield D, Carlson GA, Iadecola C (2001) Abeta -
peptides enhance vasoconstriction in cerebral circulation. Am J Physiol Heart Circ 
Physiol 281:H2417-2424. 
 
Niwa K, Younkin L, Ebeling C, Turner SK, Westaway D, Younkin S, Ashe KH, 
Carlson GA, Iadecola C (2000) Aβ 40-related reduction in functional hyperemia in 
mouse neocortex during somatosensory activation. Proceedings of the National 
Academy of Sciences of the United States of America 97:9735-9740. 
 
O'Donnell KA, Rapp PR, Hof PR (1999) Preservation of Prefrontal Cortical Volume 
in Behaviorally Characterized Aged Macaque Monkeys. Experimental Neurology 
160:300-310. 
 
O'Sullivan M (2008) Leukoaraiosis. Practical Neurology 8:26-38. 
 
O'Sullivan M, Jones DK, Summers PE, Morris RG, Williams SCR, Markus HS 
(2001) Evidence for cortical "disconnection" as a mechanism of age-related cognitive 
decline. Neurology 57:632-638. 
 
Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM(2003a) Amyloid 
deposition precedes tangle formation in a triple transgenic model of Alzheimer's 
disease. Neurobiol Aging 24:1063 - 1070. 
 
Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM (2004) A[beta] 
Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated 
Tau Aggregates via the Proteasome. Neuron 43:321-33. 
 
Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, 
Mattson MP, Akbari Y, LaFerla FM (2003b) Triple-Transgenic Model of 
Alzheimer's Disease with Plaques and Tangles: Intracellular A[beta] and Synaptic 
Dysfunction. Neuron 39:409-421. 
 
Ogata J, Fujishima M, Tamaki K, Nakatomi Y, Ishitsuka T, Omae T (1982) Stroke-
prone spontaneously hypertensive rats as an experimental model of malignant 
hypertension. Virchows Archiv 394:185-194. 
 
Okamoto K, Yamori, Y. (1973) Spontaneous hypertension in rats versus essential 
hypertension in man. Singapore medical journal 14:393- 94. 
 
 218 
Olivier P, Fontaine RH, Loron G, Van Steenwinckel J, Biran Vr, Massonneau Vr, 
Kaindl A, Dalous J, Charriaut-Marlangue C, Aigrot M-Sp, Pansiot J, Verney C, 
Gressens P, Baud O (2009) Melatonin Promotes Oligodendroglial Maturation of 
Injured White Matter in Neonatal Rats. PLoS ONE 4:e7128. 
 
Pakkenberg B, Gundersen HJG (1997) Neocortical neuro  number in humans: Effect 
of sex and age. The Journal of Comparative Neurology 384:312-320. 
 
Pakkenberg B, Pelvig D, Marner L, Bundgaard MJ, Gundersen HJG, Nyengaard JR, 
Regeur L (2003) Aging and the human neocortex. Experimental Gerontology 38:95-
99. 
 
Palmer JC, Kehoe PG, Love S (2010) Endothelin-converti g enzyme-1 in 
Alzheimer's disease and vascular dementia. Neuropath logy and Applied 
Neurobiology 36:487-497. 
 
Palmer JC, Baig S, Kehoe PG, Love S (2009) Endothelin-Converting Enzyme-2 Is 
Increased in Alzheimerâ€™s Disease and Up-Regulated by AÎ². The American 
Journal of Pathology 175:262-270. 
 
Pan B, Fromholt SE, Hess EJ, Crawford TO, Griffin JW, Sheikh KA, Schnaar RL 
(2005) Myelin-associated glycoprotein and complementary axonal ligands, 
gangliosides, mediate axon stability in the CNS and PNS: Neuropathology and 
behavioral deficits in single- and double-null mice. Experimental Neurology 
195:208-217. 
 
Pantoni L, Garcia JH (1997) Pathogenesis of Leukoarai sis : A Review. Stroke 
28:652-659. 
 
Pantoni L, Garcia JH, Gutierrez JA, Rosenblum WI (1996) Cerebral White Matter Is 
Highly Vulnerable to Ischemia. Stroke 27:1641-1647. 
 
Pappas BA, Davidson CM, Bennett SAL, de la Torre JC, Fortin T, Tenniswood MPR 
(1997) Chronic Ischemia: Memory Impairment And Neural Pathology in the Rata. 
Annals of the New York Academy of Sciences 826:498-501. 
 
Pappolla M, Bozner P, Soto C, Shao H, Robakis NK, Zagorski M, Frangione B, 
Ghiso J (1998) Inhibition of Alzheimer a beta-Fibrillogenesis by Melatonin. Journal 
of Biological Chemistry 273:7185-7188. 
 
Pappolla MA, Chyan YJ, Poeggeler B, Frangione B, Wilson G, Ghiso J, Reiter RJ 
(2000) An assessment of the antioxidant and the antiamyloidogenic properties of 
melatonin: implications for Alzheimer's disease. Journal of Neural Transmission 
107:203-231. 
 
Pardon M-C, Kendall DA, Pérez-Diaz F, Duxon MS, Marsden CA (2004) Repeated 
sensory contact with aggressive mice rapidly leads to an anticipatory increase in core 
body temperature and physical activity that precedes the onset of aversive 
responding. European Journal of Neuroscience 20:1033- 50. 
 219 
 
Pedraza L, Fidler L, Staugaitis SM, Colman DR (1997) The Active Transport of 
Myelin Basic Protein into the Nucleus Suggests a Regulatory Role in Myelination. 
Neuron 18:579-589. 
 
Perry VH, Nicoll JAR, Holmes C (2010) Microglia in neurodegenerative disease. Nat 
Rev Neurol 6:193-201. 
 
Peters A (2002) The effects of normal aging on myelin and nerve fibers: A review. 
Journal of Neurocytology 31:581-593. 
 
Peters A (2009) The effects of normal aging on myelinated nerve fibers in monkey 
central nervous system. Frontiers in Neuroanatomy 4:12. 
 
Peters A, Sethares C (2002) Aging and the myelinated fib rs in prefrontal cortex and 
corpus callosum of the monkey. The Journal of Comparative Neurology 442:277-
291. 
 
Peters APS, Webster H de F (1991) The Fine Structure of the Nervous System: the 
Neuron and the Supporting Cells. Oxford: Oxford University Press. 
 
Pimplikar SW (2009) Reassessing the amyloid cascade hypothesis of Alzheimer's 
disease. The International Journal of Biochemistry & Cell Biology 41:1261-1268. 
 
Pluta R, Kida E, Lossinsky AS, Golabek AA, Mossakowski MJ, Wisniewski HM 
(1994) Complete cerebral ischemia with short-term survival in rats induced by 
cardiac arrest. I. Extracellular accumulation of Alzheimer's [beta]-amyloid protein 
precursor in the brain. Brain Research 649:323-328. 
 
Privat A, Jacque C, Bourre JM, Dupouey P, Baumann N (1979) Absence of the 
major dense line in myelin of the mutant mouse [`]shiverer'. Neuroscience Letters 
12:107-112. 
 
Prohovnik I, Mayeux R, Sackeim HA, Smith G, Stern Y, Alderson PO (1988) 
Cerebral perfusion as a diagnostic marker of early Alzheimer's disease. Neurology 
38:931-. 
 
Qiu C, De Ronchi, D. and Fratiglioni, L (2007) The epidemiology of the dementias: 
an update. Current Opinion in Psychiatry 20:6. 
 
Quarles RH (2007) Myelin-associated glycoprotein (MAG): past, present and 
beyond. Journal of Neurochemistry 100:1431-1448. 
 
Quarles RH, Everly JL, Brady RO (1973) EVIDENCE FOR THE CLOSE 
ASSOCIATION OF A GLYCOPROTEIN WITH MYELIN IN RAT BRAIN. 
Journal of Neurochemistry 21:1177-1191. 
 
Quarles RH, Macklin W.B., Morrell P (2006) Basic Neurochemistry:  Molecular, 
Cellular, and Medical Aspects. New York: Elsevier Inc. 
 220 
 
Querfurth HW, LaFerla FM (2010) Alzheimer's Disease. N w England Journal of 
Medicine 362:329-344. 
 
Rasband MN, Tayler J, Kaga Y, Yang Y, Lappe-Siefke C, Nave KA, Bansal R 
(2005) CNP is required for maintenance of axon–glia interactions at nodes of 
Ranvier in the CNS. Glia 50:86-90. 
 
Raz N, Rodrigue KM, Kennedy KM, Acker JD (2007) Vascular Health and 
Longitudinal Changes in Brain and Cognition in Middle-Aged and Older Adults. 
[Article]. 
 
Resnick SM, Goldszal AF, Davatzikos C, Golski S, Kraut MA, Metter EJ, Bryan RN, 
Zonderman AB (2000) One-year Age Changes in MRI Brain Volumes in Older 
Adults. Cerebral Cortex 10:464-472. 
 
Ricciardi E, Bonino D, Gentili C, Sani L, Pietrini P, Vecchi T (2006) Neural 
correlates of spatial working memory in humans: A functional magnetic resonance 
imaging study comparing visual and tactile processes. N uroscience 139:339-349. 
 
Riekse RG, Leverenz JB, McCormick W, Bowen JD, Teri L, Nochlin D, Simpson K, 
Eugenio C, Larson EB, Tsuang D (2004) Effect of Vascular Lesions on Cognition in 
Alzheimer's Disease: A Community-Based Study. Journal of the American Geriatrics 
Society 52:1442-1448. 
 
Roach A, Takahashi N, Pravtcheva D, Ruddle F, Hood L (1985) Chromosomal 
mapping of mouse myelin basic protein gene and structu e and transcription of the 
partially deleted gene in shiverer mutant mice. Cell 42:149-155. 
 
Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang Y, Chi H, Lin 
C, Holman K, Tsuda T, Mar L, Sorbi S, Nacmias B, Piacentini S, Amaducci L, 
Chumakov I, Cohen D, Lannfelt L, Fraser PE, Rommens JM, George-Hyslop PHS 
(1995) Familial Alzheimer's disease in kindreds with missense mutations in a  
 gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 
376:775-778. 
 
Rogaeva E, Meng Y, Lee JH, Gu Y, Kawarai T, Zou F, Katayama T, Baldwin CT, 
Cheng R, Hasegawa H, Chen F, Shibata N, Lunetta KL, Pardossi-Piquard R, Bohm 
C, Wakutani Y, Cupples LA, Cuenco KT, Green RC, Pinessi L, Rainero I, Sorbi S, 
Bruni A, Duara R, Friedland RP, Inzelberg R, Hampe W, Bujo H, Song Y-Q, 
Andersen OM, Willnow TE, Graff-Radford N, Petersen RC, Dickson D, Der SD, 
Fraser PE, Schmitt-Ulms G, Younkin S, Mayeux R, Farrer LA, St George-Hyslop P 
(2007) The neuronal sortilin-related receptor SORL1 is genetically associated with 
Alzheimer disease. Nat Genet 39:168-177. 
 
Rogers J, Strohmeyer R, Kovelowski C, Li R (2002) Microglia and inflammatory 
mechanisms in the clearance of amyloid β peptide. Glia 40:260-269. 
 
 221 
Roher AE, Weiss N, Kokjohn TA, Kuo Y-M, Kalback W, Anthony J, Watson D, 
Luehrs DC, Sue L, Walker D, Emmerling M, Goux W, Beach T (2002) Increased Aβ 
Peptides and Reduced Cholesterol and Myelin Proteins Characterize White Matter 
Degeneration in Alzheimer's Disease Biochemistry 41:11080-11090. 
 
Rombouts SARB, Goekoop R, Stam CJ, Barkhof F, Scheltens P (2005) Delayed 
rather than decreased BOLD response as a marker for early Alzheimer's disease. 
NeuroImage 26:1078-1085. 
 
Rosenberg GA, Kornfeld M, Stovring J, Bicknell JM (1979) Subcortical 
arteriosclerotic encephalopathy (Binswanger). Neurology 29:1102. 
 
Rosenberg GA, Sullivan N, Esiri MM, Sobel RA (2001) White Matter Damage Is 
Associated With Matrix Metalloproteinases in Vascular Dementia Editorial 
Comment : Matrix Metalloproteinases and Diffuse White Matter Injury. Stroke 
32:1162-1168. 
 
Rosenbluth J (1966) REDUNDANT MYELIN SHEATHS AND OTHER 
ULTRASTRUCTURAL FEATURES OF THE TOAD CEREBELLUM. The Journal 
of Cell Biology 28:73-93. 
 
Roth AD, RamÍRez G, AlarcÓN R, Von Bernhardi R (2005) Oligodendrocytes 
damage in Alzheimer's disease: Beta amyloid toxicity and inflammation. Biological 
Research 38:381-387. 
 
Rowbotham GF, Little E (1965) Circulations of the crebral hemispheres. British 
Journal of Surgery 52:8-21. 
 
Roy S, Zhang B, Lee VMY, Trojanowski JQ (2005) Axonal transport defects: a 
common theme in neurodegenerative diseases. Acta Neuropathologica 109:5-13. 
 
Rubin BAM, Horovitz ZP. (1978) Captopril (SQ 14,225) (D-3-mercapto-2-
methylpropranoyl-L-proline): a novel orally active inhibitor of angiotensin-
converting enzyme and antihypertensive agent. Progress in Cardiovascular Discovery 
21:12. 
 
Ruitenberg A, den Heijer T, Bakker SLM, van Swieten JC, Koudstaal PJ, Hofman A, 
Breteler MMB (2005) Cerebral hypoperfusion and clini al onset of dementia: The 
Rotterdam study. Annals of Neurology 57:789-794. 
 
Ryan NS, Rossor MN (2010) Correlating familial Alzheimers disease gene mutations 
with clinical phenotype. Biomarkers in Medicine 4:99-112. 
 
Salat DH, Greve DN, Pacheco JL, Quinn BT, Helmer KG, Buckner RL, Fischl B 
(2009) Regional white matter volume differences in nondemented aging and 
Alzheimer's disease. NeuroImage 44:1247-1258. 
 
 222 
Salthouse TN (1962) Luxol Fast Blue Arn: A New Solvent Azo Dye with Improved 
Staining Qualities for Myelin and Phospholipids. Biotechnic and Histochemistry 
37:313 - 316. 
 
Salzer JL, Holmes WP, Colman DR (1987) The amino acid sequences of the myelin-
associated glycoproteins: homology to the immunoglobulin gene superfamily. The 
Journal of Cell Biology 104:957-965. 
 
Sarti C, Pantoni L, Bartolini L, Inzitari D (2002) Cognitive impairment and chronic 
cerebral hypoperfusion: What can be learned from experimental models. Journal of 
the Neurological Sciences 203-204:263-266. 
Scheinberg P (1988) Dementia due to vascular disease--a multifactorial disorder. 
Stroke 19:1291-1299. 
 
Schenk F, Morris RGM (1985) Dissociation between comp nents of spatial memory 
in rats after recovery from the effects of retrohippocampal lesions. Experimental 
Brain Research 58:11-28. 
 
Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, 
Hutton M, Kukull W, Larson E, Levy-Lahad L, Viitane M, Peskind E, Poorkaj P, 
Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selko D, Younkin S (1996) 
Secreted amyloid [beta]-protein similar to that in the senile plaques of Alzheimer's 
disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to 
familial Alzheimer's disease. Nat Med 2:864-870. 
 
Schmid-Schonbein H (1983) Macrorheology and Microrhe logy of Blood in 
Cerebrovascular Insufficiency. European Neurology 22:2-22. 
 
Schmitz T, Chew L-J (2008) Cytokines and Myelination in the Central Nervous 
System. TheScientificWorldJOURNAL 8:1119-1147. 
 
Selkoe DJ (1991) The molecular pathology of Alzheimer's disease. Neuron 6:487-
498. 
 
Selkoe DJ, Podlisny MB (2002) DECIPHERING THE GENETIC BASIS OF 
ALZHEIMER'S DISEASE. Annual Review of Genomics and Human Genetics 3:67-
99. 
 
Selkoe DJ, Podlisny MB, Joachim CL, Vickers EA, Lee G, Fritz LC, Oltersdorf T 
(1988) Beta-amyloid precursor protein of Alzheimer disease occurs as 110- to 135-
kilodalton membrane-associated proteins in neural and nonneural tissues. 
Proceedings of the National Academy of Sciences of the United States of America 
85:7341-7345. 
 
Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, 
Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ 
(2008) Amyloid-[beta] protein dimers isolated directly from Alzheimer's brains 
impair synaptic plasticity and memory. Nat Med 14:837-842. 
 
 223 
Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin 
C, Li G, Holman K, Tsuda T, Mar L, Foncin JF, Bruni AC, Montesi MP, Sorbi S, 
Rainero I, Pinessi L, Nee L, Chumakov I, Pollen D, Brookes A, Sanseau P, Polinsky 
RJ, Wasco W, Da Silva HAR, Haines JL, Pericak-Vance MA, Tanzi RE, Roses AD, 
Fraser PE, Rommens JM, St George-Hyslop PH (1995) Cloning of a gene bearing 
missense mutations in early-onset familial Alzheimer's disease. Nature 375:754-760. 
 
Shibata M, Ohtani R, Ihara M, Tomimoto H (2004) White Matter Lesions and Glial 
Activation in a Novel Mouse Model of Chronic Cerebral Hypoperfusion. Stroke 
35:2598-2603. 
 
Shibata M, Yamasaki N, Miyakawa T, Kalaria RN, Fujita Y, Ohtani R, Ihara M, 
Takahashi R, Tomimoto H (2007) Selective Impairment of Working Memory in a 
Mouse Model of Chronic Cerebral Hypoperfusion. Stroke 38:2826-2832. 
 
Simpson JE, Fernando MS, Clark L, Ince PG, Matthews F, Forster G, O'Brien JT, 
Barber R, Kalaria RN, Brayne C, Shaw PJ, Lewis CE, Wharton SB, Group 
MRCCFaANS (2007a) White matter lesions in an unselect d cohort of the elderly: 
astrocytic, microglial and oligodendrocyte precursor cell responses. Neuropathology 
and Applied Neurobiology 33:410-419. 
 
Simpson JE, Ince PG, Higham CE, Gelsthorpe CH, Fernando MS, Matthews F, 
Forster G, O'Brien JT, Barber R, Kalaria RN, Brayne C, Shaw PJ, Stoeber K, 
Williams GH, Lewis CE, Wharton SB, the MRCCFaANSG (2007b) Microglial 
activation in white matter lesions and nonlesional white matter of ageing brains. 
Neuropathology and Applied Neurobiology 33:670-683. 
 
Skaper S, Evans N, Soden P, Rosin C, Facci L, Richardson J (2009) 
Oligodendrocytes are a Novel Source of Amyloid Peptid  Generation. 
Neurochemical Research 34:2243-2250. 
 
Sloane JA, Hinman JD, Lubonia M, Hollander W, Abraham CR (2003) Age-
dependent myelin degeneration and proteolysis of oligodendrocyte proteins is 
associated with the activation of calpain-1 in the rhesus monkey. Journal of 
Neurochemistry 84:157-168. 
 
Small SA, Duff K (2008) Linking A[beta] and Tau in Late-Onset Alzheimer's 
Disease: A Dual Pathway Hypothesis. Neuron 60:534-542. 
 
Song S-K, Kim JH, Lin S-J, Brendza RP, Holtzman DM (2004) Diffusion tensor 
imaging detects age-dependent white matter changes i  a transgenic mouse model 
with amyloid deposition. Neurobiology of Disease 15:640-647. 
 
Spain A, Daumas S, Lifshitz J, Rhodes J, Andrews PJD, Horsburgh K, Fowler JH 
(2010) Mild Fluid Percussion Injury in Mice Produces Evolving Selective Axonal 




Squier TC (2001) Oxidative stress and protein aggregation during biological aging. 
Experimental Gerontology 36:1539-1550. 
 
St George-Hyslop PH (2000) Genetic Factors in the Genesis of Alzheimer's Disease. 
Annals of the New York Academy of Sciences 924:1-7. 
 
Staugaitis SM, Smith PR, Colman DR (1990) Expression of myelin basic protein 
isoforms in nonglial cells. The Journal of Cell Biology 110:1719-1727. 
 
Stephanova DI, Daskalova M, Alexandrov AS (2005) Differences in potentials and 
excitability properties in simulated cases of demyelinating neuropathies. Part I. 
Clinical Neurophysiology 116:1153-1158. 
 
Sternlicht MD, Werb Z (2001) HOW MATRIX METALLOPROTEINASES 
REGULATE CELL BEHAVIOR. Annual Review of Cell and Developmental 
Biology 17:463-516. 
 
Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, Mount SL, Raman R, 
Davies P, Masliah E, Williams DS, Goldstein LSB (2005) Axonopathy and 
Transport Deficits Early in the Pathogenesis of Alzheimer's Disease. Science 
307:1282-1288. 
 
Stommel A, Berlet HH, Debuch H (1989) Buoyant density and lipid composition of 
purified myelin of aging human brain. Mechanisms of Ageing and Development 
48:1-14. 
 
Stout JC, Jernigan TL, Archibald SL, Salmon DP (1996) Association of Dementia 
Severity With Cortical Gray Matter and Abnormal White Matter Volumes in 
Dementia of the Alzheimer Type. Arch Neurol 53:742-749. 
 
Strittmatter WJ, Saunders AM, Schmechel D, Pericak-V nce M, Enghild J, Salvesen 
GS, Roses AD (1993) Apolipoprotein E: high-avidity binding to beta-amyloid and 
increased frequency of type 4 allele in late-onset familial Alzheimer disease. 
Proceedings of the National Academy of Sciences of the United States of America 
90:1977-1981. 
 
Sturrock RR (1976) Changes in Neuroglia and Myelinatio  in the White Matter of 
Aging Mice. Journal of Gerontology 31:513-522. 
 
Sun S-W, Song S-K, Harms MP, Lin S-J, Holtzman DM, Merchant KM, Kotyk JJ 
(2005) Detection of age-dependent brain injury in a mouse model of brain 
amyloidosis associated with Alzheimer's disease using magnetic resonance diffusion 
tensor imaging. Experimental Neurology 191:77-85. 
 
Svennerholm L, Boström K, Helander CG, Jungbjer B (1991) Membrane Lipids in 
the Aging Human Brain. Journal of Neurochemistry 56:2051-2059. 
 
 225 
Takeuchi H, Sekiguchi A, Taki Y, Yokoyama S, Yomogida Y, Komuro N, 
Yamanouchi T, Suzuki S, Kawashima R (2010) Training of Working Memory 
Impacts Structural Connectivity. The Journal of Neuroscience 30:3297-3303. 
 
Tamura E, Parry GJ (1994) Severe radicular pathology in rats with longstanding 
diabetes. Journal of the Neurological Sciences 127:29-35. 
 
Tanaka H, Ma J, Tanaka KF, Takao K, Komada M, Tanda K, Suzuki A, Ishibashi T, 
Baba H, Isa T, Shigemoto R, Ono K, Miyakawa T, Ikenaka K (2009) Mice with 
Altered Myelin Proteolipid Protein Gene Expression Display Cognitive Deficits 
Accompanied by Abnormal Neuronâ€“Glia Interactions and Decreased Conduction 
Velocities. The Journal of Neuroscience 29:8363-8371. 
 
Tang Y, Nyengaard JR, Pakkenberg B, Gundersen HJG (1997) Age-Induced White 
Matter Changes in the Human Brain: A Stereological Investigation. Neurobiology of 
Aging 18:609-615. 
 
Tanzi RE, Moir RD, Wagner SL (2004) Clearance of Alzheimer's A[beta] Peptide: 
The Many Roads to Perdition. Neuron 43:605-608. 
 
Thomas DJ, Marshall J, Russell RWR, Wetherley-Mein G, Boulay GHD, Pearson 
TC, Symon L, Zilkha E (1977) EFFECT OF HÆMATOCRIT ON CEREBRAL 
BLOOD-FLOW IN MAN. The Lancet 310:941-943. 
 
Thomas T, Thomas G, McLendon C, Sutton T, Mullan M (1996) [beta]-Amyloid-
mediated vasoactivity and vascular endothelial damage. Nature 380:168-171. 
 
Tiehuis A, Vincken K, van den Berg E, Hendrikse J, Manschot S, Mali W, Kappelle 
L, Biessels G (2008) Cerebral perfusion in relation t  cognitive function and type 2 
diabetes. Diabetologia 51:1321-1326. 
 
Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB, Starkey 
M, Webster MJ, Yolken RH, Bahn S (2003) Oligodendrocyte dysfunction in 
schizophrenia and bipolar disorder. The Lancet 362:798-805. 
 
Trapp BD, Bernier L, Andrews SB, Colman DR (1988) Cellular and Subcellular 
Distribution of 2′,3′-Cyclic Nucleotide 3′-Phosphodiesterase and Its mRNA in the 
Rat Central Nervous System. Journal of Neurochemistry 51:859-868. 
 
Trudel X, Brisson C, Milot A (2010) Job Strain and Masked Hypertension. 
Psychosom Med 72:786-793. 
 
Turner PR, O'Connor K, Tate WP, Abraham WC (2003) Roles of amyloid precursor 
protein and its fragments in regulating neural activity, plasticity and memory. 
Progress in Neurobiology 70:1-32. 
 
Ukmar M, Makuc E, Onor M, Garbin G, Trevisiol M, Cova M (2008) Evaluation of 
white matter damage in patients with Alzheimer’s diease and in patients with mild 
 226 
cognitive impairment by using diffusion tensor imaging. La Radiologia Medica 
113:915-922. 
 
Van Den Bergh R, Van Der Eecken H, Luyendijk W (1968) Anatomy and 
Embryology of Cerebral Circulation. In: Progress in Brain Research, pp 1-25: 
Elsevier. 
 
van Dijk EJ, Breteler MMB, Schmidt R, Berger K, Nilsson L-G, Oudkerk M, Pajak 
A, Sans S, de Ridder M, Dufouil C, Fuhrer R, Giampaoli S, Launer LJ, Hofman A, 
for the CC (2004) The Association Between Blood Pressure, Hypertension, and 
Cerebral White Matter Lesions: Cardiovascular Determinants of Dementia Study. 
Hypertension 44:625-630. 
 
Vlkolinský R, Cairns N, Fountoulakis M, Lubec G (2001) Decreased brain levels of 
2',3'-cyclic nucleotide-3'-phosphodiesterase in Down syndrome and Alzheimer's 
disease. Neurobiology of Aging 22:547-553. 
 
Vogel US, Thompson RJ (1988) Molecular Structure, Localization, and Possible 
Functions of the Myelin-Associated Enzyme 2′,3′-Cyclic Nucleotide 3′-
Phosphodiesterase. Journal of Neurochemistry 50:1667- 77. 
 
Von Bernhardi R, Tichauer JE, Eugenín J (2010) Aging-dependent changes of 
microglial cells and their relevance for neurodegenerative disorders. Journal of 
Neurochemistry 112:1099-1114. 
 
Wakita H, Tomimoto H, Akiguchi I, Kimura J (1994) Glial activation and white 
matter changes in the rat brain induced by chronic cerebral hypoperfusion: an 
immunohistochemical study. Acta Neuropathologica 87:4 4-492. 
 
Wakita H, Tomimoto H, Akiguchi I, Matsuo A, Lin J-X, Ihara M, McGeer P-L 
(2002) Axonal damage and demyelination in the white matter after chronic cerebral 
hypoperfusion in the rat. Brain Research 924:63-70. 
 
Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, 
Selkoe DJ (2002) Naturally secreted oligomers of amyloid [beta] protein potently 
inhibit hippocampal long-term potentiation in vivo. Nature 416:535-539. 
 
Weidensteiner C, Metzger F, Bohrmann ABB, Kuennecke B, von Kienlin M (2009) 
Cortical hypoperfusion in the B6.PS2APP mouse model for Alzheimer's disease: 
Comprehensive phenotyping of vascular and tissular parameters by MRI. Magnetic 
Resonance in Medicine 62:35-45. 
 
Weller R, Preston S, Subash M, Carare R (2009) Cerebral amyloid angiopathy in the 
aetiology and immunotherapy of Alzheimer disease. Alzheimer's Research & 
Therapy 1:6. 
 
Wellons  JC, Sheng H, Laskowitz DT, Burkhard Mackensen G, Pearlstein RD, 
Warner DS (2000) A comparison of strain-related susceptibility in two murine 
recovery models of global cerebral ischemia. Brain Research 868:14-21. 
 227 
Winton MJ, Lee EB, Sun E, Wong MM, Leight S, Zhang B, Trojanowski JQ, Lee 
VMY (2011) Intraneuronal APP, Not Free AÎ² Peptides in 3xTg-AD Mice: 
Implications for Tau versus AÎ²-Mediated Alzheimer Neurodegeneration. The 
Journal of Neuroscience 31:7691-7699. 
 
Wirths O, Weis J, Szczygielski J, Multhaup G, Bayer T (2006) Axonopathy in an 
APP/PS1 transgenic mouse model of Alzheimer’s disease. Acta Neuropathologica 
111:312-319. 
 
Wirths O, Weis J, Kayed R, Saido TC, Bayer TA (2007) Age-dependent axonal 
degeneration in an Alzheimer mouse model. Neurobiolgy of Aging 28:1689-1699. 
 
Wisco JJ, Killiany RJ, Guttmann CRG, Warfield SK, Moss MB, Rosene DL (2008) 
An MRI study of age-related white and gray matter volume changes in the rhesus 
monkey. Neurobiology of Aging 29:1563-1575. 
 
Witztum JL (1989) Current approaches to drug therapy for the hypercholesterolemic 
patient. Circulation 80:1101-1114. 
 
Wu EX, Tang H, Asai T, Yan SD (2004) Regional cerebral lood volume reduction 
in transgenic mutant APP (V717F, K670N/M671L) mice. Neuroscience Letters 
365:223-227. 
 
Wu Z, Guo H, Chow N, Sallstrom J, Bell RD, Deane R, Brooks AI, Kanagala S, 
Rubio A, Sagare A, Liu D, Li F, Armstrong D, Gasiewcz T, Zidovetzki R, Song X, 
Hofman F, Zlokovic BV (2005) Role of the MEOX2 homeobox gene in 
neurovascular dysfunction in Alzheimer disease. Nat Med 11:959-965. 
 
Xia W, Zhang J, Kholodenko D, Citron M, Podlisny MB, Teplow DB, Haass C, 
Seubert P, Koo EH, Selkoe DJ (1997) Enhanced Producti n and Oligomerization of 
the 42-residue Amyloid Î²-Protein by Chinese Hamster Ovary Cells Stably 
Expressing Mutant Presenilins. Journal of Biological Chemistry 272:7977-7982. 
 
Xu J, Chen S, Ahmed SH, Chen H, Ku G, Goldberg MP, Hsu CY (2001) Amyloid-
{beta} Peptides Are Cytotoxic to Oligodendrocytes. J Neurosci 21:118RC-. 
 
Yamada M, Ihara M, Okamoto Y, Maki T, Washida K, Kitamura A, Hase Y, Ito H, 
Takao K, Miyakawa T, Kalaria RN, Tomimoto H, Takahas i R (2011) The Influence 
of Chronic Cerebral Hypoperfusion on Cognitive Function and Amyloid Î² 
Metabolism in APP Overexpressing Mice. PLoS ONE 6:e1 567. 
 
Yang G, Kitagawa K, Matsushita K, Mabuchi T, Yagita Y, Yanagihara T, 
Matsumoto M (1997) C57BL/6 strain is most susceptible to cerebral ischemia 
following bilateral common carotid occlusion among seven mouse strains: selective 




Yang S, Li C, Lu W, Zhang W, Wang W, Tang Y (2009) The myelinated fiber 
changes in the white matter of aged female Long-Evans r ts. Journal of Neuroscience 
Research 87:1582-1590. 
 
Yoshiura T, Hiwatashi A, Noguchi T, Yamashita K, Ohyagi Y, Monji A, Nagao E, 
Kamano H, Togao O, Honda H (2009) Arterial spin labe ling at 3-T MR imaging for 
detection of individuals with Alzheimer’s disease. European Radiology 19:2819-
2825. 
 
Zhang F, Eckman C, Younkin S, Hsiao KK, Iadecola C (1997) Increased 
Susceptibility to Ischemic Brain Damage in Transgenic Mice Overexpressing the 







































Appendix 1:   dMBP immunostaining 
 
Degraded myelin was assessed using anti-dMBP antibody.  Anti-dMBP 
antibody positively  immunostains degraded myelin (Ihara et al., 2010).   The 
grading scale was as follows; no degraded myelin present (grade 0), minimal 
degraded myelin (grade 1), moderate areas of degradd myelin grade (2) and 
extensive areas of degraded myelin (grade 3).   Sections were examined and graded 





Figure A1  dMBP immunostaining grading scale 
Individual brain regions were scored as (A) no degraded myelin present (grade 0), (B) minimal 
degraded myelin (grade 1); arrows identify small punctuate accumulations of dMBP, (C) moderate 
areas of degraded myelin (grade 2); arrows identify m elinated fibres positively stained for dMBP, 
(D) extensive areas of degraded myelin (grade 3); arrows identify larger fibres densely stained for 
dMBP.   Images taken from the internal capsule.   Scale bar = 12.5µm. 
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Figure A1.2  Assessment of dMBP immunostaining  
 
The probability of myelin damage occurring following hypoperfusion was increased (p < 0.001; 
A,B,C) Fisher’s exact test. n=9 sham/ n=9 hypoperfused  There was a significant increase in levels of 
degraded myelin in hypoperfused mice as compared to shams (Fig. A2C;  p < 0.001, median values- 












































































































































Figure A2.1  Spatial referencece memory testing in the water maze 
 
Data are expressed ± SEM.  Sham n = 9; hypoperfused n = 9; ischaemic n=2 (A) Swim speeds did not 
differ between the groups  (p = 0.576 mean values- sham= 26.41 ± 0.97cm/s, hypoperfused= 26.44 ± 
0.93cm/s, ischaemic=24.09 ± 2.75cm/s);  one-way ANOVA.   (B) Performance of groups on the cued 
task improved significantly over training days (p < 0.001).   Hypoperfused animals performed as well 
as shams whilst ischaemic animals performed significantly worse than shams (p = 0.005);  two-way 
ANOVA with Bonferroni post test.   (C) Spatial refence learning was unaffected by hypoperfusion (p 
= 0.254), the performance of all groups improved significantly across days (p < 0.001);  two-way 
ANOVA.   All groups performed equally well during probe tests conducted at (D) 10 mins. (p = 0.459) 
and (E) 24 hours (p = 0.526) following spatial reference learning;  two-way ANOVA.   In both probe 
tests all animals spent significantly more time in the training quadrant compared to chance (dashed 




































































































































Figure A2.2  Serial spatial reference memory testing in the water maze 
 
Data are expressed ± SEM.  Sham n=11; Hypoperfused n=10, Ischaemic n=4   (A) Swim speeds did 
not differ between groups (p = 0.227 mean values- sham= 25.25 ± 1.04cm/s, hypoperfused= 26.44 ± 
0.76cm/s, ischaemic= 21.43 ± 5.24cm/s one-way ANOVA.  (B)  All groups improved significantly on 
the cued task over training days (p<0.001).  Animals with ischaemic damage performed significantly 
worse on the cued version of the watermaze task as compared to sham and hypoperfused animals 
(p=0.037) two-way Anova with Bonferroni’s post test.  (C)  Animals with ischaemic neuronal damage 
showed impaired serial spatial reference learning (p=0.031), animals with ischaemic damage took 
significantly more trials to learn platform locations across tasks (p=0.003).  All animals performed 
equally well during probe tests conducted at (D) 10 mins. (p=0.973) and (E) 24 hours (p=0.386) 
following spatial reference learning; two-way ANOVA.  In both probe tests all animals spent 
significantly more time in the training quadrant compared to chance (dashed line).  (F)  Ischaemic 
animals learned significantly fewer platform locations as compared to sham and hypoperfused 
animals across the first 10 days (p=0.013) mean values- sham= 9.55 ± 0.16 tasks, hypoperfused= 





















































Figure A2.3  Spatial working memory testing in the 8-arm radial arm maze 
 
Data are expressed ± SEM.  Sham n=10; Hypoperfused n=3, Ischaemic n=7 (A) all animals made 
significantly fewer revisiting errors across trials (p<0.0001).  Both ischaemic and hypoperfused 
animals made significantly more revisiting errors as compared to shams (p=0.001); two-way ANOVA 
with Bonferroni’s post test.  (B)  All animals made significantly more novel arm entries in the first 8 
entries as training progressed (p=0.019), ischaemic animals made significantly fewer novel arm 
entries made in the first eight entries as compared to sham and hypoperfused animals animals 
























































Cohort 1: 0.18mm coil one month hypoperfusion
Cohort 2: 0.16mm coil one month hypoperfusion
 
 
Figure A3  Image analysis of intracellular APP expression in cortical neurons 
Data are expressed as mean R.O.D. ± SEM.  Cohort 1, n= 2 sham/ n=12 hypoperfused; cohort 2, 
n=7 sham and 8 hypoperfused.  Image analysis of intracellular APP levels in layer IV/ V cortical, 
pyramidal neurons yielded results similar to those obtained from analysis of intracellular 
hippocampal APP expression.  Intracellular APP leves did not differ between sham (A, D) and 
experimental animals (B, E) from either group examined; cohort 1 (0.18mm coil; p=0.399, mean 
values- sham= 0.32 ± 0.01 hypoperfused= 0.33 ± 0.01  C); cohort 2 (0.16mm coil; p=0.053, mean 
values- sham= 0.29 ± 0.01 hypoperfused= 0.27 ± 0.01  F). Student’s two-tailed t-test.  Scale bar = 
50µm 
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Cohort 1: 0.18mm coil one month hypoperfusion
Cohort 2: 0.16mm coil one month hypoperfusion
 
 
Figure A4  Image analysis of intracellular Aβ expression in cortical neurons 
Data are expressed as mean R.O.D. ± SEM.  Cohort 1, n= 2 sham/ n=12 hypoperfused; cohort 2, 
n=7 sham and 8 hypoperfused.  Image analysis of intracellular Aβ levels in layer IV/ V cortical, 
pyramidal neurons yielded results similar to those obtained from analysis of intracellular 
hippocampal Aβ expression.  Intracellular Aβ levels did not differ between sham (A, D) and 
experimental animals (B, E) from either cohort examined; cohort 1 (0.18mm coil; p=0.822, mean 
values- sham= 0.13 ± 0.01 hypoperfused= 0.13 ± 0.01  C); cohort 2 (0.16mm coil; p=0.536, mean 





































Cohort 1: 0.18mm coil one month hypoperfusion





Figure A5  Comparison of the C83/ C99 fragment ratio between sham and 
hypoperfused mice 
Data are expressed as mean C83/ C99 Ratio ± SEM.  Cohort 1, n=12 sham/ n=12 hypoperfused; 
cohort 2, n=7 sham and 8 hypoperfused.  There was no change in the C83/ C99 fragment ratio 
between sham and hypoperfused animals in either of the cohorts tested; cohort 1 (0.18mm coil; 
p=0.526, mean values- sham= 3.71 ± 0.15 hypoperfused= 3.59 ± 0.11 A), cohort 2 (0.16mm coil; 
p=0.243, mean values- sham= 2.72 ± 0.14 hypoperfused= 3.06 ± 0.23 B).  Student’s two tailed t-test. 
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Figure A6  White matter protein levels in aged 3xTg-AD mice following 
hypoperfusion 
There was no change in levels of any white matter proteins examined between aged sham and 
hypoperfused animals; APP (p=0.320, mean values- sham= 1.05 ± 0.06 hypoperfused= 0.96 ± 0.05 
A4 A), MAG (p=0.0.194, mean values- sham= 1.25 ± 0.13 hypoperfused= 1.09 ± 0.05 A4 B); MBP 
(p=0.0.656, mean values- sham= 1.98 ± 0.14 hypoperfus d= 2.04 ± 0.07 A4 C); CNPase (p=0.502, 
mean values- sham= 1.79 ± 0.07 hypoperfused= 1.69 ± 0.09 A4 D).  
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